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ABSTRACT 
 
It is well established that the 12-lipoxygenase (12-LOX) pathway of arachidonic acid 
(AA) metabolism is stimulated within the myocardium by episodes of ischaemia, and 
there is considerable evidence showing that eicosanoids derived via this pathway protect 
against the damaging effects of myocardial ischaemia-reperfusion (I/R) injury. Recent 
evidence suggests that transient receptor potential vanilloid receptor 1 (TRPV1), 
expressed on sensory C-fibres, may play an important protective role against 
myocardial I/R injury; and in neurones, the 12-LOX metabolite of AA 12(S)-
hydroperoxyeicosatetraenoic acid [12(S)-HpETE], has been proposed as an endogenous 
ligand for TRPV1. However, whether 12(S)-HpETE underlies TRPV1 channel 
activation during myocardial I/R is unknown. 
 
Treatment of isolated Langendorff rat hearts with 12-LOX/AA significantly attenuated 
I/R injury (~40% inhibition of infarct size), an effect reversed by the 12-LOX inhibitor 
baicalein or by chemical desensitisation of local C-fibre afferents in vivo using 
capsaicin. Both 12(S)-HpETE and AA caused dose-dependent coronary vasodilatation 
(~pEC50s of 18.2 and 6.9, respectively) that was profoundly suppressed by the TRPV1 
antagonist capsazepine, or in hearts of TRPV1 knockout mice compared to wild-type 
mice, or by treatment with the calcitonin gene-related peptide (CGRP) receptor 
antagonist, CGRP8-37. I/R in vitro reduced expression of myocardial TRPV1 protein, 
whereas in vivo, TRPV1 protein expression in the heart and dorsal root ganglia (DRG) 
increased, and DRG TRPV1 messenger ribonucleic acid levels decreased – suggesting 
that whilst TRPV1 protein may be down-regulated during I/R in vitro, when neurones 
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innvervating the heart are associated with their cell bodies, TRPV1 expression may be 
increased, possibly under the control of neurotrophic factors. 
 
Together, the findings from this thesis identify a novel 12-LOX/AA/TRPV1 pathway 
activated and up-regulated during myocardial I/R injury, providing an endogenous 
damage-limiting mechanism – the targeting of which may prove useful in treating 
myocardial infarction or protecting against I/R injury associated with common surgical 
procedures including cardiac transplantation. 
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1. INTRODUCTION 
 
1.1. General background 
The principal function of the cardiovascular system is to provide individual tissues with 
a rapid supply of oxygen and nutrients such as glucose, amino acids and fatty acids, and 
to rapidly remove metabolic waste products such as carbon dioxide, creatinine and urea. 
The presence of a cardiovascular system is essential in large animals such as humans, 
due to the distances over which transport needs to occur. Whilst small, simple 
organisms can rely solely on diffusional transport, the rate of diffusion increases as the 
square of distance, and over distances greater than approximately 0.1 mm, a faster 
transport system is required. In humans, diffusion plays a vital role in transport both 
intracellularly and between cells and the bloodstream, but over long distances, 
diffusional transport is simply too slow to keep up with cellular requirements, and 
convective transport is necessary, which is provided by the cardiovascular system. 
Whilst diffusion is a passive process, convective transport is an active process, and the 
energy for convective transport is provided by contraction of the heart. 
 
The heart comprises two pumps, the left and right ventricles, each filled from a 
contractile reservoir, known as the left and right atrium, respectively. Deoxygenated 
blood is pumped from the right ventricle to the lungs, via the pulmonary artery, and then 
oxygenated blood returns to the left atrium via the pulmonary veins - the pulmonary 
circulation. An equal volume of oxygenated blood is then pumped from the left 
ventricle to the rest of the body, via the aorta, and deoxygenated blood returns to the 
right atrium via the superior and inferior vena cava – the systemic circulation. 
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Oxygenated blood enters the coronary circulation via the ostia situated at the root of the 
aorta. The right coronary artery and its branches supply the right atrium, right ventricle, 
and also parts of the left atrium and left ventricle, whilst the left coronary artery and its 
branches supply the left atrium, left and right ventricles, and the interventricular septum. 
Deoxygenated blood is returned to the right atrium mainly via the coronary sinus, 
although there is also a network of microscopic veins which empty into all four heart 
chambers. 
 
At rest, the output of the left ventricle is distributed to peripheral tissues roughly 
according to the metabolic rate, although there are exceptions. For example, skeletal 
muscle receives approximately 20% of the cardiac output, and accounts for 
approximately 20% oxygen consumption, whereas the kidneys account for only 6% 
oxygen consumption, yet receive 20% of the cardiac output, due to the high blood flow 
necessary for their excretory role (Levick, 2003). As a result of the disproportionately 
high blood flow to the kidneys, some other organs receive a lower proportion of the 
cardiac output than expected, and, relative to its metabolic needs, heart tissue is one of 
the most poorly perfused in the body. In the coronary circulation, it is essential that the 
rate of oxygen delivery matches the demands of the heart, and under normal 
circumstances, coronary flow closely correlates with myocardial oxygen consumption. 
 
If coronary flow is compromised in any way, thereby reducing the supply of oxygen to 
the heart (a condition known as ‘ischaemia’) this can have serious detrimental effects. 
Indeed, ischaemia resulting in myocardial dysfunction may lead to heart failure, which 
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is a major cause of morbidity and mortality in the western world (Beyar, 2008). 
Myocardial ischaemia is usually a result of the atheromatous narrowing (stenosis) of 
one of more coronary arteries (Levick, 2003), which may additionally result in 
thrombosis (Buja, 2005). Sudden obstruction of an atheromatous coronary artery by 
thrombosis may cause myocardial infarction, whilst gradual stenosis generally causes 
exercise-induced angina, only having a significant effect on resting coronary flow once 
the narrowing is severe (Levick, 2003). At the beginning of this century, acute coronary 
occlusion by thrombosis stood as the main cause of morbidity and mortality in the 
western world, and was predicted by the World Health Organisation to be the leading 
cause of death worldwide by 2020 (Yellon and Baxter, 2000) – although more recent 
data suggests that with the incidence of hypertension worldwide set to increase to 29% 
by 2025 (Kearney et al., 2005), this may actually represent a greater risk of morbidity 
and mortality. 
 
The primary insult in myocardial ischaemia is a reduction in the supply of oxygen to the 
heart resulting in reduced free energy, from adenosine 5’-triphosphate (ATP) 
hydrolysis, to levels that are inadequate for the maintenance of vital cell processes such 
as ion channel function (Dirksen et al., 2007). As discussed in more detail in section 
1.2.1, in order to compensate for the loss of ATP production, via mitochondrial 
oxidative phosphorylation, there is an increase in glycolysis and a concomitant 
accumulation of H
+
 and lactate. These cause intracellular acidosis and inhibition of 
glycolysis – leading to the development of impaired contraction with persistent 
electrical activity (excitation-contraction uncoupling) and alterations in ion transport 
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systems, both intracellularly and within the sarcolemma, creating an environment 
susceptible to the development of arrhythmias (Buja, 2005). Importantly, the 
consequences of ischaemia are not necessarily restricted to the myocardium itself; but 
rather, as has been recognised in other organs, the vascular wall and endothelial cells are 
also affected (Carden and Granger, 2000). 
 
Myocardial ischaemic injury produces a range of clinical manifestations, reflecting the 
metabolic and ultrastructural changes that occur in response to ischaemia and which 
lead to irreversible cell injury and ultimately cell death (Buja, 2005). The most effective 
means of preventing the progression of ischaemic cell death following coronary artery 
occlusion is prompt re-opening of the occluded vessel to allow reperfusion (Ambrosio 
and Tritto, 1999). However, whilst reperfusion is essential for recovery from 
myocardial ischaemia, reperfusion of the ischaemic tissue causes additional damage 
beyond that caused by the ischaemic insult per se – a phenomenon referred to as 
‘ischaemia-reperfusion (I/R) injury’ (Carden and Granger, 2000) – and has therefore 
been described as a ‘double-edged sword’ (Braunwald and Kloner, 1985). Reperfusion 
may occur spontaneously, but clinically, myocardial I/R injury is associated with 
commonly-used procedures for treatment of acute coronary occlusion and prevention of 
myocardial infarction such as thrombolysis, percutaneous coronary intervention, and 
coronary bypass surgery (Moens et al., 2005). There is currently, therefore, considerable 
interest in elucidating the mechanisms underlying myocardial injury following 
ischaemia and reperfusion in the hope that novel therapeutic targets may be identified 
that protect against, or at least minimise the extent of, tissue damage. 
 
Chapter 1: Introduction 
 
 
 
 
30 
 
One pathway that is activated by myocardial ischaemia is the phospholipase A2 
(PLA2)/arachidonic acid (AA) pathway (Chien et al., 1984). Of particular interest to this 
thesis is the metabolism of AA to eicosanoids via lipoxygenases. It is well established 
that the 12-lipoxygenase (12-LOX) pathway of AA metabolism is stimulated within the 
myocardium by episodes of ischaemia and hypoxia (Chen et al., 1999), and a 
considerable body of evidence suggests that in the coronary circulation, endogenous 
lipoxygenases generate metabolites that are protective against the damaging effects of 
I/R (Chen et al., 1999, Gabel et al., 2001, Murphy et al., 1995, Patel et al., 2003, 
Starkopf et al., 1998, Tsutsumi et al., 2006) - although the precise mechanism 
underlying this effect is unknown. Chen and co-workers demonstrated that 12-LOX-
mediated cardioprotection in the isolated rat heart involves 5-hydroxydecanoate-
sensitive K
+
 channels, implying a role for mitochondrial ATP-sensitive K
+
 (KATP) 
channels in this response (Chen et al., 1999). Activation of K
+
 channels by lipoxygenase 
(LOX) metabolites has also been shown to underlie the vasodilator actions of AA 
(Faraci et al., 2001, Miller et al., 2003) and indeed, LOX-derived metabolites of AA are 
now recognised as serving an endothelium-derived hyperpolarising factor function in 
certain arteries, inducing vasodilator responses to stimuli such as acetylcholine and 
bradykinin (BK), via activation of K
+
 channels (Campbell et al., 2003, Chawengsub et 
al., 2009, Gauthier et al., 2004, Zhang et al., 2007). There is also evidence to suggest 
that the vasodilator actions of coronary LOX metabolites involves sensory C-fibres 
(McLean et al., 2002), furthermore, that the non-selective cation channel transient 
receptor potential vanilloid receptor 1 (TRPV1), expressed on C-fibres, may play an 
important protective role against I/R injury within the heart (Wei et al., 2009, Zhong 
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and Wang, 2007, Zhong and Wang, 2008, Zhong and Wang, 2009). Indeed, in neurones, 
the 12-LOX metabolite of AA 12(S)-hydroperoxyeicosatetraenoic acid [12(S)-HpETE] 
has been proposed as an endogenous ligand for TRPV1 (Hwang et al., 2000), however, 
whether 12(S)-HpETE underlies TRPV1 activation during myocardial I/R, or whether 
the beneficial effects of 12-LOX involve activation of TRPV1 is unknown. 
 
The overall aim of this thesis was to investigate the possibility that, following activation 
of the neuronal non-selective cation channel TRPV1 located on sensory C-fibre nerve 
terminals, LOX-derived eicosanoids (either generated endogenously within the 
endothelium, or from exogenous 12-LOX and AA) could afford protection against 
myocardial injury following ischaemia and reperfusion. 
 
1.2. Myocardial I/R injury 
1.2.1. Ischaemic injury 
Within minutes of the onset of ischaemia due to obstruction of a coronary artery, 
myocardium undergoes considerable metabolic, functional and morphological changes 
that are manifested as reduced contractility and arrhythmogenesis. Furthermore, if the 
residual coronary flow is severely compromised, such changes can lead to irreversible 
cell damage and ultimately cell death – a sequence of events referred to as ‘myocardial 
infarction’ (Levick, 2003). Reduced blood flow has a number of immediate 
consequences, but the main metabolic changes that occur can be attributed to inadequate 
ATP production via oxidative phosphorylation, and the build-up of by-products of 
anaerobic glycolysis (Baxter and Ebrahim, 2002). Accumulation of toxic metabolites 
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triggers activation of enzymes such as PLA2, which generates AA and subsequently 
inflammatory mediators such as prostaglandins (PGs) and leukotrienes (LTs), and also 
lysozymes, which are proteolytic cells important for disposal of necrotic cells (Khalil et 
al., 2006). 
 
Under aerobic conditions, carbohydrates such as glucose are catabolised within the 
cytosol via the glycolytic pathway, converting one molecule of glucose into two 
molecules of pyruvate, generating a net gain of two molecules of ATP. Pyruvate then 
enters the mitochondria, whereupon it is converted to acetyl coenzyme A (acetyl CoA), 
which then enters the Krebs cycle. The Krebs cycle does not form ATP directly, but 
generates one molecule of guanosine 5’-triphosphate (GTP) per molecule of acetyl CoA 
that can be converted to ATP. However, the Krebs cycle is of considerable importance 
since it generates H
+
 used in oxidative phosphorylation – which is quantitatively the 
most important metabolic pathway used to produce ATP from the breakdown of fuel 
molecules, generating a maximum of 34 molecules of ATP per molecule of glucose. 
Unlike oxidative phosphorylation, neither the Krebs cycle nor glycolysis use molecular 
oxygen directly. However, the Krebs cycle depends on oxidative phosphorylation for 
regeneration of the hydrogen-free form of the coenzymes nicotinamide adenine 
dinucleotide and flavine adenine dinucleotide – therefore the Krebs cycle can only occur 
under aerobic conditions. Furthermore, acetyl CoA is only generated by aerobic 
glycolysis: under anaerobic conditions, pyruvate is converted to lactate (Vander et al., 
1994). 
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Oxidative phosphorylation is thus the principal process via which eukaryotes generate 
ATP to fuel most active cellular processes, and it consumes approximately 90% of 
available oxygen under normoxic conditions (Taylor and Pouyssegur, 2007). Within the 
cardiomyocyte, the contractile apparatus consumes approximately two-thirds of ATP 
generated, whilst the remainder is used by pumps such as the sarcolemmal Na
+
/K
+
-
ATPase, and the sarcoplasmic reticulum Ca
2+
-ATPase, which play a major role in 
maintaining ion homeostasis (Solaini and Harris, 2005). Under anaerobic conditions, 
heart muscle is unable to produce sufficient energy to maintain vital cell function 
(Giordano, 2005). 
 
Increased CO2 tension as a result of reduced blood flow and reduced O2 tension (Loor 
and Schumacker, 2008), together with the build-up of H
+
 and lactate produced by 
anaerobic metabolism, causes intracellular acidosis and inhibition of glycolysis which 
leads to impaired myocardial contractility and alterations in the activity of ion transport 
systems, promoting ventricular arrhythmias and causing ultrastructural changes to 
ischaemic myocytes including swelling of the cytoplasm, sarcoplasmic reticulum and 
mitochondria – the progression from reversible to irreversible myocardial cell damage 
being accompanied by changes to the myocardial interstitium and microvasculature 
(Buja, 2005). Irreversible myocardial cell damage commences within approximately 20 
minutes of vessel occlusion, and the full extent is realised within 6 hours: once 
ischaemic tissue becomes infarcted, it cannot regenerate, and contractile function is lost 
(Downey et al., 2007). The mechanisms underlying arrhythmia and reduced contractility 
resulting from acute myocardial ischaemia are summarised in Figure 1.1. 
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Figure 1.1. The multiple effects of acute myocardial ischaemia. Summary of mechanisms by 
which acute myocardial ischaemia (usually the result of coronary artery disease) causes 
impaired cardiac contractility and development of arrhythmias. Green highlighting denotes an 
increase; red highlighting denotes a decrease. Modified from Levick (2003), p89. 
 
Arrhythmias induced by ischaemia tend to occur within two distinct phases, occurring 
either within the first 30 minutes of ischaemia or approximately 2 hours after the onset 
of ischaemia. Severe ventricular arrhythmias develop in hearts with only minimal 
irreversible myocyte injury, since the homogeneity of injury in hearts with a high 
degree of irreversible myocyte injury is not conducive to the electrical instability that 
underlies arrhythmogenesis (Ravingerova et al., 1995). Ventricular fibrillation (VF) is a 
potentially lethal form of arrhythmia that can cause sudden cardiac death, which in 
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approximately 75-80% cases is due to myocardial ischaemia, and which can occur 
before the development of myocardial infarct (Luqman et al., 2007). 
 
As already mentioned, the deleterious effects of ischaemia are not restricted to 
cardiomyocytes, but the microvasculature is also vulnerable to ischaemic injury. Intimal 
vascular endothelial cells are particularly susceptible to injury following acute 
ischaemia, which may be detected by alterations in coronary vascular reactivity to 
vasodilators such as thrombin – as first demonstrated by Ku (1982). In ischaemic canine 
coronary arteries, thrombin, which characteristically produces a biphasic response 
(vasodilatation followed by vasoconstriction) produced an enhanced vasoconstrictor 
response whilst the vasodilator response was abolished; an effect very similar to that of 
mechanical denudation of the intimal endothelium (Ku, 1982). Myocardial no-reflow 
(described further in section 1.2.2) is a common manifestation of reperfusion injury, but 
ischaemic injury is an important contributory component – prolonged ischaemia causing 
ultrastructural damage to the microvasculature including endothelial swelling and 
‘blistering’ of the endothelial surface, which can result in obstruction of the capillary 
lumen (Reffelmann and Kloner, 2006). It is now understood that a certain threshold 
duration of ischaemia is necessary for the development of zones of no-reflow, but that 
once this threshold is reached, such zones of no-reflow increase with duration of 
ischaemia – which is related to infarct size and hence extent of microvascular damage 
(Reffelmann and Kloner, 2006). 
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A prolonged period of hypoxia (as occurs during ischaemia) leads to alterations in 
cardiac myocyte membrane potential and ion distribution, an increase in intracellular 
volume, reduced membrane fluidity, and disruption of cytoskeletal arrangements – 
which may also be accompanied by depletion of energy stores, either increased or 
reduced production of specific bioactive agents, and ultimately, either induction or 
suppression of certain genes (Carden and Granger, 2000). An important consequence of 
prolonged ischaemia is the elevation of intracellular calcium (‘calcium overload’), due 
to the combined effect of opening of L-type Ca
2+
 channels, inhibition of sarcolemmal 
and sarcoplasmic reticular Ca
2+
 pumps, and activation of the Na
+
/Ca
2+
 exchanger, which 
contributes to reperfusion injury (Dirksen et al., 2007) as discussed below. There is 
evidence to suggest that in endothelial cells, the endoplasmic reticulum is the main 
source of the calcium overload during ischaemia (Ladilov et al., 2000). 
 
1.2.2. Reperfusion injury 
Reperfusion of ischaemic myocardium to prevent cell death is paramount to its survival, 
and the sooner a patient can receive treatment such as intravenous thrombolysis or 
primary coronary intervention, the greater the limitation of ischaemic injury (Beyar, 
2008). However, there is considerable experimental evidence to suggest that reperfusion 
per se also causes tissue damage, referred to as ‘reperfusion injury’. The possibility that 
reperfusion of ischaemic myocardium might have deleterious effects was first raised by 
Jennings and co-workers, who, using a canine model of coronary artery occlusion, 
found evidence that reperfusion accelerated necrosis of myocytes that had been 
irreversibly injured by an ischaemic episode (Jennings et al., 1960). It is now 
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understood that, in addition to accelerating death of cardiomyocytes that were 
irreversibly injured during ischaemia, reperfusion may also cause injury and death of 
cells that remained viable at the end of the period of ischaemia (Ovize et al., 1997). 
 
The clinical relevance of reperfusion injury (compared to that of ischaemic injury) and 
even the very existence of reperfusion injury (in its own right as opposed to accelerated 
expression of pre-existent injury) were disputed for some time (Garcia-Dorado, 2004) – 
some authors even doubting that they would live to see the day when a consensus was 
reached on whether or not lethal (as opposed to sub-lethal) myocardial reperfusion 
injury exists (Bolli, 1997)! There are a number of reports in the literature of studies 
which have failed to demonstrate the existence of lethal myocardial reperfusion injury 
in an experimental setting; for example, two studies using canine hearts, which found 
that the wave front of necrosis caused by ischaemia did not advance with reperfusion 
(Ganz et al., 1990, Zahger et al., 1995) – and for many years, evidence in support of 
lethal myocardial reperfusion injury within a clinical setting was sparse (Ferrari and 
Hearse, 1997). However, more recently, evidence from experimental and, importantly, 
clinical studies also, have been taken to support the existence of such a phenomenon 
(Gross and Auchampach, 2007). One important discovery is that of postconditioning, 
which involves brief periods of reperfusion alternating with ischaemia at the very 
beginning of reperfusion (Zhao and Vinten-Johansen, 2006). The cardioprotective 
effects of postconditioning were first described by Zhao and co-workers, who, using a 
canine I/R model, showed that infarct size was significantly reduced in hearts subjected 
to a postconditioning protocol consisting of three cycles of 30 seconds of reperfusion 
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followed by 30 seconds of re-occlusion of the left anterior descending (LAD) coronary 
artery at the onset of reperfusion (Zhao et al., 2003). A couple of years later, 
postconditioning was reported to also be cardioprotective in humans (Laskey, 2005, 
Staat et al., 2005), and cardioprotective effects of postconditioning such as reduced 
infarct size and improved left ventricular function have reported both short-term 
[measured after 7 days of reperfusion; (Yang et al., 2007b, Zhao et al., 2009)] and long-
term [measured 6 months and 1 year after myocardial infarction (Thibault et al., 2008)]. 
Postconditioning also appears to protect against myocardial damage caused by I/R 
during cardiac surgery, when used as an adjunct to cold blood cardioplegia (Luo et al., 
2008b). 
 
Clinical manifestations of reperfusion injury include reperfusion-induced arrhythmias 
[distinct from ischaemia-induced arrhythmias (Ravingerova et al., 1995)], myocardial 
stunning, and endothelial- and microvascular dysfunction including the no-reflow 
phenomenon (Moens et al., 2005). Myocardial stunning refers to the prolonged 
depression of contractile function in myocardium salvaged by reperfusion, observed 
after periods of ischaemia of insufficient duration to cause irreversible tissue damage 
(Buja, 2005). The first description of myocardial stunning in the literature is by 
Heyndrickx and co-workers, who observed that in conscious dogs, reperfusion 
following brief (5 or 10 minute) periods of coronary artery occlusion resulted in a rapid 
return to pre-ischaemic values of coronary flow and electrophysiological function, 
whereas regional mechanical function remained depressed for over 3 and 6 hours 
respectively (Heyndrickx et al., 1975). Studies demonstrating a reduction in myocardial 
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stunning with treatments administered at the onset of reperfusion illustrate that, 
although reduced myocardial contractility can be, in part, attributed to ischaemic injury 
(as mentioned in section 1.2.1), reperfusion injury is also a contributory factor 
(Ambrosio and Tritto, 1999). Stunning is mediated by oxygen-derived free radicals and 
calcium loading (discussed below), which may cause reversible injury in myocytes that 
eventually recover contractile function: if perfusion is reduced chronically, myocardial 
function is impaired chronically – a condition referred to as ‘hibernation’ (Buja, 2005). 
Sustained hibernation leads to myocardial cell death (Buja and Vela, 2008). 
 
The no-reflow phenomenon (impeded blood flow to ischaemic tissue despite re-opening 
of the occluded vessel) was originally described in the brain, and appears to be a process 
that becomes more evident with prolonged periods of ischaemia, rather than an event 
that occurs immediately upon reperfusion (Rezkalla and Kloner, 2002). It was first 
reported in the heart by Kloner and co-workers, who reported that 90 minutes of 
ischaemia in the canine heart resulted in failure to achieve uniform reperfusion, which 
was associated with extensive damage to capillaries and myocardial cell swelling 
(Kloner et al., 1974). As mentioned in section 1.2.1, myocardial ischaemia may cause 
swelling and ‘blistering’ of the capillary endothelium, and this may result in occlusion 
of blood vessels and directly reduce flow upon reperfusion (Reffelmann and Kloner, 
2006). In addition, reperfusion is associated with cardiomyocyte swelling and 
intracellular and interstitial oedema, likely attributable to by-products of the glycolytic 
pathway, and this oedema may cause mechanical compression of the microvasculature 
(Niccoli et al., 2009). Occlusion of microvessels may also result from neutrophil 
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activation by proinflammatory cytokines such as tumour necrosis factor α (TNFα) 
released upon reperfusion, and their adhesion to the vessel wall (Ambrosio and Tritto, 
1999). Furthermore, vasoconstrictor agents released by damaged endothelial cells, 
platelets and neutrophils collectively cause prolonged vasoconstriction of the coronary 
microvasculature, which also reduces coronary flow (Niccoli et al., 2009). 
 
Indeed, neutrophils play a major role in reperfusion injury, and in addition to forming a 
mechanical plug in the microvasculature, they contribute to endothelial dysfunction, 
producing potent vasoconstrictor substances, and also migrating across the endothelium 
into reperfused tissue, where they release cytotoxic and chemotactic substances, 
including highly reactive oxygen-derived free radicals (Moens et al., 2005). A 
combination of increased production of such oxygen radicals and reduced scavenging 
capacity of post-ischaemic tissue results in normal cellular defences being overwhelmed 
upon reperfusion, leading to direct oxidative damage to cellular structures (including 
mitochondria) and also indirectly causing tissue damage via modulation of factors that 
are important mediators in reperfusion injury (Ambrosio and Tritto, 1999). Particularly 
damaging is the neutrophil production of proteases that can degrade virtually all the 
components of the endothelial basement membrane, as well as junctional proteins vital 
for maintaining endothelial barrier function (Carden et al., 1998). Indeed, an increase in 
vascular permeability of the venules is a characteristic manifestation of reperfusion 
injury, endothelial cell dysfunction in postcapillary venules accounting for the majority 
of I/R-induced inflammatory responses (Carden and Granger, 2000). In arterioles, the 
principal manifestation of endothelial dysfunction is impaired endothelium-dependent, 
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nitric oxide (NO)-mediated, receptor-dependent vasodilatation (Banda et al., 1997, 
Conger et al., 1991, Harrison, 1997) whilst in capillaries, the effects are reduced number 
of perfused capillaries and an increase in fluid filtration into the interstitium (Carden 
and Granger, 2000). 
 
In addition to reperfusion injury to the vasculature, myocytes are also at risk of 
irreversible injury caused by reperfusion – primarily by the action of oxygen-derived 
free radicals and calcium overload (Buja, 2005, Niccoli et al., 2009, Moens et al., 2005). 
Oxygen-derived free radicals are generated by injured myocytes and endothelial cells 
within the ischaemic zone, as well as by neutrophils entering the ischaemic zone which 
are activated upon reperfusion (Buja, 2005). Cell injury caused by oxygen-derived free 
radicals includes strand breaks to deoxyribonucleic acid (DNA), denaturation of 
membrane proteins (including ion channels and enzymes), and peroxidation of 
phospholipids, the latter which leads to loss of membrane integrity and consequently 
cell death (Zweier and Talukder, 2006). The degree of reperfusion injury is exacerbated 
by the amplification of oxygen-derived free radical production by neutrophils attracted 
by platelet activating factor, which is produced by the endothelium in response to 
oxygen-derived free radical stimulation (Jordan et al., 1999). 
 
The calcium overload hypothesis of reperfusion injury explains the deleterious effects 
of reperfusion on cardiomyocytes in terms of the accumulation of toxic levels of 
intracellular calcium due to failure of the cell’s mechanisms for calcium homeostasis – 
the accelerated accumulation of Ca
2+
 caused by reperfusion following transient 
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ischaemia having been first reported by Shen and Jennings (Shen and Jennings, 1972a, 
Shen and Jennings, 1972b). Importantly, calcium overloading occurs in both the cytosol 
and mitochondria (Lemasters et al., 2009). As mentioned in section 1.2.1, calcium 
overload begins during ischaemia, but intracellular Ca
2+
 increases further upon 
reperfusion (Dirksen et al., 2007). In response to the build-up of lactate and H
+
 from 
anaerobic glycolysis during ischaemia, H
+
 is removed from cells in exchange for Na
+
 
via the Na
+
/H
+
 exchanger in the plasma membrane, and additional Na
+
 entry occurs via 
Na
+
 channels (Baines, 2009). Accumulation of Na
+
 in cells during ischaemia reduces 
the Na
+
 gradient across the plasma membrane, which causes the Na
+
/Ca
2+
 exchanger to 
operate in reverse (continuing into the early stages of reperfusion) thereby causing 
cytosolic accumulation of Ca
2+
 in an attempt to restore Na
+
 balance (Piper et al., 2003). 
The resulting increase in intracellular free Ca
2+
 (‘calcium overload’) initiates 
uncontrolled hypercontraction and also, together with increased intracellular Na
+
 due to 
impairment of Na
+
/K
+
-ATPase activity, swelling of cardiomyocytes that contributes to 
cell membrane rupture upon reperfusion (Niccoli et al., 2009). Hypercontracture 
(uncontrolled activation of the contractile machinery that causes a sustained shortening 
and stiffening of cardiomyocytes) due to high intracellular free Ca
2+
 and high energy 
levels upon reperfusion is known as calcium overload-induced contracture, and is 
distinct from rigor-type contracture, which occurs during slow restoration of ATP and is 
not always dependent upon calcium overload (Ladilov et al., 2003, Piper et al., 2003). 
Significantly for the development of reperfusion injury, hypercontracture and 
subsequent myocyte death due to rupture of the sarcolemma may propagate through the 
reperfused myocardium via movement of Na
+
 through gap junctions, forming areas of 
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‘contraction band necrosis’ (Rodriguez-Sinovas et al., 2007). This term describes the 
distinct histological appearance of cell damage within reperfused myocardium, which is 
characterised by so-called ‘contraction bands’ (hypercontracted sarcomeres) and 
numerous ruptures of the sarcolemma (Piper et al., 2006). 
 
Calcium overload has been postulated to stimulate opening of the mitochondrial 
permeability transition pore (mPTP), which is thought to play a role in injury caused by 
I/R (Baines, 2009, Lemasters et al., 2009, Solaini and Harris, 2005), as discussed in 
section 1.2.3. However, there is some evidence to suggest that in myocardial 
reperfusion injury, the mPTP is activated by reactive oxygen species (ROS) generated 
by mitochondria, as opposed to calcium overload (Lemasters et al., 2009). In addition to 
reperfusion-induced calcium overloading occurring in myocytes irreversibly injured 
during ischaemia, reperfusion can also cause irreversible injury to cardiomyocytes that 
sustained reversible injury during ischaemia; and this switch from reversible to 
irreversible injury is due to calcium overload (Buja, 2005). 
 
It is thus now apparent that a fine balance exists between the beneficial and the 
detrimental effects of reperfusion, and indeed, the outcome of reperfusion is related to 
the duration of ischaemia: if coronary blood flow is restored within 2-3 hours of the 
onset of myocardial ischaemia, then the degree of tissue salvage significantly outweighs 
the extent of irreversible reperfusion injury (Buja, 2005). Clearly, limitation of the 
tissue damage caused by reperfusion is of considerable importance; however, in order 
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that this can be achieved, it is necessary to first elucidate the mechanisms via which 
injury occurs. 
 
1.2.3. Mechanisms of ischaemic and reperfusion injury 
Since the start of research into the pathology and pathogenesis of acute ischaemic injury 
of the myocardium almost 50 years ago, a wealth of experimental evidence has shown 
that a typical cardiomyocyte response to ischaemia involves cell swelling, progressive 
ionic disturbances and membrane damage – all features of cell injury and death via 
oncosis (Majno and Joris, 1995). More recently, evidence has begun to accumulate 
which suggests that apoptosis also plays a role in cardiomyocyte injury and death in 
response to acute ischaemia (Buja, 2005, Buja and Vela, 2008, Jugdutt and Idikio, 
2005). 
 
It is important to note at this point that there exists some confusion in the literature 
regarding terminology surrounding this area of research. Until cell death began to be 
described at a cellular level, cell death induced by a variety of toxic stimuli (for 
example, ischaemia) was referred to as ‘necrosis’ by pathologists, different subtypes of 
necrosis being described on the basis of distinct changes at the tissue level (Shirai, 
1999). In 1972, it was recognised that in addition to necrosis, another form of cell death 
existed, which involved cell shrinkage as opposed to cell swelling, and which was 
called ‘apoptosis’ (Kerr et al., 1972). A large number of publications in the literature 
speak of apoptosis and necrosis as two different pathways of cell death. However, more 
recently, the term ‘necrosis’ has been applied to the common process of cell degradation 
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following cell death via multiple pathways, namely oncosis, apoptosis or autophagy 
(Buja and Vela, 2008), and may thus be regarded as a ‘post-mortal condition’ as 
opposed to a ‘pre-mortal process’ (Van Cruchten and Van Den Broeck, 2002). 
Depending on the severity of the ischaemic episode, oncosis, apoptosis and necrosis 
may co-exist during the early stages of ischaemic injury, and the existence of several 
overlapping morphological features during this period has added to the confusion 
surrounding terminology (Jugdutt and Idikio, 2005). 
 
The characteristics of oncosis have been defined to include the following: (1) cell death 
involves cell swelling, swelling of organelles and increased membrane permeability, (2) 
underlying such changes is the failure of ion pumps within the plasma membrane, (3) it 
is typically caused by stimuli that disrupt ATP production and increase plasma 
membrane permeability, as does ischaemia, (4) it progresses within 24 hours to typical 
necrosis, (5) it is usually accompanied by condensation of chromatin (karyolysis), and 
(6) DNA breaks down in a non-specific manner (Majno and Joris, 1995). Oncosis is 
triggered by exogenous stimuli (Buja, 2005), and is a passive (i.e. ATP-independent) 
process which progresses from reversible to irreversible injury in three stages: (1) 
discrete alterations in ion transport systems, which can be reversed, (2) increased 
membrane permeability, which is potentially reversible, and (3) irreversible physical 
disruption of the cell membrane, which importantly allows leakage of cell constituents 
and initiates an inflammatory response (Buja and Vela, 2008). Progressive membrane 
damage via oncosis can cause loss of cellular homeostasis in at least four ways: (1) 
direct damage to the cell membrane, (2) damage to the respiratory apparatus of the 
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mitochondria, thereby inhibiting oxidative phosphorylation, reducing ATP production 
and lowering pH, (3) proteolysis of membrane-associated cytoskeletal proteins, and (4) 
uncontrolled degradation of membrane phospholipids via phospholipases, and 
peroxidation of membrane lipids via oxygen-derived free radicals, for example (Buja 
and Vela, 2008). 
 
In contrast, apoptosis is an ATP-dependent process that occurs in response to both 
endogenous and exogenous stimuli, under physiological or pathological conditions, and, 
as mentioned above, is associated with cell shrinkage (Buja, 2005). Cell death via 
apoptosis is under genetic control, and involves the fragmentation of nuclear DNA 
(Wyllie, 1980). Cells are eventually divided into apoptotic bodies, consisting of densely 
packed intact organelles or nuclear material surrounded by an intact plasma membrane, 
which are engulfed by nearby phagocytic cells, thereby avoiding an inflammatory 
response (Kerr et al., 1972). Two main death pathways have been proposed to mediate 
apoptosis in cardiomyocytes – the so-called ‘external pathway’, which involves cell 
surface receptors, and the ‘intrinsic pathway’, which involves the mitochondria and 
endoplasmic reticulum - both leading to activation of specific enzymes known as 
caspases (Buja and Vela, 2008). 
 
In the external pathway, ligands such as Fas and TNFα bind to specific cell-surface 
receptors, activating death domains within the receptor, thereby facilitating binding of 
associated death domain molecules to which procaspase-8 binds and is then converted 
to caspase-8, which activates procaspase-3 to caspase-3, which triggers the apoptotic 
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response (Van Cruchten and Van Den Broeck, 2002). The intrinsic pathway involves 
either release of Ca
2+
 from the endoplasmic reticulum and activation of caspase-12 
(Buja and Vela, 2008, Jugdutt and Idikio, 2005, Van Cruchten and Van Den Broeck, 
2002), and/or the mitochondrial protein cytochrome c (Baines, 2009, Buja and Vela, 
2008, Jugdutt and Idikio, 2005, Van Cruchten and Van Den Broeck, 2002). 
Translocation of pro-apoptotic factors such as members of the Bcl-2 family, and their 
incorporation into the mitochondrial outer membrane, leads to permeabilisation of the 
outer membrane and subsequent release of factors such as cytochrome c and 
endonuclease G from the intermembrane space into the cytosol, and the subsequent 
activation of caspases within the cytosol or fragmentation of DNA within the nucleus, 
respectively (Baines, 2009). Alternatively, apoptosis may be induced via 
permeabilisation of the inner mitochondrial membrane – noxious stimuli such as ROS 
or calcium overload of the mitochondrial matrix triggering opening of the mPTP, 
resultant dissipation of the proton electrochemical gradient that is fundamental to 
mitochondrial function, and subsequent depletion of ATP and further ROS production, 
culminating in mitochondrial swelling and rupture (Baines, 2009). In addition, opening 
of the mPTP (which has been shown to remain closed during ischaemia in the isolated 
rat heart) facilitates release of cytochrome c and other pro-apoptotic factors that can 
cause cardiomyocyte death (Piot et al., 2008). Importantly, there is a low level of ROS 
production by mitochondria under normal physiological conditions, during oxidative 
phosphorylation, but damage to cells is prevented by enzymes such as mitochondrial 
and sarcoplasmic superoxide dismutases: however, the marked increase in ROS 
production upon reperfusion overwhelms the cell’s innate protective mechanisms to 
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remove excess ROS, thereby causing damage to protein, lipid and mitochondrial DNA 
(Solaini and Harris, 2005). 
 
1.2.4. Protection against I/R injury 
A wide variety of pharmacological agents have been shown to protect against I/R injury 
following myocardial ischaemia in experimental studies, including anti-apoptotic 
agents, oxygen free radical scavengers, antioxidants, Ca
2+
 antagonists, inhibitors of 
neutrophil recruitment, inhibitors of the Na
+
/H
+
 exchanger; as well as NO and also a 
number of agonists for G-protein-coupled receptors (GPCRs) including adenosine-
related agents and BK [refer to Wang et al., (2002) for review]. In the clinical setting, 
protection against reperfusion injury is the prime concern, since reperfusion is usually 
achieved via clinical intervention thereby offering an opportunity to administer 
pharmacological protection against reperfusion injury either before, at the time of, or 
just after, reperfusion. In contrast, myocardial ischaemia usually occurs without 
warning, and is ‘silent’, occurring without symptoms such as angina, which can serve as 
a warning that the heart is experiencing stress or damage (Gutterman, 2009). 
 
Pharmacological agents that have been evaluated in clinical trials include inhibitors of 
Na
+
/H
+
 exchange, adenosine, statins, NO donors, glucose/insulin regimens and the anti-
anginal drug trimetazidine, with generally negative or conflicting results (Rodriguez-
Sinovas et al., 2007). For example, whilst results from a small clinical trial (100 
patients) showed that the Na
+
/H
+
 exchange inhibitor cariporide administered before 
reperfusion following acute anterior myocardial infarction reduced myocardial injury 
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and improved global and regional left ventricular (LV) function (Rupprecht et al., 
2000), in a larger-scale clinical trial (959 patients), the Na
+
/H
+ 
exchange inhibitor 
eniporide administered before reperfusion following acute myocardial infarction failed 
to reduce myocardial injury or improve clinical outcome (Zeymer et al., 2001). 
Similarly, in a large-scale clinical trial (11590 patients) with cariporide, the Na
+
/H
+
 
exchange inhibitor failed to show any significant benefit, compared to a placebo, when 
assessed for its ability to protect against myocardial infarction – although the results 
suggested that in I/R, high doses of the drug may reduce infarct size and protect LV 
function (Theroux et al., 2000). When tested in 608 patients with acute myocardial 
infarction, low-dose adenosine administered at the time of thrombolysis did not 
significantly improve LV function when assessed at the time of hospital discharge, 
although both cardiovascular and all cause mortality appeared to be reduced over a 12-
month period (Quintana et al., 2003). The results from a study of 2118 patients with ST-
segment elevation myocardial infarction were similarly disappointing, and whilst infarct 
size was reduced, no significant benefits were seen with adenosine compared to placebo 
in terms of new congestive heart failure or death from any cause within 6 months (Ross 
et al., 2005). Likewise, despite promising results from experimental studies using 
trimetazidine (an inhibitor of fatty acid oxidation), in a large-scale clinical trial of 19725 
patients with acute myocardial infarction, no overall reduction in mortality was 
observed in patients treated with trimetazidine compared to placebo – mortality actually 
increasing in thrombolysed patients whilst decreasing in non-thrombolysed patients 
(EMIP-FR-GROUP, 2000). However, one group of drugs that generally have positive 
effects following percutaneous coronary intervention or coronary artery bypass graft 
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surgery, if administered pre-procedurally, is statins – which reduce the incidence of 
myocardial infarction (Briguori et al., 2004, Penning-van Beest et al., 2007) and 
reperfusion injury (Collard et al., 2006, Mulukutla et al., 2004, Pasceri et al., 2004), and 
increase epicardial perfusion (Ishii et al., 2006). 
 
Currently, the mPTP is a popular choice of potential target for pharmacological agents 
aimed at treating myocardial infarction (Baines, 2009). Inhibition of the mPTP by 
cyclosporin A has been previously shown to offer protection against myocardial 
reperfusion injury in isolated rat hearts (Di Lisa et al., 2001); and in newborn piglets, 
cyclosporin A prevents reperfusion-induced changes in mitochondrial metabolism that 
trigger apoptosis (Oka et al., 2008). Interestingly, there is promising preliminary data to 
suggest that cyclosporin A may offer protection against reperfusion injury in a clinical 
setting: in a recent pilot study, patients with acute myocardial infarction who received 
cyclosporin A before undergoing percutaneous coronary intervention, had smaller 
infarcts than those who received a placebo (Piot et al., 2008). 
 
This finding by Piot and co-workers is particularly encouraging, as in many cases, 
pharmacological agents that offer cardioprotection in an experimental setting 
subsequently fail to show cardioprotection in the clinical setting. For example, as 
mentioned above, results from clinical trials with inhibitors of the Na
+
/H
+
 exchanger 
have been disappointing, despite these drugs offering cardioprotection in animal 
models. One possible explanation for this discrepancy is that in animal studies, 
cardioprotection occurred mainly during the period of ischaemia, whereas in clinical 
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trials, logistically Na
+
/H
+
 inhibitors could only be administered at the time of 
reperfusion, which occurred between 3.1 and 3.8 hours after symptoms of acute 
myocardial infarction were reported (Rodriguez-Sinovas et al., 2007). These figures are 
well over the target 90 minute to 2 hour window for effective reperfusion and optimal 
salvage of ischaemic myocardium (Buja and Weerasinghe, 2008). Indeed, although 
confounding factors such as co-morbid conditions in patients can reduce the efficacy of 
apparently cardioprotective pre-clinical treatments when applied to the clinical setting, 
the main problem for clinicians is the length of time between the onset of ischaemia and 
reperfusion of the occluded coronary vessel - which in the majority of clinical trials has 
been in excess of 2 hours and may result in too great an extent of ischaemic injury for 
treatment at reperfusion to be of significant benefit (Dirksen et al., 2007). 
 
1.3. The PLA2/AA cascade and LOX-derived eicosanoids 
An observation fundamental to the hypotheses proposed in this thesis (see section 1.6) 
is the finding, by Chien and co-workers, that the PLA2/AA cascade (whereby AA is 
generated from membrane phospholipids via activation of PLA2) is up-regulated in 
myocardial ischaemia, as evidenced by increased levels of AA measured in canine 
myocardium (Chien et al., 1984). AA metabolism is facilitated by three main classes of 
enzymes – LOX, cyclooxygenase (COX) and cytochrome P-450 (CYP) enzymes – the 
resulting products being collectively known as eicosanoids. An additional non-
enzymatic oxidative pathway yields isoprostanes (Feinmark, 2007). Although the 
precise mechanism underlying the release of eicosanoids by the heart in response to I/R 
is unknown, eicosanoid production in ischaemic tissue has been recognised for over a 
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quarter of a century (Vane, 1983). The pathways involved in AA metabolism are 
summarised in Figure 1.2, showing the LOX pathway in most detail. 
 
Figure 1.2. Simplified scheme of the pathways involved in AA metabolism. The LOX 
pathway is highlighted in red. Chemical structures of the LOX-derived eicosanoids 12-HpETE 
and 12-hydroxyeicosatetraenoic acid (12-HETE) are also shown. AA is metabolised via CYP, 
LOX and COX enzymes yielding epoxyeicosatrienoic acids (EETs) or 
dihydroxyeicosatetraenoic acids (DiHETEs), numerous HpETEs, hydroxyeicosatetraenoic acids 
(HETEs) and LTs, or PGs and thromboxane A2 (TXA2), respectively. 
 
Lipoxygenases are peroxidising enzymes which catalyse the dioxygenation of free 
and/or esterified polyunsaturated fatty acids to their corresponding hydroperoxy 
derivatives; and in addition to their role in eicosanoid production, they are involved in a 
number of other processes including cell maturation and atherogenesis (Meruvu et al., 
2005). As indicated in Figure 1.2, there are four different subtypes of LOX, 5-, 8-, 12- 
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and 15-LOX, named according to the position of the carbon atom along the AA 
molecule where oxygenation occurs (Yamamoto et al., 1997). Each LOX produces a 
stereo-specific HpETE, which is highly unstable and rapidly undergoes spontaneous 
non-enzymatic degradation to form the corresponding HETE (Luo et al., 2006). In some 
cases, a mixture of products is formed by a particular LOX, with the relative 
proportions possibly varying among species: where one product predominates, the 
enzyme is named according to the oxygenation site of the major product (Brash, 1999). 
A further complexity of this pathway is the existence of more than one LOX of a 
particular subtype in a species, but in this case the enzyme is named according to the 
cells from which it was originally isolated – platelet, leukocyte or epidermis (Gabel et 
al., 2001). In humans, a total of six functional LOX genes have been identified; 5-LOX, 
platelet 12-LOX, 12/15-LOX, 12(R)-LOX, 15-LOX2 and epidermal LOX3 (Kuhn et al., 
2007). 
 
Of particular interest is the 12-LOX pathway, which is stimulated via hypoxic or 
ischaemic stress (Andersson et al., 2006, Bernaudin et al., 2002, Preston et al., 2006), 
and has been suggested to be involved in the cardioprotective effects of ischaemic 
preconditioning (IPC; a phenomenon related to the aforementioned postconditioning, 
whereby repeated, brief, sub-lethal periods of ischaemia can offer protection against a 
subsequent, prolonged ischaemic episode) (Chen et al., 1999, Gabel et al., 2001, Patel et 
al., 2003, Tsutsumi et al., 2006). Both 12(S)-HETE (Murphy et al., 1995) and 12(S)-
HpETE (Chen et al., 1999) have been implicated as mediators of IPC, and a number of 
different biological effects of these metabolites have been proposed to underlie their 
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protective action. The protective effects of LOX products against injury caused by I/R 
have been attributed by one group to their capacity to stimulate downstream pathways 
that ultimately inhibit Ca
2+
 channels and thereby attenuate the rise in intracellular free 
Ca
2+
 associated with a prolonged ischaemic episode (Murphy et al., 1995). As 
mentioned in sections 1.2.1 and 1.2.2, calcium overload has been proposed as one of the 
main hypotheses to explain the pathogenesis of myocardial injury resulting from 
ischaemia and reperfusion, occurring in both endothelial cells (Ladilov et al., 2000) and 
myocytes. Thus prevention of Ca
2+
 movements that may otherwise cause calcium 
overload during ischaemia, and/or reperfusion, may offer some protection against cell 
injury and death (Dirksen et al., 2007). Indeed, pharmacological agents that block Ca
2+
 
channels to prevent Ca
2+
 entry into the cytoplasm and uptake into mitochondria are 
amongst those that have been reported to be cardioprotective in an experimental setting 
(Solaini and Harris, 2005); however, results from clinical trials with Ca
2+
 channel 
blockers have been inconclusive (Dirksen et al., 2007). 
 
Cardioprotection has also been demonstrated by pharmacological agents that cause 
vasodilatation, which may counteract injury sustained by the coronary vasculature and 
the associated reduced coronary flow (Strande et al., 2009). For example, use of the 
selective serotonin reuptake inhibitor sertraline, which was originally developed as an 
antidepressant, has been linked to a reduced likelihood of myocardial infarction in 
patients – which, in addition to the reported antiplatelet and endothelium-protective 
properties, may be attributed to the coronary vasodilator actions of sertraline (van Melle 
et al., 2004). The flavonoid catechin (a major component of red wine) is also 
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cardioprotective, and there is evidence to suggest that in addition to acting as a 
scavenger of oxygen-derived free radicals, catechin may exert its cardioprotective 
effects via its vasodilator actions (Modun et al., 2003). It is possible that similarly, the 
vasodilator actions of LOX metabolites underlie their reported cardioprotective effects – 
although it is important to note that in the rat model of global ischaemia used in the 
experiments included in this thesis, this may be less likely due to the absence of 
recruitable coronary collateral vessels. The presence of collateral vessels in the coronary 
circulation has been identified as an important factor in the therapeutic value of 
vasodilator drugs – an increase in collateral flow to areas of ischaemic myocardium 
underlying any therapeutic benefit observed (Fam and McGregor, 1964). The 
vasodilator actions of AA have been attributed to 12-LOX metabolites (Miller et al., 
2003, Nishiyama et al., 1998, Zink et al., 2001), and both 12(S)-HpETE and 12(S)-
HETE are potent vasodilators of coronary microvessels in the pig, possibly contributing 
to endothelium-dependent dilatation of the coronary microvasculature (Zink et al., 
2001). 12-LOX metabolites also cause vasodilatation of large cerebral (Faraci et al., 
2001) and small mesenteric (Miller et al., 2003, Zhou et al., 2005) arteries in the rat, and 
also the rat and rabbit stomach (Salvati and Whittle, 1981). Mechanistically, the 
vasodilator effects of 12(S)-HETE and 12(S)-HpETE have been attributed to activation 
of Ca
2+
-dependent K
+
 channels in rat basilar and small mesenteric arteries, where the 
non-selective K
+
 channel blocker tetraethylammonium and the large conductance Ca
2+
-
dependent K
+
 channel blocker, iberiotoxin, markedly inhibited AA-induced 
vasodilatation (Faraci et al., 2001, Miller et al., 2003). Ca
2+
-dependent K
+
 channels have 
 
Chapter 1: Introduction 
 
 
 
 
56 
 
also been implicated in 12(S)-HETE-induced vasodilatation of the porcine coronary 
microcirculation (Zink et al., 2001). 
 
An alternative or additional pathway of LOX product-mediated vasodilatation has been 
implicated, whereby LOX-derived eicosanoids activate TRPV1 located on sensory C-
fibres (see section 1.4). In a series of experiments using isolated rat hearts perfused in 
the Langendorff mode, McLean and co-workers demonstrated that TRPV1, located on 
sensory C-fibres, is involved in endothelium-dependent vasodilatation in response to 
protease-activated receptor-2 (PAR2) activation. The authors suggested that since this 
vasodilatation was not sensitive to inhibitors of NO, or prostanoid generation, but was 
inhibited by the non-selective LOX inhibitors nordihydroguaiaretic acid (NDGA) and 
eicosatetraynoic acid, and also by the selective 12-LOX inhibitor baicalein, the 
vasodilator response was mediated by a LOX-derived eicosanoid (McLean et al., 2002). 
Interestingly, AA metabolites have been proposed as the endogenous ligands for 
TRPV1, with 12(S)-HpETE being the most potent of these (Hwang et al., 2000). 12-
LOX messenger ribonucleic acid (mRNA) is co-expressed with TRPV1 in neurones of 
rat dorsal root ganglia (DRG) (Shin et al., 2002), one of three locations for the cell 
bodies of sensory neurones (Caterina and Julius, 2001). Such close proximity supports 
the thesis that a 12-LOX metabolite, such as 12(S)-HpETE, could be an endogenous 
activator of this channel. Indeed, recent evidence indicates that 12(S)-HpETE, 
functioning as an agonist of TRPV1, mediates interaction between TRPV1 and 
cannabinoid type 1 (CB1) receptors in rat mesencephalic neurones, facilitating the 
neurotoxic effects of some CB1 receptor agonists (Kim et al., 2008c), and that 12(S)-
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HpETE causes microglial damage in the substantia nigra, via activation of TRPV1 (Kim 
et al., 2006). 
 
1.4. Sensory C-fibres 
Based upon anatomical and functional criteria, there are three main types of primary 
afferent neurones – Aα-/Aβ-, Aδ- and C-fibres (Chuang et al., 2001). Slowly conducting 
C-fibres have small diameter cell bodies, unmyelinated axons, and are principally 
responsible for responding to noxious stimuli, although some faster conducting Aδ-
fibres (which have medium diameter cell bodies and thinly myelinated axons) are also 
involved in the transmission of pain (Caterina and Julius, 1999). Primary afferent 
neurones with the largest diameter cell bodies have rapidly conducting, myelinated 
axons, and these Aβ-fibres usually respond to stimuli such as pressure and touch, 
without causing pain (Chuang et al., 2001). Those C-fibres and Aδ-fibres which respond 
to noxious stimuli are known as ‘nociceptors’, and may be classified according to the 
type of stimulus to which they respond – mechanical, chemical and thermal – although 
some respond to all three and are known as polymodal nociceptors (Caterina and Julius, 
1999). Those nociceptors that are sensitive to capsaicin, that is, which express TRPV1, 
are mainly C-fibres (Caterina and Julius, 2001). 
 
Nociceptive C-fibres, like most other primary afferent neurones, have their cell bodies 
located in one of three locations: (a) DRG, which innervate the trunk, limbs and viscera 
and which project centrally to the dorsal horn of the spinal cord, (b) trigeminal ganglia, 
which innervate the head, neck and oral cavity and which project centrally to the 
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trigeminal nucleus within the brainstem, and (c) nodose ganglia, which innervate the 
viscera and which project centrally to the floor of the fourth ventricle (Caterina and 
Julius, 2001). Of those C-fibres that have their cell bodies within the DRG, they may be 
further classified into two main groups according to neurochemical and anatomical 
differences: (1) peptidergic nociceptors, expressing nociceptive peptides such as 
calcitonin gene-related peptide (CGRP) and substance P (SP), which are dependent on 
the neurotrophic factor nerve growth factor (NGF), and which express the NGF receptor 
tyrosine kinase receptor A (TrkA) and which project to lamina I and lamina II outer of 
the dorsal horn; and (2) non-peptidergic nociceptors, which are dependent on the glial 
cell line-derived neurotrophic factor (GDNF) and which express the GDNF receptor 
tyrosine kinase Ret, bind isolectin B4, and which project to inner lamina II in the dorsal 
horn (Snider and McMahon, 1998). 
 
Nociceptors thus consist of a cell body, and an axon which bifurcates into a peripheral 
branch (which innervates target tissue in the periphery and which transduces noxious 
stimuli within the periphery) and a central branch (which conveys information to second 
order neurones at central synapses within the central nervous system [CNS] and which 
conveys action potentials from the periphery to the CNS) (Woolf and Ma, 2007). 
Activation of ion channels within the plasma membrane of peripheral nerve terminals in 
response to noxious stimuli leads to depolarisation of the peripheral terminal and 
activation of voltage-gated Na
+
 channels, thereby generating an action potential that is 
transmitted to the central terminal of the axon, where depolarisation results in Ca
2+
 
influx via voltage-gated Ca
2+
 channels, and release of transmitters and/or modulators 
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such as the amino acid neurotransmitter glutamate, and neuropeptide transmitters SP 
and CGRP, ultimately leading to a conscious awareness of pain (Woolf and Ma, 2007). 
In addition to propagation of action potentials to the CNS, action potentials may be 
conveyed antidromically along an axon side branch, and cause depolarisation of the 
peripheral terminal of the side branch, and Ca
2+
-mediated release of neuropeptide 
transmitters such as CGRP and SP that cause vasodilatation of nearby blood vessels – 
this so-called sensory axon reflex mediating the ‘flare’ component of the Lewis triple 
response (Levick, 2003). As illustrated in Figure 1.3, activation of capsaicin-sensitive 
(i.e. TRPV1 positive) neurones may thus lead to local, ‘sensory-efferent’ effects as well 
as central effects (Kark et al., 2008). 
 
Figure 1.3. Schematic illustration of the functional anatomy of capsaicin-sensitive 
neurones. The pathway of CGRP synthesis, release and peripheral action is indicated. CGRP is 
a very potent vasodilator, and although it may be co-expressed with other neuropeptides, it is 
the predominant neurotransmitter in capsaicin-sensitive sensory nerves. Activation of TRPV1 
located at the peripheral nerve terminal results in depolarisation of the nerve and release of 
CGRP, which acts via CGRP receptors [formerly called CGRP1 receptors (Hay et al., 2008)] 
located on blood vessels to cause vasodilatation. 
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Nociceptors are present in nearly all body tissues - including the heart and blood 
vessels, which are densely innervated by primary afferents expressing receptors that 
respond to noxious chemical, mechanical and thermal stimuli (Premkumar and 
Raisinghani, 2006). As shown in Figure 1.4, the heart is innervated by sympathetic and 
parasympathetic fibres. The cell bodies of axons of cardiac sensory neurones exiting the 
heart via sympathetic cardiac nerves are situated in the lower cervical (C8) and upper 
thoracic (T1-T3) DRG, whilst those of axons that exit the heart via the vagus nerve are 
situated in the nodose ganglia; and the axons of neurones innervating the pericardium 
follow the phrenic nerves to their cell bodies within the DRG of the upper cervical 
ganglion (C3-C5) (Benson et al., 1999). Afferent fibres within the heart possess diffuse 
or compact branched sensory nerve endings that are mainly located in the epicardium, 
particularly those of sympathetic afferent fibres, whereas it appears that the myocardium 
does not contain sensory endings, but rather that mixed nerves comprising both 
myelinated and unmyelinated fibres form bundles that are traced through the connective 
tissues of the septa between the cardiac muscles (Foreman, 1999). 
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Figure 1.4. Sensory innervation of the heart and pericardium. The myocardium is 
innervated by sympathetic primary afferent fibres that follow the sympathetic efferent cardiac 
nerves, via the sympathetic ganglia (middle cervical ganglion [MCG], inferior cervical and 
upper thoracic ganglia) back to their cell bodies, located in the lower cervical (C8) and upper 
thoracic (T1-T3) DRG. Parasympathetic afferent fibres innervating the heart follow the vagus 
nerve back to their cell bodies in the nodose ganglia. Afferent fibres which innervate the 
pericardium follow the phrenic nerve back to their cell bodies that are located in the upper 
cervical (C3-C5) DRG. Modified from Benson et al. (1999), p922. 
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An inherent characteristic of nociceptors is their plasticity. Under normal conditions, 
nociceptive C-fibres are only activated by noxious stimuli; however, in response to 
tissue damage and inflammation, for example as a result of ischaemia, chemical 
mediators such as BK are released that sensitise nociceptors, potentiating their 
activation so that previously innocuous stimuli are perceived as noxious, or previously 
noxious stimuli now produce a prolonged or exaggerated response (Woolf and Ma, 
2007). Some so-called ‘silent’ nociceptors only become responsive after chemical and 
inflammatory mediators such as BK and prostaglandin E2 (PGE2) have been released 
(Bueno and Fioramonti, 2002), and there is evidence suggesting that in the heart, 
recruitment of silent nociceptors may provide additional, discriminative input to the 
central nervous system, such as location, intensity and duration of ischaemia (Pan and 
Chen, 2002). Sensitising stimuli may act via GPCRs, ligand-gated ion channels or 
tyrosine kinase receptors in the peripheral terminal of C-fibres, to trigger signalling 
cascades within the axon terminal that ultimately leads to sensitisation (McMahon and 
Jones, 2004). C-fibres are also subject to central sensitisation, whereby the transmission 
of noxious stimuli to the CNS may be modified at the central terminal of axons within 
the spinal cord (Dickenson, 1997). At least three mechanisms of central sensitisation 
have been identified, which all implicate a role for the N-methyl-D-aspartate receptor 
for glutamate (present in post-synaptic membranes) in the enhanced response to noxious 
stimuli (McMahon and Jones, 2004). 
 
As previously alluded to, capsaicin-sensitive (i.e. TRPV1 positive) neurones serve both 
afferent and efferent functions: in addition to transduction and transmission of noxious 
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stimuli from the periphery to the CNS, activation of transducer ion channels within the 
peripheral terminal can also result in the release of neuropeptides from the peripheral 
terminal, thereby mediating an efferent function. In addition to SP and CGRP, at least 
10 different neuropeptide transmitters have been identified that are released from the 
peripheral terminals of capsaicin-sensitive (i.e. TRPV1 positive) neurones, including 
neurokinin A (NKA), neuropeptide K, eledoisin-like peptide, somatostatin, vasoactive 
intestinal polypeptide, cholecystokinin-octapeptide, galanin, corticotrophin-releasing 
factor, arginine vasopressin, and bombesin-like peptides (Wang, 2008). Peripheral 
release of neuropeptides may occur via three routes: (1) direct activation of the 
peripheral terminal, (2) activation of a collateral peripheral terminal of the same 
nociceptor, via an axon-reflex, and (3) retrograde activation of a capsaicin-sensitive 
neurone via an antidromic electrical stimulus (Caterina and Julius, 2001). Indeed, it is 
via release of CGRP and also NO from their peripheral terminals, that capsaicin-
sensitive (i.e. TRPV1-expressing) fibres are thought to exert their cardioprotective 
effects (Nagy et al., 2004). The actions of NO believed to underlie its cardioprotective 
effects include a direct vasodilator effect (maintaining coronary perfusion), inhibition of 
platelet aggregation (thereby decreasing no-reflow), inhibition of leukocyte adherence 
to endothelium and subsequent infiltration (reduced production of ROS and ROS-
induced tissue damage), increased KATP channel opening and reduced mitochondrial 
Ca
2+
-uptake (reduced mitochondrial calcium overload) and increased cardiomyocyte 
function (increased contractile function and relaxation) (Schulz et al., 2004). There is 
also evidence to suggest that NO can protect against reperfusion-induced arrhythmias – 
although this action may be species-dependent: whilst NO was found to be 
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cardioprotective in isolated rat hearts (Pabla and Curtis, 1995), in isolated primate 
hearts, NO failed to protect against reperfusion-induced VF (Pabla and Curtis, 2007). 
 
Similarly, CGRP-mediated cardioprotection has been proposed to involve multiple 
mechanisms, including enhanced coronary perfusion as a result of coronary 
vasodilatation (Huang et al., 2008). Whilst vasodilatation in response to CGRP has been 
proposed to increase the number of neutrophils (amongst other circulating cells) and the 
supply of chemotactic compounds to an area of inflammation, the direct effect of CGRP 
on neutrophils may be inhibitory (Brain and Grant, 2004). There is also evidence to 
suggest that CGRP exerts its cardioprotective effects via inhibition of oxidative stress – 
for example, CGRP has been shown to protect against apoptosis induced by oxidative 
stress in rat vascular smooth muscle cells (Schaeffer et al., 2003) and rat 
cardiomyocytes (Sueur et al., 2005). Using isolated murine hearts, Huang and co-
workers have recently demonstrated that in hearts from CGRP knockout (KO) mice, 
levels of markers of oxidative stress were significantly elevated compared to their wild-
type (WT) counterparts following I/R injury (Huang et al., 2008), offering further 
support for CGRP protecting against oxidative stress. In addition, CGRP-mediated 
cardioprotection has been associated with inhibition of production of cardiac TNFα 
(Peng et al., 2000), inhibition of proliferation of aortic and pulmonary artery smooth 
muscle cells (Chattergoon et al., 2005), and preservation of endothelial function (Tang 
et al., 1997, Ye et al., 2007). 
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1.5. TRPV1 
1.5.1. TRPV1 structure, function and distribution 
TRPV1 was the first member of the vanilloid family of transient receptor potential 
(TRP) ion channels to be cloned (Caterina et al., 1997). A further five family members 
have since been identified (Moran et al., 2004, Pedersen et al., 2005, Ramsey et al., 
2006). TRPV1, like all TRP proteins, shares a tertiary structure similar to that of the 
voltage-gated K
+
 channel (KV) – comprising six membrane-spanning domains, (S)1-6, 
and intracellular N- (amino)- and C- (carboxyl)- terminals (see Figure 1.5). KV channels 
are formed of four such 6-transmembrane monomers, and it would appear that this is the 
same for TRP channels also - the loop between S5 and S6 of each subunit forming the 
lining of the channel pore, along with the S5-S6 linker of the four subunits (Bandell et 
al., 2007). Furthermore, a specific domain within the C-terminus of the TRPV1 protein 
comprising glutamic acid (Glu) residue 684 to arginine (Arg) residue 721 (referred to as 
the ‘TRP-like domain’) has been implicated in the tetramerisation of monomers into 
functional channels (Garcia-Sanz et al., 2004). Evidence suggests that subunits tend to 
preferentially homo-associate, and in some cases hetero-associate (Bai et al., 2008, 
Guinamard and Bois, 2007, Hellwig et al., 2005, Watanabe et al., 2008). Contrary to the 
long-held tenet that TRP channels were voltage independent, evidence now suggests 
that some family members, including TRPV1, exhibit a weak voltage dependence 
(Nilius et al., 2005) – a further likeness to KV channels. 
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Figure 1.5. The predicted membrane topology of TRP channel subunits. Note the pore-
lining loop (‘P-loop’) between S5 and S6. The length of the intracellular N- and C-terminal tails 
varies considerably among family members, as does the number of ankyrin binding domains 
(coloured red) located in the N-terminus – for example, TRPV channels possess three to four 
ankyrin binding domains whilst members of the melastatin family of TRP channels do not have 
any (Montell et al., 2002). 
 
TRPV1 was identified during the search for a molecular target for two plant toxins – 
capsaicin, the pungent ingredient of hot chilli peppers (Capsicum sp.), and its 
ultrapotent analogue, resinferatoxin (RTX, from Euphorbia sp.) – both compounds 
termed vanilloids due to the presence of a 4-hydroxy-3-methoxybenzyl (i.e. vanillyl) 
moiety (Szallasi and Appendino, 2004). Indeed, it was because of this vanillyl moiety 
that, after the expression cloning of TRPV1 complementary DNA (cDNA), the receptor 
for capsaicin and RTX was initially named ‘vanilloid receptor subtype 1’ (Caterina et 
al., 1997). It is important to note at this point that capsaicin has two distinct actions: (1) 
short-term stimulation followed by desensitisation of responses to capsaicin or other 
stimuli, or at very high doses of capsaicin, long-term functional or morphological 
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ablation of C-fibres; (2) transient depression of cell excitability with no long-term 
effects; and that whilst the former action is highly selective for mammalian sensory C-
fibres and is mediated by activation of a cation channel within the cell membrane (now 
identified as TRPV1), the latter is not cell selective and is seen throughout the animal 
kingdom (Holzer, 1991). It is now well established that in addition to capsaicin and 
RTX, TRPV1 is activated by many other compounds, and the term ‘vanilloid receptor’ 
seems to be something of a misnomer. 
 
Indeed, TRPV1 is activated by a wide range of endogenous ligands (collectively known 
as ‘endovanilloids’), some of which, confusingly, do not contain a vanillyl moiety (Di 
Marzo, 2004), as highlighted in Figure 1.6. The first endovanilloid to be identified was 
the lipid mediator anandamide, an endocannabinoid (Zygmunt et al., 1999). A wide 
range of additional TRPV1 agonists has now been discovered, including gingerols 
(Dedov et al., 2002), hydroxy--sanshool (a derivative of Zanthoxylum piperitum or 
‘Szechuan pepper’) (Koo et al., 2007), lipids such as oleoylethanolamide (Wang et al., 
2005), and as already mentioned, certain LOX products of AA metabolism (Hwang et 
al., 2000). Since the potency and efficacy of some endovanilloids is somewhat low, it 
has been postulated that in pathological conditions, several TRPV1 activators may be 
released together and act in synergy (Nagy et al., 2004). Protons represent an additional 
chemical stimulus for TRPV1 - which is activated if extracellular pH falls below pH 6 
(Leffler et al., 2006). Interestingly, a recent publication reported that TRPV1 is also 
activated by alkaline pH – activation by ammonia and intracellular alkalisation 
involving an intracellular histidine (His) residue 378 (Dhaka et al., 2009). However, 
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TRPV1 does not only respond to chemical stimuli, but also physical stimuli such as 
mechanical stimuli (Inoue et al., 2009) and also heat, being activated by temperatures 
above a threshold of approximately 42°C (Caterina, 2007). 
 
Figure 1.6. Chemical structures of examples of endovanilloids. Note the vanillyl moiety 
(highlighted blue) present in capsaicin and [8]-gingerol, but absent from anandamide and 
oleoylethanolamide. 
 
Interestingly, whilst protons directly activate TRPV1 receptors at pH <6, mildly acidic 
conditions potentiate activation of TRPV1 by noxious heat and vanilloids (Benham et 
al., 2002, Caterina and Julius, 2001, Szallasi and Blumberg, 1999). Likewise, whilst 
TRPV1 is directly activated by temperatures in excess of 42C, slight warming above 
room temperature potentiates the response of TRPV1 to chemical agonists (Caterina, 
2007), and vanilloids appear to reduce the threshold for heat activation of TRPV1 from 
noxious to physiological temperatures; indeed, TRPV1 is widely regarded as an 
integrator, as well as simply a detector, of physical and chemical noxious stimuli 
(Caterina and Julius, 2001). Furthermore, evidence suggests that activation by ligands 
such as capsaicin, or by temperatures in excess of 42ºC, shifts the voltage dependency 
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of TRPV1 to physiologically relevant potentials, and that the temperature sensitivity of 
TRPV1 is modified by changes in membrane potential (Nilius et al., 2005). 
 
Activators of TRPV1 thus fall into one of three categories according to their mode of 
activation, which may be (1) direct, as in the case of thermal and mechanical stimuli, (2) 
ligand-induced, which involves a conformational change in the receptor upon binding of 
endogenous or exogenous agonists, thereby opening the channel pore, and (3) receptor-
induced (Ramsey et al., 2006). The latter involves activation of a GPCR or receptor 
tyrosine kinase which activates phospholipase C (PLC), resulting in hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol-1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG), which can modulate TRPV1 function as mentioned in section 
1.5.2. Recent evidence suggests that DAG may even directly activate TRPV1 under 
physiological conditions (Woo et al., 2008). 
 
TRPV1 is expressed by capsaicin-sensitive primary afferent neurones, that is, C-fibres 
and to a lesser extent, A-fibres (Ma, 2002); primarily within the DRG, as well as the 
trigeminal and nodose ganglia (Caterina et al., 1997). Indeed, in adult rats, 58 ± 2% of 
DRG neurones have been identified as TRPV1-positive by immunospecific staining 
(Guo et al., 2001), although values as low as 32% have been detected in some studies 
(Carlton and Hargett, 2002, Hwang et al., 2005). TRPV1 is expressed both by C-fibres 
that express the TrkA receptor for NGF and which are peptidergic, as well as by non-
peptidergic C-fibres that are TrkA negative (Kobayashi et al., 2005). Primary afferent 
neurones and their C- or Aδ-fibres innervate a wide variety of tissues, including 
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virtually all vascular beds (Funakoshi et al., 2006, Guo et al., 1999, Kobayashi et al., 
2005, Ma, 2002, Michael and Priestley, 1999). Evidence suggests that TRPV1 
activation can result in opposing effects in different vascular beds – for example, Kark 
and co-workers demonstrated that intra-arterial administration of capsaicin to the 
isolated perfused right hind limb of the rat caused vasodilatation in the skin but 
vasoconstriction in skeletal muscle (Kark et al., 2008). Furthermore, the authors 
proposed that TRPV1 activation in the skin caused vasodilatation via an NO- and 
endothelium-dependent mechanism following neuronal stimulation and release of 
vasoactive neuropeptides, whilst vasoconstriction in skeletal muscle was a direct result 
of increased intracellular Ca
2+
 in smooth muscle cells due to opening of the TRPV1 
channel pore within the sarcolemma; and that the balance between the activities of these 
two pathways dictates whether the effect of TRPV1 activation is vasodilatation or 
vasoconstriction (Kark et al., 2008). TRPV1 has also been identified in endothelial cells 
of rat mesenteric arteries (Poblete et al., 2005), and also smooth muscle cells of rat 
pulmonary arteries and aorta (Yang et al., 2006). 
 
TRPV1 immunoreactivity has been detected in the human bladder (Lazzeri et al., 2004), 
prostate gland (Dinis et al., 2005) and skin (including cutaneous sensory nerve fibres, 
mast cells, epidermal keratinocytes, dermal blood vessels and sweat gland ducts, 
amongst other compartments) (Stander et al., 2004), where it is likely that it plays a role 
in sensory (mainly nociceptive) processes. TRPV1 has also been identified in human 
lung, where it appears to play a role in particulate matter-induced apoptosis via 
sustained Ca
2+
 entry into airway epithelial cells (Agopyan et al., 2004). Interestingly, 
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TRPV1 agonists and antagonists such as capsaicin and capsazepine, respectively, are 
inhibitors of mitochondrial function, and it has been suggested that it is via non-TRPV1 
receptor mechanisms that they cause cell death (Athanasiou et al., 2007). Recently, 
TRPV1 expression has been reported in human peripheral lymphocytes (Saunders et al., 
2007), where its precise role remains to be determined. There is also evidence of 
TRPV1 immunoreactivity in several areas of the human brain, for example the 
trigeminal ganglion, where it is postulated to play a role in migraine (Hou et al., 2002); 
also the cortex, hippocampus, and cerebellum, suggesting that TRPV1 may be involved 
in processes extending beyond perception of noxious stimuli (Mezey et al., 2000). 
Indeed, functional TRPV1 receptors are also expressed on human cerebromicrovascular 
endothelial cells, where they, together with CB1 and CB2 (cannabinoid type 2) 
receptors, have been proposed to play a role in regulating cerebral blood flow and also 
permeability of the blood brain barrier (Golech et al., 2004). Whilst it was originally 
thought that TRPV1 was only expressed in the cell membrane, it is now known that 
these ion channels are also found on endoplasmic reticulum (Liu et al., 2003, Marshall 
et al., 2003) and within cytoplasmic vesicles (Ferrer-Montiel et al., 2004), where they 
appear to serve as a reserve that may be rapidly translocated to the cell membrane 
(Morenilla-Palao et al., 2004). 
 
Considering the involvement of TRPV1 in nociception, it is perhaps not particularly 
surprising that an increasing amount of evidence points to these channels being 
subjected to a number of interacting levels of control ranging from reversible 
phosphorylation to levels of gene expression (Cortright and Szallasi, 2004), which may 
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contribute to the plasticity that nociceptors demonstrate. Figure 1.7 overleaf shows the 
topological organisation of a TRPV1 channel subunit, highlighting the molecular 
determinants of TRPV1 properties, including residues critical for capsaicin binding (an 
intracellular site, involving tyrosine [Tyr] residue 511) and sensitivity to acidification 
(involving extracellular Glu 600 and Glu 648) (Ferrer-Montiel et al., 2004). As 
indicated in Figure 1.7, the RTX binding pocket is thought to involve methionine (Met) 
residue 547 in the S4 domain (Chou et al., 2004), and also Tyr 511 in the S3 domain 
(Tominaga and Tominaga, 2005). Ligand binding is additionally believed to involve 
Arg 114 and Glu 761 in the N- and C-cytosolic tails respectively (Jung et al., 2002). 
Also shown are amino acid residues important for interaction with protein kinases such 
as adenosine 3’,5’-cyclic monophosphate (cAMP)-dependent kinase (protein kinase A; 
PKA) and protein kinase C (PKC); as well as the TRP-like domain, thought to be a 
molecular determinant of the tetramerisation of the receptor (Garcia-Sanz et al., 2004). 
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Figure 1.7. Topical organisation of a TRPV1 channel subunit. Some of the specific regions 
and amino acids involved in TRPV1 function are shown. The N-terminus contains three akyrin 
binding domains, a site for phosphorylation by PKA and a binding site for calmodulin (CaM). 
The C-terminus also contains a binding site for CaM, as well as for PIP2, and also sites for 
phosphorylation by PKC and Ca
2+
/CaM-dependent kinase II (CaMK II). Numbers refer to those 
of the amino acid residues in the primary rat sequence. Modified from Tominaga and Tominaga 
(2005), p144. 
 
1.5.2. Modulation of TRPV1 activity 
Phosphorylation by protein kinases is thought to underlie sensitisation of TRPV1, and 
as such this phenomenon may therefore be regarded as being of the utmost importance 
with respect to modulation of channel activity. Two kinases that have been implicated 
in phosphorylation of TRPV1 are PKA and PKC. One amino acid residue that is 
responsible for PKA-dependent modulation of TRPV1 is serine (Ser) residue 116. 
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Phosphorylation of this residue appears to prevent desensitisation – entry of the receptor 
into the desensitised state only being permitted if Ser 116 is dephosphorylated (Bhave et 
al., 2002, Mohapatra and Nau, 2003). Desensitisation of TRPV1 describes the rapid loss 
of activity when an agonist such as capsaicin is bound, and is thought to involve an 
agonist-induced conformational change in protein structure that ultimately leads to 
closing of the channel pore (Szallasi and Blumberg, 1999). That TRPV1 desensitisation 
renders previously excited sensory neurones unresponsive to a wide range of unrelated 
stimuli, is of considerable therapeutic interest: indeed, capsaicin-containing creams are a 
well-established treatment for painful conditions such as diabetic neuropathy (Szallasi 
et al., 2006), and more recently, dermal patches have been developed containing 
capsaicin, such as the NGX-4010 patch which is effective against post-herpetic 
neuralgia (Wong and Gavva, 2009). In addition to regulating receptor desensitisation, 
PKA phosphorylation of TRPV1 also increases its sensitivity, for example to 
anandamide (Cortright and Szallasi, 2004). Activation of PKA occurs via cAMP – 
intracellular levels of which may be elevated by agents such as PGE2 (Lopshire and 
Nicol, 1998). A somewhat complex pathway has also been suggested involving 
modulation of TRPV1 in peripheral terminals of capsaicin-sensitive neurones by 
metabotropic glutamate receptor 5 (mGluR5), via PKA phosphorylation, to increase 
thermal sensitivity (Hu et al., 2002). Recent evidence suggests that a simpler signalling 
scheme operates at central terminals, whereby DAG produced by PLC-mediated 
hydrolysis of PIP2 in response to mGluR5 activation modulates presynaptic TRPV1 
directly, rather than by initiating a chain of signalling events (Kim et al., 2009). 
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PKC-dependent phosphorylation of TRPV1 also has significant effects on channel 
activity. There is evidence to suggest that re-phosphorylation by PKC reverses receptor 
desensitisation (Mandadi et al., 2004), and although phosphorylation by PKC does not 
directly activate TRPV1, it plays a major role in its sensitisation (Bhave et al., 2003). 
Activation of PKC potentiates gating of TRPV1 by capsaicin and protons (Crandall et 
al., 2002), and anandamide and heat (Vellani et al., 2001). It has been suggested that the 
mechanism for this involves direct phosphorylation of TRPV1 by PKC, and also the 
PLC-mediated hydrolysis of PIP2, a negative regulator of channel activity, which binds 
to the C-terminus of channel subunits (Cortright and Szallasi, 2004). Interestingly, PIP2, 
which, incidentally, generally increases the activity of ion channels (Suh and Hille, 
2005), has also been shown to function as a modulator of TRPV1 in its own right – 
depletion of PIP2 associated with TRPV1 activation, and re-synthesis of PIP2 facilitating 
recovery of the channel from desensitisation (Liu et al., 2005). Indeed, in agreement 
with the observation that PIP2 generally activates ion channels, more recent data 
obtained from experiments using excised membrane patches shows that PIP2 acts as an 
activator of TRPV1 at high concentrations of capsaicin (1 and 10 µM; i.e. high levels of 
stimulation) whilst at low concentrations (1 nM; i.e. low levels of stimulation) the effect 
of PIP2 on TRPV1 channel activity is partially inhibitory (Lukacs et al., 2007). It would 
thus appear that the reported effects of PIP2 on TRPV1 activity depend on the 
experimental conditions, and whether the interaction between lipid and receptor is 
direct, or whether it is indirect, in which case an additional cytoplasmic factor would be 
required, which will be absent in excised patches (Rohacs et al., 2008). 
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Activation of PKC has also been implicated in BK-induced sensitisation of nociceptors 
to heat (Cesare and McNaughton, 1996) - specifically, the PKC-ε isoform (Cesare et al., 
1999, Premkumar and Ahern, 2000, Sugiura et al., 2002). Two residues that have been 
shown to be targeted by PKC- are Ser 502 and Ser 800 (Numazaki et al., 2002). In 
addition, PKC potentiation of TRPV1 activity is, in part, dependent upon PKC-
stimulated delivery of vesicular channels to the cell surface by exocytosis, and such 
mobilisation of stored channels may contribute to sensitisation (Morenilla-Palao et al., 
2004). Indeed, the potentiation of TRPV1-mediated membrane currents by insulin and 
insulin-like growth factors has been, in part, attributed to PKC-dependent translocation 
of TRPV1 from the cytosol to plasma membrane (Van Buren et al., 2005). Similarly, 
sensitisation of TRPV1 by NGF is largely due to phosphorylation followed by insertion 
of channels into the plasma membrane (Zhang et al., 2005). 
 
Additional modulators of TRPV1 activity have been identified, including the 
nonreceptor cellular tyrosine kinase, c-Src kinase (Jin et al., 2004), and splice variants 
of the rat (Tian et al., 2006) and murine (Wang et al., 2004a) TRPV1. The Ca
2+
-binding 
protein CaM binds to a 35-amino acid region of the C-terminus of TRPV1 (Numazaki et 
al., 2003), and it appears that Ca
2+
/CaM regulates TRPV1 desensitisation, decreasing 
the capsaicin-activated current (Rosenbaum et al., 2004). Importantly, it has also been 
demonstrated that TRPV1 must be phosphorylated by CaMK II in order that it can be 
activated by vanilloids such as capsaicin (Jung et al., 2004). Perhaps of particular 
relevance to this thesis is the finding that the lipid oleoylethanolamide both activates 
and modulates activity of TRPV1 by phosphorylation of Ser 502 and Ser 800 (Ahern, 
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2003). As shown in Figure 1.7, Ser 502 is a site phosphorylated by PKA, PKC and also 
CaMK II, thus apparently serving as a key site for TRPV1 regulation. Recently, TRPV1 
activity has been shown to be positively regulated by a membrane protein named Pirt 
(‘phosphoinositide interacting regulator of TRP’), which strongly potentiates TRPV1-
mediated currents when additionally bound to phosphoinositides such as PIP2 (Kim et 
al., 2008a). 
 
Whilst relatively short-term increases in sensitivity to TRPV1-mediated nociception 
may be achieved via modulation of channel gating as a result of direct phosphorylation, 
or by rapid exocytosis of intracellular stores of TRPV1 channels, longer-term increases 
may be achieved via increased biosynthesis of TRPV1 channels in afferent terminals 
(Tohda et al., 2001) and by increased gene expression, for example, in heat hyperalgesia 
(Amaya et al., 2003) and gastrointestinal inflammation (Geppetti and Trevisani, 2004). 
Indeed, it has been recently demonstrated that PKC is involved in the up-regulation of 
TRPV1 mRNA levels and protein expression in neurogenic inflammation (Xu et al., 
2009). 
 
1.5.3. TRPV1 in the cardiovascular system 
Immunohistochemical studies indicate that capsaicin-sensitive peptidergic neurones are 
expressed throughout the cardiovascular system (Rubino and Burnstock, 1996). As 
mentioned in section 1.4, at least 10 different peptides have been identified which are 
released from TRPV1-expressing neurones, including SP, CGRP and NKA (Wang, 
2008). These primary afferent neurones are either lightly myelinated Aδ-fibres (Ma, 
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2002) or unmyelinated C-fibres, and their principal function is to convey information 
about nociceptive stimuli to the CNS, which may either transmit this information to 
higher centres in the brain, or trigger dorsal root reflexes that are carried back to the 
periphery via C-fibres and Aδ-fibres, and which play an important role in neurogenic 
inflammation (Lin et al., 2000, Wang et al., 2004b). Capsaicin-sensitive cardiac nerves 
appear to regulate a number of complex cellular processes, including gene expression, 
that contribute to myocardial function in both physiological and pathological states 
(Zvara et al., 2006). The heart is innervated by primary afferents expressing TRPV1 
receptors: in the adult rat, TRPV1-expressing fibres are distributed predominantly on 
the epicardial surface of the ventricles (Zahner et al., 2003), whilst in mice at postnatal 
stage 7, TRPV1-expressing fibres appear to be sparse in the epicardium but more 
abundant in the ventricle walls and also along blood vessels (Funakoshi et al., 2006). 
Indeed, it has been shown that TRPV1 contributes to the Bezold-Jarisch reflex that 
occurs during arterial injection of capsaicin (Nagy et al., 2004) and suggested that 
TRPV1 may mediate cardiac reflex responses to oxygen radicals (Schultz and Ustinova, 
1998). TRPV1 expression has also been detected in vascular smooth muscle cells (Kark 
et al., 2008) as well as vascular endothelial cells (Golech et al., 2004, Luo et al., 2008a). 
 
It is perhaps tempting to assume that TRPV1, being sensitive to protons, is involved in 
mediating angina – the pain experienced when heart tissue becomes ischaemic, resulting 
in a fall in pH. However, there is evidence to suggest that myocardial acidity resulting 
in angina is in fact detected by another ion channel, acid-sensing ion channel 3 
(ASIC3). Activation of this channel reproduces the functional characteristics of the ion 
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channel responsible for the enormous acid-evoked depolarising currents seen in cardiac 
afferents (Sutherland et al., 2001) although the authors were hesitant to conclude that 
ASIC3 is the only sensor of cardiac pain resulting from ischaemic conditions. Indeed, 
more recent evidence obtained from another group suggests that stimulation of cardiac 
spinal afferent nerves, in response to ischaemia, is primarily mediated by TRPV1 (Pan 
and Chen, 2004). It is thus possible that TRPV1 antagonists may represent an effective 
alternative treatment for refractory ischaemic chest pain (Watanabe et al., 2008). 
 
1.5.4. TRPV1 and cardioprotection 
Taking into consideration the efferent functions of capsaicin-sensitive (i.e TRPV-
expressing) neurones, there is an increasing body of evidence implicating a role for 
TRPV1 in cardioprotection. Indeed, in patients suffering myocardial infarction, a rise in 
C-fibre-derived neuropeptides [(Lechleitner et al., 1992) for example] has been 
proposed to reflect an endogenous protective pathway limiting damage. As outlined in 
section 1.4, one of the main neuropeptides released from the peripheral terminals of 
capsaicin-sensitive neurones is CGRP (Caterina and Julius, 2001), which has been 
identified in 40% of primary afferent neurones, including those innervating the heart 
(Sueur et al., 2005). CGRP is possibly best known for its vasodilator properties. It is the 
most potent vasodilator known to man, and is capable of causing selective 
vasodilatation in multiple vascular beds – the coronary vasculature being an 
exceptionally responsive target (Huang et al., 2008). Interestingly, it has been shown 
that cleavage of CGRP into CGRP1-14 and CGRP15-37 by matrix metalloproteinase 2 
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promotes vasoconstriction, due to inhibition of CGRP-dependent vasodilatation 
(Fernandez-Patron et al., 2000). 
 
As previously mentioned, evidence suggests that CGRP is an endogenous 
cardioprotective agent, and, as discussed in section 1.4, vasodilatation is just one of the 
potential mechanisms that have been proposed to underlie the cardioprotective effects of 
CGRP – additional possible mechanisms including inhibition of neutrophils (Brain and 
Grant, 2004), inhibition of oxidative stress (Schaeffer et al., 2003, Sueur et al., 2005), 
inhibition of cardiac TNFα production (Peng et al., 2000), inhibition of proliferation of 
aortic and pulmonary artery smooth muscle cells (Chattergoon et al., 2005), and 
preservation of endothelial function (Tang et al., 1997, Ye et al., 2007). The 
cardiovascular effects of CGRP also include positive inotropy (Marshall et al., 1986) 
and in rats, administration of exogenous CGRP reduces the incidence of reperfusion-
induced arrhythmia such as ventricular tachycardia and fibrillation (Zhang et al., 1994). 
More recently, CGRP has also been linked to the delayed anti-arrhythmic effect of the 
NO-releasing compound nitroglycerin (Baharvand et al., 2009). 
 
CGRP has been shown to participate in IPC, protecting against myocardial injury 
following I/R in isolated rat hearts (Chai et al., 2006, Li et al., 1996, Zhou et al., 1999), 
and rat (Wolfrum et al., 2005) and porcine (Kallner and Franco-Cereceda, 1998) hearts 
in vivo. Endogenous CGRP release has also been linked to postconditioning (Li et al., 
2008). Furthermore, both TRPV1 and CGRP have been implicated in the protection 
against myocardial I/R injury afforded by heat-stress (Bhave et al., 2003) and by 
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rutaecarpine, a herbal drug used in China for the treatment of hypertension and angina 
(Hu et al., 2003). Indeed, evidence suggests that rutaecarpine, via activation of TRPV1 
and release of CGRP, can decrease the susceptibility of spontaneously hypertensive rats 
to myocardial I/R injury (Li et al., 2009). Interestingly, the expression of both TRPV1 
and CGRP is depressed in diabetes mellitus, and this has been associated with the 
impaired recovery of hearts from diabetic mice following global ischaemia – an effect 
that may be reversed by pre-treatment with exogenous CGRP (Wei et al., 2009). In 
addition, one study conducted in the isolated mouse heart demonstrated that TRPV1 
plays an important role in acid-evoked release of CGRP (Strecker et al., 2005), and 
more recently it has been reported that the expression and secretion of CGRP by 
vascular endothelial cells is mediated by TRPV1, and that endothelial cell-derived 
CGRP protects against endothelial dysfunction (Luo et al., 2008a). Perhaps even more 
pertinent to the topic of this thesis is the identification of a novel mechanism involved in 
myogenic constriction, whereby it is proposed that the AA metabolite 20-HETE, 
produced in vascular smooth muscle cells in response to an increase in intravascular 
pressure, activates TRPV1 on C-fibre terminals, resulting in depolarisation of the nerve 
terminal and consequently the release of vasoactive neuropeptides (Scotland et al., 
2004). 
 
1.6. Aims 
Consolidating all of the above information, it was hypothesised that activation of the 
LOX pathway of AA metabolism by myocardial ischaemia causes release of LOX-
derived eicosanoids within the heart; that these LOX metabolites activate TRPV1 
 
Chapter 1: Introduction 
 
 
 
 
82 
 
located on the peripheral terminals of sensory C-fibres; and that the subsequent release 
of vasoactive peptides offers protection against myocardial I/R injury, possibly via 
vasodilatation and increased coronary perfusion, although more likely via a direct or 
indirect reduction in tissue damage. 
 
The specific aims of this thesis were: 
1. Using coronary vasodilator responses as an index of C-fibre activity, to test the 
hypotheses that: 
a. 12(S)-HpETE and/or 12(S)-HETE generated via 12-LOX metabolism of 
AA activate(s) TRPV1 on sensory C-fibres 
b. TRPV1-mediated activation of C-fibres in turn leads to the release of 
vasoactive peptides such as CGRP and SP. 
2. Using an in vitro model of I/R, to test the hypothesis that 12-LOX-derived 
eicosanoids can afford protection against myocardial injury following an I/R 
insult, via C-fibre activation and subsequent release of vasoactive peptides that 
may offer cardioprotection, most likely via mechanisms of reducing tissue injury 
that are unrelated to their vasodilator properties. 
3. Using an in vivo model of I/R injury, together with an in vitro model of I/R 
injury (which served as a control), to test the hypothesis that activation of the 
12-LOX/AA pathway via a myocardial I/R insult results in changes in TRPV1 
expression, either in the heart and/or related DRG. 
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2. METHODS 
 
2.1. Animal preparation 
All experiments were conducted in accordance with the ‘Guidance on the Operation of 
Animals (Scientific Procedures) Act 1986’, with full ethical approval from The Queen 
Mary, University of London Animal Ethical Review Committee. 
 
2.1.1. Rats 
Male Wistar rats (250-350 g; Charles River, UK) were heparinised by intraperitoneal 
(i.p.) injection of heparin sodium (1000 IU kg
-1
 i.p.) and surgically anaesthetised 
(pentobarbitone sodium, 120 mg kg
-1
 i.p.). Hearts were then rapidly excised and 
submerged in ice-cold Krebs solution composed of (mM): sodium chloride (118.5), 
potassium chloride (4.7), magnesium sulphate heptahydrate (1.2), potassium dihydrogen 
orthophosphate (1.2), sodium bicarbonate (25.0), calcium chloride (1.7) and glucose 
(12.0), where they were left until they had stopped beating. All salts were obtained from 
Sigma, UK. The perfusion solution was filtered (5 m pore size) before use, in order to 
remove particulate matter. 
 
2.1.2. Mice 
Male C57BL/6 (WT; 18–22 g, 8-10 weeks of age; Charles River, UK) and TRPV1 KO 
(18-22 g, 8-10 weeks of age; original breeding pairs, Jackson Laboratories, USA) mice 
were heparinised (heparin sodium, 500 IU kg
-1
 i.p.) and surgically anaesthetised 
(pentobarbitone sodium, 100 mg kg
-1
 i.p.). Hearts were then rapidly excised and 
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submerged in ice-cold Krebs solution as detailed above, which additionally contained 
sodium pyruvate (2 mM). 
 
2.2. Isolated perfused heart (Langendorff) preparation 
The isolated perfused heart preparation, first described by Oscar Langendorff in 1895 
(Langendorff, 1895), is still regarded as a valuable experimental model for use in 
cardiovascular and pharmacological research – despite limitations such as the heart 
being vulnerable to contusion injuries and preconditioning during the set-up procedure 
(Skrzypiec-Spring et al., 2007). Another disadvantage of this preparation is that, being 
an ex vivo preparation, the heart deteriorates over time: contractile function typically 
reduces by 5-10% h
-1
, although the rate of deterioration depends on numerous factors 
including the manual dexterity of the experimenter (Sutherland and Hearse, 2000). 
Nevertheless, the Langendorff preparation facilitates the relatively low-cost generation 
of highly reproducible data over several hours, and it has been suggested that the 
Langendorff preparation represents the ‘optimal compromise in the conflict of data 
acquisition versus clinical relevance’ (Hearse and Sutherland, 2000). 
 
A schematic diagram of the Hugo Sachs Langendorff setup is shown in Figure 2.1, 
which was used for all the studies described in this thesis that were carried out in the 
isolated perfused heart. 
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(1) Aorta block. 
(2) Aorta cannula. 
(3) Shut-off stopcock. 
(4) Flow transducer (optional). 
(5) Adjustable flow resistance, used to set perfusion pressure. 
(6) Spindle syringe for adjusting flow resistance. 
(7) Pressure gauge to indicate pressure set on flow resistance. 
(8) Air vessel plus air to reproduce compliance of the aorta. 
(9) Syringe for adjusting air volume in air vessel. 
(10) Heat exchanger, built into top part of heart chamber. 
(11) Roller pump. 
(12) Perfusate reservoir, with jacket and thermostat. 
(13) Needle valve, for adjusting flow of Carbogen.  
(14) Aerating stone to aerate perfusate. 
(15) Upper part of heart chamber, with jacket and thermostat. 
(16) Lower part of heart chamber, with jacket and thermostat. 
May be swung away downwards and backwards. 
(17) Infusion line from separate roller pump to infusion port. 
(18) Pressure transducer to measure perfusion pressure. 
(19) Intraventricular balloon with connecting catheter for 
evaluating isovolumetric ventricular pressure. 
(20) Pressure transducer for measuring isovolumetric 
ventricular pressure. 
(21) Spindle syringe with tubing catheter for fine adjustment of 
diastolic balloon pressure to the required value. 
(22) Tube for draining effluent dripping off the heart.
Figure 2.1. Schematic diagram of the Hugo Sachs Langendorff apparatus used. From 
‘Operating Manual for the apparatus Isolated Perfused Heart Size 1 (murine heart) model IH1, 
Type 844’, p5. Version 1.3. October 2000. H. Steiert. Hugo Sachs Elektronik-Harvard 
Apparatus GmbH. 
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Perfusion of the isolated heart in the Langendorff mode is said to be retrograde, since, 
contrary to the normal circulatory pathway whereby blood is ejected from the left 
ventricle into the aorta, the perfusate flows directly into the cannulated aorta. 
Retrograde flow in the aorta causes closure of the aortic valve, and thereafter, the 
perfusate follows the normal pathway through the coronary circulation - entering the 
coronary arteries via the ostia situated at the root of the aorta, and eventually emptying 
into the right atrium via the coronary sinus, as well as into all four heart chambers via 
microscopic veins in the chamber walls, as described in section 1.1. 
 
There are two modes of perfusion possible using the isolated Langendorff heart; 
constant pressure and constant flow. Under perfusion at constant hydrostatic pressure 
[typically around 60-100 mmHg (Sutherland and Hearse, 2000)], flow fluctuates, whilst 
under perfusion at constant flow (achieved using a roller pump), pressure fluctuates. For 
all the experiments described in this thesis constant flow was used. This results in a 
pressure that fluctuates as the heart beats and the coronary arteries are compressed, and 
at a constant flow of 10 ml min
-1
, the pressure fluctuation with each beat of the heart is 
approximately 10-20 mmHg. Perfusion under constant flow conditions overrides 
autoregulatory mechanisms that usually alter the amount of perfusate delivered to the 
whole heart, such as when heart rate or work changes, or the heart is subjected to 
regional ischaemia (Sutherland and Hearse, 2000). As a model of global ischaemia was 
used for isolated heart experiments, possible increases in flow to non-ischaemic regions 
as a result of regional ischaemia could not occur. However, as discussed in Chapter 6, 
one disadvantage of perfusing isolated hearts under constant flow conditions is that 
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changes in coronary flow are inferred from pressure measurements rather than measured 
directly. 
 
2.2.1. Measurement of coronary haemodynamics in rat hearts 
Hearts were cannulated via the aorta and perfused in the Langendorff mode (Hugo 
Sachs Elektronik-Harvard Apparatus GmbH Isolated Heart IH-SR Type 844/1). Hearts 
were perfused with Krebs solution at 37C under constant flow (10 ml min-1) using a 
calibrated roller pump (Gilson Minipuls 2). The COX inhibitor indomethacin (5 M) 
(Jakubowski et al., 2005, McLean et al., 1999) was added to the Krebs solution for all 
experiments, to inhibit COX-dependent metabolism of AA which would yield 
vasodilator prostaglandins PGE2, PGI2 and PGD2, and also to remove any influence of 
prostaglandins produced as a consequence of COX induction by 12-LOX products 
which would also yield prostaglandins (Han et al., 2002). The NOS inhibitor N
G
-nitro-
L-arginine methyl ester (L-NAME; 300 M) (McLean et al., 1999, Stavrou et al., 2001) 
was also added to the Krebs solution for initial experiments with 12(S)-HETE and 
12(S)-HpETE, but was omitted for simplicity after results clearly showed that L-NAME 
had no effect on responses to either 12-LOX product. The reservoir of Krebs was 
continuously aerated with 95% O2/5% CO2 (pH 7.4). Air temperature was maintained 
via a heated (37°C) water jacket. 
 
Coronary perfusion pressure (CPP), which corresponds to coronary vascular resistance, 
was measured using an in-line pressure transducer (Isotec, Hugo Sachs Elektronik-
Harvard Apparatus GmbH, Germany) connected to ADInstruments PowerLab/4SP 
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equipment, and recorded using ADInstruments PowerLab
®
 Chart software version 4.2 
for Windows. As illustrated in Figure 2.1, the pressure transducer for measuring CPP 
[see (18)] was connected to a side arm at the base of the aorta block, and for accurate 
pressure measurement, the pressure transducer was set at exactly the same level as the 
heart. Hearts were left to equilibrate for approximately 20 min after cannulation, until 
CPP had stabilised, and then bolus doses of the vasodilators BK (30 pmol) and sodium 
nitroprusside (SNP; 1 nmol) were administered via the aorta, to test endothelium-
dependent and -independent function, respectively. Hearts were excluded if the response 
to either BK or SNP was a reduction in CPP of 10 mmHg, or if post-equilibration CPP 
was 60 mmHg. 
 
2.2.1.1. Drug administration 
Drugs were administered by bolus injection via a side arm in the perfusion line (point 
A, Figure 2.2) in a volume of 10 l. To investigate the mechanism of vasodilator 
responses, and also for I/R experiments, antagonists or inhibitors were infused either via 
an infusion port [see (17), Figure 2.1], or, if a second infusion was required, via the 
main perfusion line (point B, Figure 2.2). Vehicle controls for these were conducted in 
the same manner. 
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Figure 2.2. Schematic diagram showing the points of drug administration via the perfusion 
line in the Hugo Sachs Langendorff setup. 
 
In general, each experiment involved two heart preparations at any one time, one heart 
perfused with drug and the other vehicle control. However, if a further two hearts were 
required in a particular experimental group, then both heart preparations would be 
perfused with drug in the same experiment. In many cases, the numbers in control and 
experimental groups were not equal, due to hearts being excluded if they did not 
respond adequately to either BK (30 pmol) or SNP (1 nmol); and if it was found that a 
statistical difference existed between data obtained from control and experimental 
groups, further experiments to equalise group sizes were not carried out as it was felt 
that this would have been an unnecessary use of animals. Whilst hearts were not 
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assigned to groups or to a particular Langendorff rig according to a stringent 
randomisation process such as use of a random number table – a limitation addressed in 
Chapter 6 of this thesis – there was a degree of randomisation where control hearts were 
assigned to either one of two rigs at random on each experimental day. In general, for 
each experimental protocol, two hearts were set up concomitantly, one serving as 
control and the other drug treated. For the I/R experiments, in vitro drug treatments, of 
which there were 5 different types, were chosen at random on each day. 
 
2.2.1.2. Calculation of changes in CPP 
In all cases, determination of CPP was conducted viewing the original ADInstruments 
PowerLab
®
 Chart recording at a ratio of 20:1. Mean CPP was measured over a 5-s 
period before drug administration (or, in the case of I/R experiments, a 5-s period before 
the onset of ischaemia or reperfusion), and then at the peak response (or a 5-s period 
after the onset of ischaemia or reperfusion). The mean response to any given drug was 
calculated as mean CPP before drug administration minus mean CPP at peak after drug 
administration. 
 
2.2.2. Investigation of the vasodilator activity of 12(S)-HETE and 12(S)-HpETE 
Since both 12(S)-HETE and 12(S)-HpETE have been shown to activate TRPV1 [12(S)-
HpETE being more potent than 12(S)-HETE (Hwang et al., 2000)], I investigated the 
effects of both 12-LOX products on CPP. Following equilibration of hearts as detailed 
above, attempts were made to construct dose-response curves to 12(S)-HETE (10
-11–
310-9 mol); however responses were highly variable and clearly subject to 
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tachyphylaxis. In an attempt to improve responses, a dose-response curve to 12(S)-
HETE (10
-14–10-10 mol) was constructed by administering a single dose of 12(S)-HETE 
per heart. However, no observable improvement in the magnitude or reproducibility of 
the responses to 12(S)-HETE was seen. I then investigated whether responses to a 
single dose of 12(S)-HETE (10 pmol, which had caused the maximal response in 
previous experiments) were enhanced by pre-constricting hearts with either L-NAME 
(300 M) or the thromboxane receptor agonist U46619 (10 nM). Despite both raising 
tone, the magnitude of response to 12(S)-HETE was smaller than in controls – thus 
experiments using 12(S)-HETE were abandoned. 
 
Dose-response curves to 12(S)-HpETE (10
-20–10-15 mol) were then constructed. Each 
dose was administered and then decreases in CPP recorded. Once basal CPP was 
restored the next dose was given. 
 
2.2.2.1. Determination of the role of sensory C-fibres and TRPV1 in 12(S)-HpETE-
induced vasodilatation 
To determine if C-fibres were involved in mediating 12(S)-HpETE-induced 
vasodilatation, a dose-response curve to 12(S)-HpETE (10
-20–10-15 mol) was 
constructed and then hearts were treated with a desensitising dose of capsaicin (1 M 
for 20 min) (Holzer, 1991). Hearts were then left for 30 min before repeating the dose-
response curve to 12(S)-HpETE, to allow time for any vasoactive neurotransmitters 
released during C-fibre activation to wash out of the system. This protocol is known to 
result in capsaicin desensitisation, whereby capsaicin-sensitive primary afferent 
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neurones become refractory to further stimulation – such short-term desensitisation 
being more likely due to excitation-secretion uncoupling in sensory terminals than 
depletion of neuropeptides (Maggi, 1995). 
 
To determine whether TRPV1 might be involved in the vasodilator response to 12(S)-
HpETE, hearts were infused with the TRPV1 antagonist capsazepine (3 M for 20 min) 
(Bevan et al., 1992), and then, whilst continuing with the infusion of the antagonist, a 
dose-response curve to 12(S)-HpETE (10
-20–10-15 mol) was constructed. Control hearts 
were treated with vehicle alone. 
 
2.2.2.2. Investigation of the effect of sensory neuropeptide antagonists on 12(S)-
HpETE-induced vasodilatation 
Having investigated the possible involvement of C-fibres and TRPV1 in the vasodilator 
response to 12(S)-HpETE, I then went on to try to determine which sensory 
neurotransmitter(s) might mediate this response - candidate neurotransmitters including 
CGRP and the tachykinins SP, NKA, and neurokinin B (NKB). Out of the tachykinins, 
SP is the preferred agonist at NK1 receptors, NKA at NK2 receptors, and NKB at NK3 
receptors (Emonds-Alt et al., 1995, Harrison and Geppetti, 2001, Maggi et al., 1993). 
 
12(S)-HpETE, like 12(S)-HETE, is a highly unstable compound, being light- and 
oxygen-sensitive, and appropriate precautions were taken when preparing and 
administering solutions. Although the manufacturers (Cayman Chemicals, Ann Arbor, 
MI, USA) recommend that aqueous solutions of 12(S)-HETE and 12(S)-HpETE are 
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used within 24 h, there is very little data in the literature regarding the lifetimes of these 
compounds. Indeed, considerable variability in responses to 12(S)-HpETE had been 
observed in the previous set of experiments when attempting to construct dose-response 
curves, just as had been the case with 12(S)-HETE. 
 
Therefore, based on the dose-response curve to 12(S)-HpETE from the previous set of 
experiments, a single dose of 12(S)-HpETE (0.1 fmol) was chosen; a maximally 
effective vasodilator dose, and then responses compared before and after treatment with 
the CGRP receptor antagonist, CGRP8-37 (0.3 M, 20 min pre-treatment) (Chiba et al., 
1989); the non-peptide NK1 receptor antagonist, SR 140333 (1 M, 15 min pre-
treatment) (Emonds-Alt et al., 1993); the cyclic peptide NK2 receptor antagonist, MEN 
11420 (1 M, 15 min pre-treatment) (Santicioli et al., 1997); or the non-peptide NK3 
receptor antagonist, SR 142801 (1 M 15 min pre-treatment) (Emonds-Alt et al., 1995). 
Single doses of peptides (CGRP, 30 pmol; SP, 30 pmol; NKA and NKB, 25 nmol) were 
also administered in the absence and then the presence of the corresponding antagonist, 
to confirm the effectiveness of the antagonist concentration chosen according to reports 
in the literature. 
 
2.2.3. 12-LOX and AA: an alternative approach to studying 12(S)-HpETE-induced 
vasodilatation? 
In an attempt to circumvent the problem of variability in responses to 12(S)-HpETE 
encountered in the previous sets of experiments, I then carried out a series of 
preliminary experiments (performed only as a general guide to subsequent more 
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detailed experiments) to investigate whether administration of the substrate for 
production of 12(S)-HpETE, AA, in combination with the enzyme, 12-LOX, might 
provide a more reproducible response – a method devised by Gryglewski and Vane 
(1972). Hearts were cannulated via the aorta and mounted in the Langendorff mode as 
previously described (section 2.2.1). 
 
In pilot experiments it was first determined whether AA caused vasodilatation. AA (30 
nmol) was chosen to investigate this issue since Gryglewski and Vane (1972) had 
previously shown this to be an effective dose of AA in the rabbit aorta. Responses were 
measured in the absence and presence of indomethacin (5 M) to determine the non-
COX-dependent component of the response. To ascertain whether 12-LOX might 
underlie any remaining response, hearts were treated with the 12-LOX inhibitor 
baicalein (10 M for 30 min). This concentration of baicalein has previously been 
shown to block 12-LOX activity in vascular preparations (Chen et al., 1999, McLean et 
al., 2002) and with the reported IC50 for baicalein being 0.12 M in enzyme 
preparations (Dailey and Imming, 1999) maximal inhibition should be achieved at the 
concentration chosen. Longer pre-treatment times of 45 and 55 min were tested, but no 
greater inhibition was evidenced (data not shown). Following on from this, AA was 
administered in the presence of 12-LOX. Two concentrations of 12-LOX were tested – 
2 and 20 g ml-1 (Gryglewski and Vane, 1972) - against a bolus dose of AA (30 nmol). 
From this study I established that 2 g ml-1 was a sufficient concentration of 12-LOX to 
use, with 20 g ml-1 producing no greater effect. 
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Repeat dose-response curves to AA (10
-10–10-6 mol) were then constructed either in the 
absence or presence of 12-LOX (2 g ml-1) to determine whether 12-LOX enhanced the 
magnitude of responses to AA and whether repeat dose-response curves could be 
constructed. A total of 40 min washout was allowed between curves to determine the 
reproducibility of the response. These preliminary experiments demonstrated that repeat 
dose-response curves could not be constructed due to an apparent tachyphylaxis of the 
response, and therefore in all future experiments only a single dose-response curve was 
conducted in any heart. 
 
2.2.4. Investigation of the mechanism of 12-LOX/AA-induced coronary 
vasodilatation 
Having established a protocol for use with 12-LOX/AA by means of the preliminary 
experiments described in section 2.2.3, the mechanism of AA-induced vasodilatation 
was investigated in the isolated rat heart. All of the following experiments were 
conducted in the presence of exogenous 12-LOX (2 g ml-1) (Gryglewski and Vane, 
1972). 
 
To determine whether AA-induced coronary vasodilatation was mediated by 12-LOX 
products of AA metabolism, dose-response curves to AA (10
-10–10-6 mol) were 
constructed in the presence of either the non-selective LOX inhibitor NDGA (10 M, 
30 min pre-treatment) (Hwang et al., 2000) or vehicle alone (0.1% ethanol). Dose-
response curves to AA (10
-10–10-6 mol) were also constructed after treatment with the 
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selective 12-LOX inhibitor baicalein (10 M, 30 min pre-treatment) (Chen et al., 1999, 
McLean et al., 2002) or vehicle alone (0.05% dimethyl sulphoxide, DMSO). 
 
2.2.4.1. Determination of the role of sensory C-fibres and TRPV1 in 12-LOX/AA-
induced vasodilatation 
To investigate the possible involvement of C-fibres and sensory TRPV1 in mediating 
the vasodilator response to AA, dose-response curves to AA (10
-10–10-6 mol) were 
constructed following treatment with capsaicin (1 M for 20 min, 30-min washout) 
(Holzer, 1991) or the TRPV1 antagonist capsazepine (3 M, 20 min pre-treatment) 
(Bevan et al., 1992). Control hearts were treated with vehicle alone. 
 
2.2.4.2. Investigation of the effect of sensory neuropeptide antagonists on 12-
LOX/AA-induced vasodilatation 
Having established a role for TRPV1 in the vasodilator response to AA, the identity of 
the neurotransmitter(s) involved in this response was then investigated. As previously 
mentioned, candidate neurotransmitters include CGRP, SP, NKA, and NKB. However, 
based on preliminary findings (see section 2.2.2.2), and findings from 
immunohistochemical studies in human, rat, guinea pig and porcine cardiac tissues 
(Rubino and Burnstock, 1996, Wang, 2005), experiments were focussed on CGRP and 
SP. Dose-response curves to AA were constructed in the absence or presence of the 
CGRP receptor antagonist, CGRP8-37 (0.3 M, 20 min pre-treatment) (Chiba et al., 
1989), and in a separate set of experiments, the NK1 receptor antagonist SR 140333 (1 
M, 15 min pre-treatment) (Emonds-Alt et al., 1993). The effect of co-infusion of the 
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CGRP and NK1 receptor antagonists on responses to AA was also investigated, where 
dose-response curves to AA (10
-10–10-6 mol) were constructed in the absence or 
presence of CGRP8-37 (0.3 M, 20 min pre-treatment) together with SR 140333 (1 
M, 15 min pre-treatment) and responses compared to those in vehicle control-treated 
hearts. A different set of controls was obtained for each antagonist since the vehicle for 
each drug was different. 
 
2.2.5. Measurement of cardiac function in rat hearts subjected to an I/R insult 
Left ventricular function and infarct size were measured as end-points of 
cardioprotection. Rat hearts were mounted in the Langendorff mode as outlined in 
section 2.2.1. Briefly, left ventricular developed pressure (LVDP; LV peak end systolic 
pressure minus LV end diastolic pressure) was measured by means of an in-line 
pressure transducer (Isotec, Hugo Sachs Elektronik-Harvard Apparatus GmbH, 
Germany) attached to a fluid-filled latex balloon, which was inserted into the left 
ventricle and inflated to obtain an end diastolic pressure of 8-10 mmHg, and an initial 
LVDP of ideally 80 mmHg minimum (Andelova et al., 2005, Angelone et al., 2008, 
Cerra et al., 2006, Randall et al., 1997, Zhang et al., 2008). Transducers were connected 
to ADInstruments PowerLab/4SP equipment, and measurements recorded using 
ADInstruments PowerLab
®
 Chart 4 software version 4.2 for Windows. Following 
cannulation and balloon insertion, hearts were left to equilibrate for approximately 30 
min, to allow CPP and LVDP to stabilise so that baseline values could be recorded. 
Hearts were then subjected to a 25-min normothermic global ischaemic episode, 
simulated by cessation of perfusion, followed by a 120-min reperfusion period – an I/R 
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stimulus that has been previously shown to generate an infarct size of approximately 
50% (Hobbs et al., 2004). In order that hearts did not cool with the cessation of 
perfusion to simulate ischaemia, they were suspended in small plastic beakers that were 
continually supplied with Krebs solution at 37C, from the overflow pipe. The reason 
for using a model of global ischaemia for functional studies whilst using regional 
ischaemia (see section 2.3) in hearts used for mRNA and protein measurement, is 
discussed in Chapter 6. 
 
Infarct size was determined using the p-nitroblue tetrazolium (NBT) method, used to 
identify necrotic tissue, based on dehydrogenase enzyme activity. Viable tissue contains 
intact dehydrogenase systems, which stain dark blue with the diformazan of NBT, 
whereas tissue that has been partially damaged by ischaemia stains patchy red with the 
monoformazan of NBT, and tissue that has undergone necrosis and therefore lacks 
dehydrogenase activity does not stain at all (Derias and Adams, 1978, Webb et al., 
2004) (see Figure 2.3). At the end of experiments, each heart was cut into three portions 
of similar size and snap frozen in liquid nitrogen. Each portion was allowed to thaw 
slightly, and then cut up into small pieces that were incubated with NBT (0.5 mg ml
-1
 
for 20 min at 37C). After this time, the pieces were sorted into dark blue, reddish and 
unstained tissue, and then infarct size calculated as follows: 
Infarct size (% tissue damaged) = [u + (r/2)]/[u + r + d]  100 
where u, r and d are the wet weights of the unstained, reddish and dark blue tissue, 
respectively. 
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Figure 2.3. Photograph of heart tissue taken from whole heart treated with NBT after in 
vitro I/R experiment. Viable tissue (dark blue), tissue that has been partially damaged (patchy 
red), necrotic tissue (unstained). 
 
The effect of various treatments on I/R injury, given up to 40 min prior to the ischaemic 
insult, was determined by comparing post-ischaemic LVDPs and CPPs (expressed as a 
percentage of the baseline LVDP or CPP) and infarct size. As already mentioned, the 
duration of ischaemia and reperfusion used in these studies is a standard I/R protocol 
that typically results in an infarct size of approximately 50% in the heart (Hobbs et al., 
2004) - which thereby allows any beneficial or detrimental effects of treatment on I/R 
injury to be detected. Pilot studies were conducted to investigate the effect of 
indomethacin (5 M) on infarct size, subjecting hearts to the I/R protocol described 
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above either with or without indomethacin added to the Krebs solution. No significant 
effect was seen and therefore to isolate 12-LOX-dependent effects of AA, indomethacin 
was included in all experiments, in line with the previous experiments investigating the 
vasodilator effects of 12-LOX products. 
 
2.2.6. Investigation of the effects of 12-LOX and AA on I/R injury 
Following equilibration, hearts were treated with 12-LOX (2 g ml-1) and AA (30 M) 
or vehicle control, for 30 min prior to ischaemia, in the absence or presence of baicalein 
(10 M, 15 min pre-treatment) (Faraci et al., 2001). The effect of baicalein treatment 
alone was also determined (10 M, 45 min). Hearts were then subjected to the I/R insult 
as previously described (refer to section 2.2.5). Infusions were stopped at the onset of 
ischaemia and not restarted with reperfusion (Chen et al., 1999). 
 
A concentration of 30 M AA was chosen based on experiments described in section 
2.2.3, which found that a bolus dose of 30 nmol was the lowest functionally effective 
dose tested. This is a dose that demonstrates biological activity without causing too 
substantial a vasodilator response. In order to give 30 nmol in 10 l, a solution of 3 mM 
was made up, which was infused at a rate of 0.1 ml min
-1
 into Krebs flowing at a rate of 
10 ml min
-1
. 
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2.2.7. Determination of the role of sensory C-fibres in 12-LOX/AA-mediated 
cardioprotection 
To determine whether any protective effect(s) of 12-LOX/AA could be abolished by 
desensitisation of C-fibres, the effect of capsaicin treatment was then investigated. 
Capsaicin treatment in vitro as outlined in the earlier experiments, requires 20 min 
exposure to capsaicin followed by a 30-min washout period prior to treatment with 12-
LOX/AA (as described in sections 2.2.2.1 and 2.2.4.1). As mentioned in section 2.2, the 
viability of the Langendorff preparation decreases over a period of several hours 
(Sutherland and Hearse, 2000), and it is therefore preferable to reduce the duration of an 
experiment whenever possible. To minimise the length of the experiment, C-fibres were 
desensitised in vivo, using a robust and validated in vivo capsaicin-induced 
desensitisation, as detailed below. 
 
Rats were anaesthetized (ketamine/xylazine approximately 100 mg kg
-1
/10 mg kg
-1
 i.p.) 
and then given a subcutaneous injection of capsaicin (50 mg kg
-1
, 2 ml kg
-1
) (Gamse, 
1982, Maggi et al., 1988). Capsaicin was prepared to produce a cloudy solution, which 
facilitates a more gradual release of capsaicin thereby reducing animal deaths that can 
occur as a result of capsaicin treatment (Sandro Giuliani, A. Menarini Ricerche, 
personal communication). This involved adding a mix of 10% ethanol, 10% Tween 80 
and 80% NaCl (0.9%) to capsaicin, and stirring for 1-2 min. Such treatment with 
capsaicin is widely used and effectively desensitises C-fibres in vivo, resulting in a 
depletion of neuropeptide content in excess of 95% (Maggi, 1995). 
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Three days after animals had been treated with capsaicin, hearts were excised as 
detailed in section 2.1.1, cannulated via the aorta and mounted in the Langendorff mode 
as described in section 2.2.1. Hearts were perfused with Krebs solution containing 
indomethacin (5 M) and treated with 12-LOX and AA (2 g ml-1 and 30 M 
respectively) for 30 min prior to the I/R protocol as described previously in section 
2.2.5. LVDP was measured throughout the experiment by means of a latex balloon, and 
infarct size determined at the end of the experiment using the NBT method, as described 
in section 2.2.5. The effect of treatment on CPP was also examined. 
 
To determine the effect of capsaicin treatment alone on infarct size, LVDP and CPP, 
hearts were perfused with Krebs solution containing indomethacin (5 M) and treated 
with capsaicin (1 M for 20 min, 30-min washout) (Holzer, 1991) before being 
subjected to 25 min ischaemia followed by 120 min reperfusion. 
 
2.2.8. Measurement of coronary haemodynamics in murine hearts 
Hearts were cannulated via the aorta and mounted in the Langendorff mode (Hugo 
Sachs Elektronik-Harvard Apparatus GmbH Isolated Heart IH-SR Type 844/1). Hearts 
were perfused with Krebs solution containing indomethacin (5 M) and sodium 
pyruvate (2 mM) at 37C under constant flow (2 ml min-1) using a calibrated roller 
pump (Gilson Minipuls 2). The reservoir of Krebs was continuously aerated with 95% 
O2/5% CO2 (pH 7.4). Air temperature was maintained via a heated (37C) water jacket. 
CPP was measured as detailed in section 2.2.1. Hearts were perfused for approximately 
15 min after cannulation in order for a stable baseline CPP to be obtained, and then 
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drugs were administered either by bolus injection in a volume of 10 l via a side arm in 
the perfusion line (point A, Figure 2.2) or infused at a rate of 0.02 ml min
-1
 via an 
infusion port [see (17), Figure 2.1] and also via the main perfusion line (point B, Figure 
2.2). 
 
2.2.9. 12-LOX/AA-induced coronary vasodilatation in TRPV1 KO mice 
Having gained evidence from studies in the isolated rat heart to suggest that TRPV1 is 
involved in the coronary vasodilator response to AA, responses to AA were investigated 
in isolated hearts of TRPV1 KO and WT mice. 
 
As with the studies in the rat hearts, 12-LOX (2 g ml-1) was continuously perfused 
through the heart and then dose-response curves to AA (10
-10–10-6 mol) constructed by 
administration of bolus doses (10 l) of AA. Changes in CPP were measured as detailed 
in section 2.2.1.2. 
 
2.3. Assessment of TRPV1 mRNA levels and protein expression 
2.3.1. In vivo model of I/R 
To investigate whether I/R might trigger changes in TRPV1 expression at the level of 
the cell body or within the heart itself, experiments using an in vivo model of I/R injury 
were performed, by Dr. Michelle McDonald. Briefly, male Wistar rats (200-300 g; 
Charles River, UK) were anaesthetised (sodium thiopentone, 120 mg kg
-1
 i.p.) 
tracheotomised, intubated and ventilated with a Harvard ventilator (70 strokes min
-1
, 
tidal volume 10 ml kg
-1
, inspiratory oxygen concentration 30%). Body temperature was 
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maintained at 37  1C with the aid of a rectal probe thermometer attached to a 
homeothermic blanket control unit (Harvard Apparatus Ltd., UK). The right carotid 
artery was cannulated and connected to a Spectramed Statham P23XL pressure 
transducer (Spectramed Inc., USA) to monitor mean arterial blood pressure (MAP). 
Baseline MAP ranged between 100-130 mmHg. If MAP was found to be 95 mmHg, 
the animal was sacrificed by anaesthetic overdose immediately. The right jugular vein 
was cannulated for the administration of drugs. The chest was then opened by a mid-
sternal thoracotomy, the pericardium incised, and an atraumatic needle placed with an 
occluder around the LAD. Animals were then left to stabilise for 30 min, after which 
time the LAD was occluded by tightening the occluder. After a 25-min regional 
ischaemic episode, the occluder was re-opened to allow the reperfusion of the 
previously ischaemic myocardium for 120 min. Control animals underwent a sham 
operation, which involved all of the aforementioned surgery, but the LAD was not 
occluded (Wayman et al., 2001). (For reasons that are addressed in Chapter 6, the LAD 
was not re-occluded at the end of the experiment in order to distinguish between 
perfused and non-perfused tissue using Evans Blue dye.) 
 
2.3.2. Sample collection 
Rat hearts were subjected to either an in vitro or in vivo I/R protocol, as described in 
sections 2.2.5 and 2.3.1 respectively. For the in vitro studies, following the completion 
of the I/R insult, the left ventricle was rapidly isolated, snap frozen in liquid nitrogen, 
and then transferred to storage at –80C until required. At the end of simulated 
(re)perfusion in vivo, hearts were rapidly excised and left and right ventricles bisected 
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longitudinally and snap frozen. The entire left ventricle was snap frozen. In addition, 
DRG were removed from each side of the spinal cord, from the cervical enlargement to 
the 5
th
 thoracic spinal nerves. This region of the spinal cord was selected since it relates 
to the cardiac sensory system and the nerves innervating the left ventricle: the cell 
bodies of sensory axons following the sympathetic pathways are found in upper thoracic 
DRG, whilst sensory innervation of the fibrous and serous parietal pericardium follows 
the phrenic nerves to the cervical DRG (Benson et al., 1999). All samples were snap 
frozen in liquid nitrogen, and then transferred to storage at -80°C – half of these 
samples being intended for use in Western blot experiments (refer to section 2.3.4). 
 
2.3.3. Quantitative real-time polymerase chain reaction (PCR) analysis 
2.3.3.1. Total mRNA extraction from heart tissue (in vitro and in vivo samples) 
mRNA was extracted from left ventricles of hearts using TRIzol

 (Invitrogen™ Life 
Technologies, USA) according to the manufacturer’s instructions. Briefly, each sample 
was first pulverised using a stainless steel pestle and mortar cooled to -80°C, and then 
transferred to a polypropylene tube containing TRIzol

 (1 ml 100 mg
-1
 of tissue). 
Samples were then homogenised using an Ultra-Turrax

 T 8 homogeniser (IKA 
Labortechnik, Germany) for 330 s and then left for 5 min at room temperature to allow 
complete dissociation of nucleoprotein complexes. Chloroform (200 l per 1 ml 
TRIzol

; Sigma, UK) was then added to each homogenised sample and mixed by 
inversion for approximately 15 s, before incubating at room temperature for 3 min. 
Samples were then centrifuged at 3490 g for 20 min at 10C, and the (upper, 
colourless) aqueous phase transferred to a fresh tube, to which an equal volume of 
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isopropanol (Sigma, UK) was added to achieve ribonucleic acid (RNA) precipitation. 
Samples were mixed by inversion as before, and then incubated at room temperature for 
10 min, before centrifuging at 9447 g for 15 min at 5C. The supernatant was then 
removed from each tube, and the RNA pellet washed with 75% ethanol (1 ml; Sigma, 
UK). Samples were then mixed by vortexing, and centrifuged at 9447 g for 15 min at 
4C. The supernatant was emptied from each tube, and tubes left to air dry for 15 min. 
Each RNA sample was then re-suspended in 100 l RNase-free water, and vortexed. 
Samples were then incubated for up to 1 h at 60C, vortexing again after 5 min, and the 
purified RNA then stored at –80C until required. 
 
2.3.3.2. Total mRNA extraction from DRG (in vivo samples) 
Since the sample size of DRG samples was 20 mg, mRNA was extracted from DRG 
using a Nucleospin
®
 RNA II isolation kit (Macherey-Nagel, Germany) for small sample 
sizes according to the manufacturer’s instructions. Briefly, each sample was first 
pulverised using a stainless steel pestle and mortar cooled to -80°C, re-suspended and 
then homogenised in a mix of ‘RA1’ buffer (350 l) and β-mercaptoethanol (3.5 l; 
Sigma, UK) and vortexed vigorously. The lysate was then filtered by spinning the 
sample in a Nucleospin
®
 Filter unit at 5590 ×g for 1 min at 4°C. RNA binding 
conditions were then adjusted by adding 70% ethanol (350 l) to the lysate, and mixing 
by vortexing. The lysate was loaded into a Nucleospin
®
 RNA II column placed in a 2 ml 
centrifuge tube and centrifuged at 4329 ×g for 30 s at 4°C, in order to bind the RNA. 
The silica membrane was then desalted by adding Nucleospin
®
 membrane desalting 
buffer, and then dried by centrifugation for 1 min at 5590 ×g at 4°C. Digestion of DNA 
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was then performed by adding 95 l DNase reaction mixture (which consisted of 10 l 
reconstituted DNase I and 90 l DNase reaction buffer) to the centre of the silica 
membrane of the column, and incubating for 15 min at room temperature. The silica 
membrane was then washed three times, and then dried. For the first wash, ‘RA2’ buffer 
(200 l) was added to the column, which was then centrifuged for 30 s at 4329 ×g at 
4°C. The column was then transferred to a new collecting tube. For the second wash, 
‘RA3’ buffer (600 l) was added to the column, which was again centrifuged for 30 s at 
4329 ×g at 4°C. The collecting tube was then emptied and used again. For the final 
wash, ‘RA3’ buffer (250 l) was added to the Nucleospin® RNA II column, which was 
then centrifuged for 2 min at 5590 ×g at 4°C to completely dry the membrane. The 
column was then transferred to a nuclease-free micro-centrifuge tube. In order to elute 
the RNA, 50 l RNase-free distilled H2O was then added and the tube centrifuged for 1 
min at 5590 ×g at 4°C. To increase the concentration of RNA obtained, the flow-
through was then poured back into the column and centrifuged again. The purified RNA 
was then stored at -80°C until required. 
 
2.3.3.3. First-strand cDNA synthesis (reverse transcription, RT) 
The concentration of total RNA in each sample of purified RNA from in vitro and in 
vivo heart samples was determined using a spectrophotometer (Pharmacia LKB 
Ultrospec III, Pharmacia, Sweden) whereby the absorbance of each sample was 
measured at a wavelength of 260 nm (A260). Distilled H2O was used as a reference (0), 
since this was used to dilute samples. Samples were diluted by a factor (F) of 50. 
Triplicate readings were taken for each sample in order to calculate the mean A260. 
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Using this assay, an A260 of 1 corresponds to a 40 g ml
-1
 solution. From this, it was 
possible to calculate the volume of sample required to give 1 g mRNA as follows: 
    1 A260 = 40 g ml
-1
 
    x A260 = x  40 g ml
-1
 
    x A260 = x  40 g/1000 ml 
    x A260 = x  (40  F)/1000 
    x A260 = x  2000/1000 
    x A260 = x  2 g ml
-1
 
To calculate the volume of each sample required to give 1 g mRNA, multiply A260 by 2, 
and then calculate the reciprocal of this number. 
 
However, due to the small sample size of DRG samples, it was necessary to use a more 
sensitive method for determination of RNA concentration, and a RiboGreen
®
 RNA 
Quantitation Kit (Molecular Probes, USA) was used according to the manufacturer’s 
instructions. The high-range assay was performed that allows quantitation of 2 ng ml
-1
 
to 1 g ml-1 RNA. Briefly, TE assay buffer composed of 
tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl; 10 mM) and 
ethylenediaminetetraacetic acid (EDTA; 1 mM) (pH 7.5) was prepared by diluting 20-
fold with RNase-free distilled H2O. The RiboGreen

 stock solution was then diluted 
200-fold using RNase-free distilled H2O. RNA samples were diluted in 1 TE. Instead 
of preparing a full RNA standard curve, just one concentration of the RNA standard was 
used, selected from previous standard curves. After loading 95 l 1 TE followed by 5 
l diluted RNA (or 90 l 1 TE and 10 l RNA standard), 100 l 1 RiboGreen was 
then added to each well, and the 96-well microplate was covered in foil and left for 5 
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min at room temperature, before reading on a fluorescence microplate reader (Wallac 
VICTOR
2
 1420 Multilabel Counter, Perkin Elmer, USA). Duplicates were run for each 
sample, including two ‘blank’ wells that contained 1 TE, and a mean reading 
calculated. The mean ‘blank’ reading was then subtracted from each mean sample 
reading, to give a value (y). The concentration of RNA (x) for each sample assayed was 
then calculated as follows using a formula derived from the mean of previous standard 
curves: 
x = (y – 3310.9)/101887 
To calculate the concentration of RNA in each sample, multiply x by the test dilution 
factor (i.e. 5 l RNA added to 95 l 1x TE) and the tube dilution factor (i.e. by how 
much RNA samples were diluted initially). 
 
Having determined the concentration of total RNA in each sample, RT was then 
performed using Moloney murine leukaemia virus (M-MLV) Reverse Transcriptase 
(Invitrogen™ Life Technologies, USA) according to the manufacturer’s instructions. 
Briefly, 2 l random hexamers (50 ng/l), 1 l deoxynucleoside 5’-triphosphate (dNTP) 
mix [10 mM each of 2’-deoxyadenosine 5’-triphosphate (dATP), 2’-deoxyguanosine 5’-
triphosphate (dGTP), 2’-deoxycytidine 5’-triphosphate (dCTP) and 2’-deoxythymidine 
5’-triphosphate (dTTP) at neutral pH] and the volume of mRNA calculated to give 2 
g/reaction tube, were added to a nuclease-free micro-centrifuge tube and then the total 
volume made up to 12 l with RNase-free distilled H2O. The mixture was heated to 
65C for 5 min, and then immediately chilled on ice. Then 8 l of the reaction mix 
[which consisted of 4 l 5 First-Strand buffer, 2 l 0.1 M dithiothreitol, 1 l 
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RNaseOUT Recombinant Ribonuclease Inhibitor and 1 l M-MLV RT] was added to 
the 12 l mRNA mix, and incubated for 10 min at 25C, followed by 50 min at 37C. 
The reaction was terminated by heating for 15 min at 70C, and then the mix chilled at 
4C. The cDNA was then stored at –20C until required for PCR. 
 
2.3.3.4. Optimisation of conditions for quantitative real-time PCR 
Pairs of primers (forward and reverse – see Table 2.1) were designed to amplify 
TRPV1, and also TRPV2, and TRPV4 which served as controls. These primers were 
designed and tested for sequence specificity using the computer database BLAST 
(http://www.ncbi.nlm.nih.gov/BLAST). Care was taken to ensure that primers were 
approximately 20 base pairs (bp) in length, had a guanine (G) and cytosine (C) content 
of approximately 50%, spanned across more than one exon, and ideally did not contain 
a G or a C at the 3’ end. It was not possible to design primers to amplify TRPV3, since 
at the time, the full cDNA for rat TRPV3 was unavailable. Primer melting temperatures 
(Tm, ideally 50-60C) were calculated using an online calculator 
(http://www.promega.com/biomath/default.htm), and restriction enzyme sites checked. 
Primers were also required to amplify -actin, which served as an internal reference to 
determine the relative quantities of mRNA, and these had been previously designed by 
PrimerBank (http://pga.mgh.harvard.edu/primerbank/). All primers were produced (high 
performance liquid chromatography purified) by Thermo Electron Corporation (Ulm, 
Germany). 
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Preliminary tests were then conducted to optimise conditions for use with each pair of 
primers as detailed below, and a standard curve consisting of serial dilutions of cDNA 
was run for each to determine the conditions required to obtain a linear curve over 3 
logs with a correlation coefficient of 0.98. Information in the literature concerning real-
time PCR with rat TRPV1, TRPV2 and TRPV4 was scarce at the time, therefore it was 
necessary to spend some time determining the optimal conditions for use with each pair 
of primers using conventional PCR, before it was possible to go on to use the primers in 
real-time PCR. 
 
There were a number of different factors to consider when optimising conditions for use 
with each pair of primers, firstly in conventional PCR, and then subsequently in real-
time PCR. Adjustments that were made to the conditions for conventional PCR included 
the temperature for the annealing phase of the PCR cycle, the duration of the 
polymerisation phase of the PCR cycle, the concentration of magnesium chloride 
(MgCl2) used in the PCR mix, and whether DMSO (Sigma, UK) was added to the mix. 
For real-time PCR, the volume of primers added to the PCR mix, the number of PCR 
cycles, the amount of sample used, and again the temperature for the 
annealing/extension phase of the PCR cycle, were all parameters that were adjusted to 
obtain the optimal conditions for each pair of primers. 
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Table 2.1. Rat primer sequences, melting temperatures and PCR product size 
Gene Primer sequence (5’→3’) Tm (ºC) PCR product size (bp) 
TRPV1 Forward tca tgg gtg aga ccg tca aca ag 58.5 167 
Reverse tcc ttg ccg tca gga gtg aa 55.4 
TRPV2 Forward act cgg tgc ggg aga tca tc 56.2 145 
Reverse acc aag tag cag gcg aag tt 50.8 
TRPV4 Forward cgc ctg act gat gag gag tt 51.6 198 
Reverse tgc cgt ctg ccc tcg gta gta 59.2 
β-actin Forward gaa atc gtg cgt gac atc aaa 54.7 216 
Reverse tgt agt ttc atg gat gcc aca g 52.6 
 
2.3.3.4a. Conditions for conventional PCR 
The temperature chosen for conventional PCR is usually approximately 5C lower than 
the lowest primer melting temperature, but since the melting temperatures for the 
reverse TRPV2 and forward TRPV4 primers were low (50.8C and 51.6C 
respectively), a temperature of 55C was selected initially for TRPV1 and TRPV4 
primers, and 50C for TRPV2 primers. The PCR machine was set to run for 35 cycles, 
and a concentration of 2 mM MgCl2 was used. PCR products were visualised by 
electrophoresis on a 2% agarose (Sigma, UK) gels stained with ethidium bromide 
(Sigma, UK) (20-30 min, approx. 100 V), under ultra-violet light. A 100 base pair 
SmartLadder SF™ (Eurogentec, UK) was used as a DNA marker. A 2% gel was 
selected since all PCR products were less than 200 bp in length (see Table 2.1). From 
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the first test runs with TRPV1, TRPV2 and TRPV4 primers, no band of cDNA was 
evident with TRPV1 primers. Bands of cDNA were evident between the 100 and 200 
base pair markers with TRPV4 and TRPV2 primers; however, an additional band at 
around the 400 base pair marker was evident with TRPV2 primers, indicating that 
conditions for use with TRPV2 primers needed to be optimised further in order that 
only the gene of interest was amplified. 
 
Additional bands on a gel may be due to primer-dimer formation, contamination by 
DNA (for example, from water), or correspond to genomic DNA, a spliced variant of 
the gene of interest, or another gene that has been amplified by the primers. If, after 
changing the PCR conditions several times, the additional band is still present, it would 
suggest that either the primers are not specific for the gene of interest, or that a spliced 
variant of the gene of interest is present. 
 
Next a range of concentrations of MgCl2 was tested (1, 2, 3, 4 and 5 mM), each with 
either distilled H2O or DMSO (4%) added to the PCR mix. This time a temperature of 
55C was used for all primer pairs. Again, nothing was seen with TRPV1 primers, 
whilst for TRPV2 primers at a concentration of 2 mM MgCl2, a band was seen at 
around the 400 base pair marker, and at a concentration of 4 mM MgCl2 (distilled H2O 
mix) bands of cDNA were seen between the 100 and 200 base pair markers as expected 
with a PCR product 145 bp in length. 
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In a further attempt to eliminate the band of cDNA evident between the 300 and 400 
base pair markers using TRPV2 primers, the polymerisation phase of the PCR cycle 
was shortened from 45 s to 30 s. However, a band was still seen at around the 400 base 
pair marker, in addition to the band expected for TRPV2, between the 100 and 200 base 
pair markers. 
 
When the temperature was reduced from 55C to 50C, a band of cDNA was observed 
for TRPV1 at a concentration of 4 mM MgCl2 (distilled H2O mix). 
 
2.3.3.4b. Conditions for real-time PCR 
Having optimised the conditions for the TRPV1, TRPV2 and TRPV4 primers thus far, 
the next step was to further optimise primer conditions using real-time PCR. For this, a 
temperature of 58C was selected for the annealing/extension phase of the PCR cycle, 
and a total of 45 cycles. Although the temperature for the annealing/extension phase is 
typically 60C for real-time PCR, a slightly lower temperature was chosen initially 
since relatively low temperatures had been found to be optimal for primers in 
conventional PCR. PCR products were visualised by electrophoresis as detailed in 
section 2.4.5.1, and the specificity of primer pairs was further determined by evaluating 
amplification plots and dissociation curves. Primer pairs were considered to be specific 
to the gene of interest when an increase of 1CT (threshold cycle – the PCR cycle 
number at which the amount of amplified product reaches a particular threshold value) 
was seen with every 1:2 dilution of cDNA, and a single peak was seen in the 
dissociation curve. 
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A volume of 1.5 l of each primer had been used in 50 l mix for conventional PCR, 
which is equivalent to using 0.6 l in 20 l mix required for real-time PCR. However, 
to reduce the likelihood of primer-dimer formation, a volume of 0.5 l of each primer in 
20 l mix was tested to begin with. These conditions appeared to be satisfactory for use 
with the TRPV1 primers, but the additional band seen in conventional PCR with 
TRPV2 primers was still evident. For TRPV2 primers, the number of cycles was then 
reduced to 40, and then again to 35 before eliminating the additional band of cDNA. 
The number of PCR cycles for use with TRPV4 primers was also reduced to 35. 
 
A standard curve was then constructed for each pair of primers. The first curve tested 
for TRPV1 primers was from 50-0.195 ng cDNA per well, but quantities less than 3.125 
ng per well were undetectable, and there was evidence of some primer-dimer 
amplification. A standard curve of 100, 50, 25, 12.5, 6.25 and 3.125 ng cDNA per well 
was then tested, reducing the number of PCR cycles to 40, but below 50 ng per well, the 
curves fell in the same region on the amplification plot as the negatives, rendering the 
standard curve useless. The formation of primer-dimers was a consistent difficulty and 
two different approaches were then followed to try to overcome this – using either less 
primer (0.25 l each in PCR mix) or more cDNA (8 l per well instead of 4 l). Using 
the larger volume of cDNA, the standard curve was repeated starting with 200 ng cDNA 
per well and ending with 12.5 ng per well, which was satisfactory. Standard curves were 
then tested for TRPV2 and TRPV4 primers, from 200–6.25 ng cDNA per well, and 
from 50–1.563 ng cDNA per well, respectively. The standard curve for TRPV2 primers 
was then repeated from 200-12.5 ng cDNA per well, whilst the standard curve for 
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TRPV4 primers was repeated from 100-6.25 ng cDNA per well – both of which proved 
to be satisfactory. 
 
Conditions for use with the -actin primers had been previously tested in our laboratory. 
The initial conditions tested here (standard curve 50-1.563 ng cDNA per well; 40 PCR 
cycles) did not require any modification – although it was evident that 25 cycles would 
in fact be sufficient. 
 
All of the above tests were carried out using cDNA synthesised using mRNA that had 
been extracted from heart tissue collected from in vitro I/R experiments (for more 
details see sections 2.2.5, 2.4.1, 2.4.2 and 2.4.4). The conclusions drawn from these 
tests (including the amount of cDNA required per well, which was determined from the 
standard curves) are summarised in Table 2.2. 
 
Table 2.2. Optimal conditions for primers used in real-time PCR (heart samples) 
Condition TRPV1 TRPV2 TRPV4 -actin 
no. PCR cycles 40 35 35 25 
primer concentration, nM 125 125 125 100 
standard curve (ng well
-1
) 200-12.5
 
200-12.5 100-6.25 50-1.563 
cDNA (ng well
-1
) 200 40 40 10 
 
It was also necessary to ascertain whether these conditions would be satisfactory for use 
with cDNA synthesised using mRNA extracted from DRG (see section 2.3.3.2). Tests 
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showed that the optimal standard curve was 100, 12.5, 6.25 and 3.125 ng cDNA per 
well, and 10 ng cDNA per well was used with all primers. 
 
2.3.3.5. Quantitative real-time PCR 
The PCR reaction was performed using cDNA prepared as described in section 2.3.3.3, 
diluted to give 200 ng per well for TRPV1, 40 ng per well for TRPV2 and TRPV4, and 
10 ng per well for -actin. cDNA from DRG samples was diluted to give 10 ng per well 
for TRPV1, TRPV2 and TRPV4. For TRPV1, TRPV2 and TRPV4, 8 l diluted cDNA 
was added to 10 l ABsolute QPCR SYBR Green Mix (Advanced Biotechnologies 
Ltd., UK) and 0.5 l primer pairs (5 M), and then RNase free dH2O added to give a 
final volume of 20 l. For -actin, 2 l diluted cDNA was added to 10 l ABsolute 
QPCR SYBR

 Green Mix and 0.4 l primer pairs (5 M), and then the total volume 
made up to 20 l with RNase free dH2O. 
 
Quantitative real-time PCR was carried out using an ABI PRISM

 7900HT thermal 
cycler (Advanced Biotechnologies Ltd., UK). The programme used consisted of an 
initial enzyme activation step (95C for 15 min), followed by either 35 cycles (TRPV2 
and TRPV4) or 40 cycles (TRPV1 and -actin) of denaturation and annealing/extension 
(95C for 15 s and 58C for 1 min, respectively). These steps were then followed by a 
dissociation curve, which consisted of heating to 95C (15 s), cooling to 60C (15 s) and 
then gradually re-heating to 95C. PCR products were then visualised by 
electrophoresis as detailed in section 2.3.3.4a. 
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Data were recorded using the ABI PRISM
®
 7900HT software package SDS 2.1 
(Advanced Biotechnologies Ltd., UK). The primary data obtained from real-time PCR 
using the ABI PRISM
®
 7900HT thermal cycler is CT – the PCR cycle number at which 
the amount of amplified product reaches a particular threshold value, which always 
occurs during the exponential phase of DNA amplification (Bustin, 2000). The amount 
of amplified cDNA is detected by means of a fluorescent dye, such as in this case 
SYBR
®
 Green, which binds to newly synthesised double-stranded DNA. An increase in 
the number of dye molecules bound results in an increase in fluorescence, which is 
measured at the end of each PCR cycle. 
 
Using the CT values generated, changes in TRPV1, TRPV2 and TRPV4 gene expression 
relative to expression of the internal control, β-actin, were determined using the 2-CT 
method of analysis. This method is discussed in detail by Livak and Schmittgen (2001), 
but the basic principle is that the amount of target gene (i.e. TPRVx) is equal to 2
-ΔΔC
T, 
where 
ΔΔCT = (CT target – CT actin)Time x – (CT target – CT actin)Time 0 
and Time x is at any time, and Time 0 represents the 1 expression of TRPVx 
normalised to β-actin. 
 
2.3.4 Western blot 
2.3.4.1. Sample collection 
Tissue for protein analysis was collected as detailed in section 2.3.2. 
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2.3.4.2. Preparation of tissue samples for Western blot 
Tissue samples obtained and stored as described in section 2.3.2 were pulverised using a 
stainless steel pestle and mortar cooled to -80°C. Each sample was then re-suspended in 
lysis buffer – a modified radioimmunoprecipitation (RIPA) buffer composed of (mM): 
Tris-HCl (10), sodium chloride (150), EDTA (1), ethylene glycol-bis(2-
aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA; 1), 0.1% sodium dodecyl sulphate 
(SDS), 1% IGEPAL

 CA-630 (octylphenyl-polyethylene glycol), 1% deoxycholate, 1% 
Triton X-100, and Complete
®
 protease inhibitor cocktail (Roche Diagnostics GmbH, 
Germany). Unless specified otherwise, reagents were obtained from Sigma, UK. 
Samples were vortexed and then left on ice for approximately 15 min, before 
homogenising (3×10 s). In addition to cardiac samples from in vitro I/R experiments, 
DRG from the pair of 5
th
 lumbar spinal nerves were removed from four rats and stored 
at -80°C, for use as a positive control. These samples were pooled and placed in 
homogenisation buffer, vortexed, and then left on ice for approximately 15 min, before 
homogenising (2×5 s). DRG from in vivo experiments were processed as individual 
samples. All samples were then left on ice for a further 30 min, before being centrifuged 
at 4528 ×g for 10 min at 4°C, and then the supernatant harvested. 
 
The concentration of protein in each sample was then determined by means of a 
Bradford assay as outlined in section 2.3.4.3. It was then possible to calculate the 
volume of each sample required to load onto polyacrylamide gels to give an equal 
amount of protein in each lane (typically 20 g). Samples were diluted accordingly with 
18 MΩ distilled H2O, and then sample buffer added in a 1:5 dilution. Sample buffer was 
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composed of (final concentration): Tris-HCl pH 6.8 (156.3 mM), sodium dodecyl 
sulphate (SDS; 5%), glycerol (50%) and phenol red (0.025%), to which -
mercaptoethanol was added in a 1:5 dilution. The sample/sample buffer mix was then 
boiled for 5 min. 
 
2.3.4.3. Determination of protein concentration (Bradford assay) 
The total protein concentration of each sample was assayed using the Bradford method 
(Bio-Rad, UK). Briefly, standards of bovine serum albumin (BSA; Sigma, UK) were 
prepared using 18 MΩ distilled H2O, to give 0.5, 0.25, 0.125, 0.0625 and 0.0 mg ml
-1
, 
and 10 l of each was then loaded in triplicate into a flat-bottomed 96-well plate. 
Samples were then vortexed and diluted using 18 MΩ distilled water – dilutions having 
to be adjusted so that optical density (OD) fell within the linear portion of the standard 
curve – and then loaded in triplicate, 10 l being added to each well. In addition, three 
wells were loaded with 10 l lysis buffer. 200 l Coomassie brilliant blue (Bio-Rad, 
UK) was then added to each well using an automatic pipette. The plate was then read at 
a wavelength of 570 nm, and a standard curve of protein concentration versus OD 
constructed to BSA, which was then used to determine the concentration of protein in 
each test sample. 
 
2.3.4.4. SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE involves separation of proteins based on their mass - electrophoretic 
mobility of proteins generally being linearly proportional to the logarithm of their mass 
- so that smaller proteins migrate towards the anode at a faster rate than larger proteins. 
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SDS is an anionic detergent that destabilises non-covalent interactions within the 
protein molecule, causing polypeptide chains to unfold, allowing approximately one 
molecule of SDS to bind to the polypeptide for every two amino acid residues. Thus 
SDS effectively coats proteins with an overall negative charge so that charge variability 
between proteins is eliminated. In order for SDS to bind to polypeptides, however, 
protein samples must first be denatured with a reducing agent such as -
mercaptoethanol. This was included in the sample buffer as described in section 2.3.4.2. 
 
2.3.4.5. Preparation of gels 
SDS 7% (w/v) polyacrylamide mini-gels (8×10 cm, 1 mm thick) were cast using the 
Mini-PROTEAN
®
 3 Cell apparatus (Bio-Rad, UK). Gels consisted of two components, 
a running and a stacking gel (refer to Table 2.3). The running gel was prepared first, 
vortexing gently to limit air bubble formation, and then carefully poured in between two 
glass plates using a pipette. The solution was overlaid with 18 MΩ distilled H2O, and 
allowed to polymerise for 45 min. Once the running gel had set, the water was emptied 
and the plates dried, and then the stacking gel was loaded, again taking care not to 
include any air bubbles. A comb, 1 mm thick, was then inserted into the stacking gel to 
create the wells into which the samples would be loaded. The stacking gel was also left 
for 45 min to polymerise. 
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Table 2.3. SDS-PAGE gel composition 
Running gel (7%) Stacking gel 
30% stock acrylamide/ 
bisacrylamide (37.5:1) 
2.33 ml 30% stock acrylamide/ 
bisacrylamide (37.5:1) 
650 µl 
1 M Tris-HCl, pH 8.8 
(final 0.375 M) 
3.75 ml 1 M Tris-HCl, pH 6.8 
(final 0.37 M) 
625 µl 
15 MΩ distilled H2O 3.82 ml 15 MΩ distilled H2O 3.28 ml 
10% SDS (final 0.1%) 100 µl 10% SDS (final 0.1%) 50 µl 
10% ammonium persulphate 
(APS; final 0.1%) 
100 µl 10% APS (final 0.075%) 37.5 µl 
N,N,N’,N’-
tetramethylethylenediamine 
(TEMED; final 0.1%) 
10 µl TEMED (final 0.1%) 5 µl 
 
2.3.4.6. Electrophoresis 
Gels prepared as detailed in section 2.3.4.5 were removed from the casting stand and 
frame, and assembled in the electrophoresis tank. The inner chamber was filled with 1 
running buffer (refer to Table 2.4 for composition), and then the combs carefully 
removed from the stacking gels. Tissue samples prepared as detailed in section 2.3.4.2 
were loaded into the wells in the stacking gels using a Hamilton syringe. One lane in 
each gel was loaded with Prestained Protein Marker, Broad Range (Cell Signaling 
Technology™, USA), which had been boiled for 5 min before use, which was later used 
to identify the protein band corresponding to TRPV1. The stacking gel was then run at 
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90 V for 20 min, and then the running gel at 120 V for 50 min, or until the dye had 
reached the bottom of the running gel. 
 
Table 2.4. Running buffer composition 
10 running buffer 1 running buffer 
Tris-HCl (final 0.25 M) 30.3 g l
-1 
10× running buffer 100 ml l
-1 
glycine (final 1.92 M) 144 g l
-1 
10% SDS (final 0.1%) 10 ml l
-1 
 
2.3.4.7. Protein transfer 
Proteins separated by SDS-PAGE were then transferred onto Hybond™ ECL™ 
nitrocellulose membrane (Amersham Biosciences, UK) to allow detection. The gels 
were carefully removed, from in between the glass plates used in electrophoresis, and 
the layer of stacking gel removed from each. The remaining running gels were then 
placed on nitrocellulose membrane, on top of 8 layers of carefully rolled out blotting 
paper, both of which had been soaked in positive transfer buffer for 20 min. Having 
checked that any air bubbles had been removed, 8 layers of blotting paper that had been 
soaked in negative transfer buffer for 20 min, were then placed on top of the gels, and 
any air bubbles gently expelled. Positive and negative transfer buffers were composed 
as detailed in Table 2.5, all reagents being obtained from Sigma, UK. The gels were 
then subjected to transfer for 1 h at 100 mA per nitrocellulose using a Trans-Blot
®
 SD 
semi-dry transfer cell (Bio-Rad, UK). 
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Table 2.5. Composition of transfer buffers 
Positive buffer Negative buffer 
methanol 100ml per 500ml (20%) methanol 100ml 
Tris base 18.3 g (0.3 M) Tris base 1.5 g (25 mM) 
6-aminocaproic acid 2.6g (40 mM) 
 
2.3.4.8. Incubation and detection 
Blots were blocked, for 1 h at room temperature, with 5% (w/v) non-fat milk (Marvel
®
) 
in Tween-20 buffer composed of (mM): sodium chloride (150), Tris-HCl pH 7.6 (10 
mM) and 0.05% (w/v) Tween-20. After washing with Tween-20 buffer, blots were then 
incubated overnight at 4°C with a TRPV1 antibody (rabbit anti-VR1 N-terminus; 
Neuromics, USA), diluted 1:2000 in 2% (w/v) non-fat milk in Tween-20 buffer, 
prepared 3-4 h before required and kept refrigerated. In order to confirm the specificity 
of the TRPV1 antibody, a single blot was incubated with TRPV1 antibody in the 
presence of the control peptide (VR1 N Blocking Peptide; Neuromics, USA), diluted 
1:200 in 2% (w/v) non-fat milk in Tween-20 buffer. The TRPV1 antibody/peptide mix 
was made up 3 h prior to use to enable binding. Membranes were again washed with 
Tween-20 buffer and then incubated with goat anti-rabbit IgG secondary antibody 
conjugated with horseradish peroxidase (DakoCytomation Denmark A/S, Denmark), 
diluted 1:2000 in Tween-20 buffer. 
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Detection of labelled antigen was performed using an enhanced chemiluminescence 
detection system (LumiGLO™ and Peroxide Reagent, Cell Signaling Technology™, 
USA) and autoradiographic film (Amersham Biosciences, UK). 
 
2.3.4.9. Effects of I/R injury on TRPV1 protein expression 
Left ventricle samples were collected from hearts subjected to I/R in vitro or in vivo, as 
described in section 2.3.2. Samples were first homogenised and protein concentration 
determined by Bradford assay (see section 2.3.4.3). The samples were then subjected to 
SDS-PAGE (7%) as detailed in section 2.3.4.4, followed by electrotransfer onto a 
nitrocellulose membrane (see section 2.3.4.7). Protein was detected using rabbit anti-
VR1 (TRPV1) N-terminus antibody (Neuromics, USA) and goat anti-rabbit HRP-linked 
antibody (Dako, Denmark), as described in section 2.3.4.8. Detection of labeled antigen 
was performed using an enhanced chemiluminescence detection system and 
autoradiographic film. 
 
2.4. Preparation of drugs 
Indomethacin, L-NAME, SNP, 12-LOX, NDGA, baicalein (5,6,7-trihydroxyflavone) 
and NBT were made up fresh each day. All other drugs were made up as stock solutions 
and stored at -20°C until required, with the exception of capsaicin and capsazepine, 
which were stored at 4°C. Indomethacin was made in 5% sodium bicarbonate in 18 MΩ 
distilled H2O. L-NAME was dissolved in 3 ml saline (sodium chloride, 0.9%), and then 
added to Krebs. SNP and NBT were made in saline. 12-LOX was diluted in phosphate 
buffered saline. NDGA was made in 100% ethanol, and then diluted further in saline. 
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Baicalein was made in 100% DMSO, then diluted initially in 50% DMSO/50% saline, 
and then diluted further in saline. Stock solutions of BK, SP, NKA, NKB, CGRP and 
αCGRP8-37 were made in 18 MΩ distilled H2O, and then diluted further in saline. 
Capsaicin and capsazepine stock solutions were made in 100% ethanol, which were 
diluted initially in 50% ethanol/50% saline, and then diluted further in saline. Stock 
solutions (10
-2
 M) of U46619 (9,11-dideoxy-11,9-epoxymethanoprostaglandin F2) 
and PGE2 were made in 100% ethanol, then diluted to 10
-3
 M in 50% ethanol/50% 
saline, and then diluted further in saline. A stock solution of 12(S)-HpETE was made in 
100% ethanol, and then subsequent dilutions were made in Krebs – both ethanol and 
Krebs being first bubbled with a 95% N2/5% CO2 mix, to minimise oxidation of 12(S)-
HpETE. A stock solution of AA was made in 100% ethanol, and then for bolus 
injections, further dilutions were made in ethanol, whilst for infusion of AA, further 
dilutions were made in saline. Whilst bolus doses of AA were therefore given in 100% 
ethanol, this was diluted in Krebs flowing at a rate of 10 ml min
-1
 thus diluting the 
ethanol to 0.01% - and tests showed that the vehicle had no effect. Stock solutions of 
SR 140333 [(S)-1{2-[3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenylacetyl)piperidin-3-
yl]ethyl}-4-phenyl-1-azoniabicyclo[2,2,2]octane chloride] and MEN 11420 [(Asn{2-
AcNH--D-Glc}-Asp-Trp-Phe-Dap-Leu) c(2-5)] were made in 100% DMSO, and 
then further diluted in saline. A stock solution of SR 142801 [(S)-(N)-(1-{3-[1-benzoyl-
3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl)-N-
methylacetamide] was also made in 100% DMSO, but then diluted initially in 50% 
DMSO/50% saline, and then further diluted in saline. Final bath concentrations of 
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DMSO and ethanol never exceeded 0.05% and 0.15% respectively. All stock solutions 
were kept at –20 C. 
 
2.5. Sources of drugs 
Drug name Source 
CGRP8-37 Bachem (UK) 
12(S)-HpETE Cayman Chemicals (Ann Arbor, MI, USA) 
12-LOX 
AA 
baicalein Sigma (UK) 
BK Bachem (UK) 
capsaicin Sigma (UK) 
capsazepine 
CGRP 
indomethacin 
L-NAME Sigma (UK) 
MEN 11420 A. Menarini Ricerche S.p.A. (Florence, Italy)* 
NBT Sigma (UK) 
NDGA 
NKA Bachem (UK) 
NKB 
PGE2 Sigma (UK) 
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SNP Sigma (UK) 
Sodium pyruvate 
SP 
SR 140333 A. Menarini Ricerche S.p.A. (Florence, Italy)* 
SR 142801 
U46619 Sigma (UK) 
*A generous gift from Sandro Giuliani. 
 
2.6. Data analysis and statistics 
Data obtained from experiments using the Langendorff preparation are expressed as 
arithmetic mean  S.E.M. (standard error of mean), with the value of n referring to the 
number of tissue samples (obtained from separate animals) unless otherwise stated. 
Vasodilator responses are expressed as a reduction in CPP, in mmHg (calculated as 
detailed in section 2.2.1.2). Infarct sizes are expressed as percentage tissue damaged. 
 
Dose-response curves were fitted to a sigmoidal dose-response curve using GraphPad 
Prism

 Version 5.00 (GraphPad Software, San Diego, CA), which also calculated the 
mean of the negative logarithm of the molar agonist concentration that elicits 50% of 
the maximum response possible with that agonist (pEC50). In order to determine the 
S.E.M. of the pEC50, it was necessary to plot dose-response curves for each individual 
set of data, fit each to a sigmoidal dose-response curve as before, and then calculate the 
mean and S.E.M. from the individual curves. In cases where a maximum was not 
reached on dose-response curves for individual data sets, the quoted pEC50 and S.E.M. 
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are approximate values, as indicated in the text. Where dose-response curves were 
constructed in the presence of an antagonist, and responses to the agonist were greatly 
attenuated such that a full curve was not produced, the pEC50 was not determined (ND). 
 
When comparing dose-response curves, in the absence or presence of enzyme inhibitors 
or receptor antagonists, statistical significance (indicated by a probability level, P, of 
0.05 or less) was established with two-way analysis of variance (ANOVA). Two-way 
ANOVA is used to determine how a response is affected by two variables; for example, 
the effect of drug treatment and dose on CPP. When comparing curves for control, 
capsaicin and capsazepine data, two two-way ANOVA tests were performed, and the P 
value from each was doubled to account for the control data having been used twice (in 
effect, three-way ANOVA). Two-way ANOVA was also used to analyse multiple time 
course curves for LVDP and CPP data from I/R studies - curves compared from the 
point at which reperfusion was initiated. In this example, the two variables that could 
affect the response (i.e. LVDP/CPP) were drug treatment and time. Bonferroni post-
tests were then used following two-way ANOVA to compare curves at different doses 
or time points, as applicable. When comparing infarct sizes from I/R studies, one-way 
ANOVA with Dunnett’s Multiple Comparison Test (to compare each group mean to the 
control) was used, as there were three or more groups of unmatched data. When 
comparing the means of two sets of data (for example, reduction in CPP before and after 
treatment with an antagonist) Student’s t-test analysis was used – either paired or 
unpaired, depending on whether or not observations were recorded in the same heart, 
and choosing a two-tailed P value since it was not predicted which group would have 
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the larger mean (if indeed the means were found to be different), before collecting data. 
Where sample sizes were very small (for example, n=3-4), it was necessary to use a 
non-parametric test to compare two groups, and for unpaired data, the Mann-Whitney 
test was used, whilst for paired data, the Wilcoxon matched-pairs signed rank test was 
used – both these tests comparing group medians. Statistical analysis was not possible 
where n<3. All statistical tests were performed using GraphPad Prism
®
 Version 5.00, 
which was also used to prepare graphs. 
 
Results from real-time PCR were recorded and analysed using the ABI PRISM

 
7900HT software package SDS 2.1 (Advanced Biotechnologies Ltd., UK). Relative 
changes in gene expression were then analysed using the 2
-C
T method (Livak and 
Schmittgen, 2001), mRNA expression being normalised for each sample with respect to 
the corresponding β-actin expression, and results presented as the mean TRPVx/β-actin 
ratio ± S.E.M.. (For derivation of the 2
-C
T method, see Box 2.1.) 
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Box 2.1. Derivation of the 2
-C
T method. From Livak and Schmittgen (2001). 
The exponential amplification of PCR is 
described by the equation 
Xn = X0  (1 + EX)
n
 
where Xn is the number of target molecules at 
cycle n of the reaction, X0 is the initial 
number of target molecules, EX is the 
efficiency of target amplification, and n is the 
number of cycles. The threshold cycle (CT) 
indicates the fractional cycle number at 
which the amount of amplified target reaches 
a fixed threshold. Thus, 
XT = X0  (1 + EX)
C
T,X = KX 
where XT is the threshold number of target 
molecules, CT,X is the threshold cycle for 
target amplification, and KX is a constant. A 
similar equation for the internal reference 
gene reaction is 
RT = R0  (1 + ER)
C
T,R = KR 
where RT is the threshold number of 
reference molecules, ER is the efficiency of 
the reference amplification, CT,R is the 
threshold cycle for reference amplification, 
and KR is a constant. 
 
Dividing XT by RT gives the expression 
XT = X0  (1 + EX)
C
T,X = KX = K 
RT = R0  (1 + ER)
C
T,R = KR = K 
K 
For real-time amplification using TaqMan 
probes, the exact values of XT and RT depend 
on a number of factors including the reporter 
dye used in the probe, the sequence context 
effects on the fluorescence properties of the  
 probe, the efficiency of probe cleavage, 
purity of the probe, and setting of the 
fluorescence threshold. Therefore, the 
constant K does not have to be equal to unity. 
Assuming efficiencies of the target and the 
reference are the same, 
EX = ER = E, 
X0  (1 + E)
C
T,X
-C
T,R = K, 
R0  (1 + E)
C
T,X
-C
T,R = K, 
or 
XN  (1 + E)
C
T = K 
where XN is equal to the normalised amount 
of target (X0/R0) and CT is equal to the 
difference in threshold cycles for target and 
reference (CT,X – CT,R). 
 
Re-arranging gives the expression 
XN = K  (1 + E)
-C
T 
The final step is to divide the XN for any 
sample q by the XN for the calibrator (cb): 
XN,q = K  (1 + E)
-C
T,q = (1 + E)
-C
T 
XN,cb = K  (1 + E)
-C
T,cb = (1 + E)
-C
T 
Here -CT = -(CT,q-CT,cb). 
 
For amplicons designed to be less than 150 
bp and for which the primer and Mg
2+
 
concentrations have been properly optimised, 
the efficiency is close to unity. Therefore, the 
amount of target, normalised to an internal 
reference and relative to a calibrator, is given 
by 
amount of target = 2
-C
T 
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Using GraphPad Prism
®
 Version 5.00, unpaired Student’s t-test analysis was then 
performed to evaluate differences in levels of mRNA abundance in hearts subjected to 
I/R against control values, P<0.05 being considered as significant. A two-tailed test was 
chosen since it was not predicted which group would have the larger mean (if indeed the 
means were found to be different), before collecting data. β-actin was selected as an 
internal reference as it is expressed in most cell types at reasonable levels (Bustin, 2000) 
and, despite evidence that β-actin expression increases in the cortex (Harrison et al., 
2000) and decreases in the hippocampal CA1 region (Farwell et al., 1998) of the brain 
following an ischaemic insult, it would appear from the literature that its level of 
expression within the heart is not affected by ischaemia (Liedtke and Lynch, 1999). 
 
Densitometric analysis was performed on scanned images from Western blots (Hewlett 
Packard Scanjet) and analysed using Scion Image
®
 software for Windows (National 
Institutes of Health, Bethesda, MD). TRPV1 expression was normalised for each 
sample with respect to the corresponding α-actin expression (which served as a loading 
control), and results were presented as the mean TRPV1/α-actin ratio ± S.E.M.. Using 
GraphPad Prism
®
 Version 5.00, unpaired Student’s t-test analysis was then performed 
to evaluate levels of protein expression after I/R versus control values, P<0.05 being 
considered significant.  
  
133 
 
3. VASODILATOR RESPONSES IN THE ISOLATED RAT 
AND MURINE HEART 
 
In order to test the hypothesis that 12-LOX products activate TRPV1 in the heart, I 
measured changes in vasodilator function. This approach was based on the combined 
evidence demonstrating both 12(S)-HETE and 12(S)-HpETE to be potent vasodilators 
of coronary microvessels (Zink et al., 2001), and evidence suggesting that a 12-LOX 
product, specifically 12(S)-HpETE, activates TRPV1 on sensory C-fibres (Hwang et al., 
2000). Since activation of C-fibres within the coronary vasculature is associated with 
vasodilatation (Rubino and Burnstock, 1996), this raised the question of whether it 
would be feasible to investigate the potential activation of C-fibres by 12-LOX 
metabolites, by measuring changes in coronary vasodilator function. 
 
3.1. Vasodilator activity of 12(S)-HETE and 12(S)-HpETE 
Although 12(S)-HpETE has been shown to be a more potent activator of TRPV1 than 
12(S)-HETE (Hwang et al., 2000), I initially tried working with 12(S)-HETE since it is 
more stable than 12(S)-HpETE – the latter being readily oxidised to 12(S)-HETE 
(illustrated in Figure 1.2). As already mentioned, 12(S)-HpETE is also light-sensitive, 
which contributes to its instability. Whilst attempts were made to construct dose-
response curves to 12(S)-HETE (10
-11–310-9 mol), it can be seen from Figure 3.1 that 
responses were highly were highly variable. Variability remained a problem even when 
doses were administered up to 45 min apart in an attempt to avoid possible 
desensitisation. 
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Figure 3.1. Example trace showing the vasodilator response to 12(S)-HETE. Sections taken 
from two different traces illustrating the variability in the vasodilator response to a bolus dose of 
12(S)-HETE (10 pmol) in isolated rat hearts. 
 
No improvement in reproducibility of responses to 12(S)-HETE was seen when a single 
dose of 12(S)-HETE (10
-14–10-10 mol) was administered per heart (n=2-4). Even when 
hearts were pre-constricted with either U46619 (10 nM) or L-NAME (300 µM), 
responses to 12(S)-HETE remained small and variable (see Figure 3.2) and so 
experiments with 12(S)-HETE were abandoned. The rationale behind using the nitric 
oxide synthase (NOS) inhibitor L-NAME in an attempt to enhance vasodilator 
responses to 12(S)-HETE is as follows. A tenet of the concept of ‘vasodilator reserve’ is 
that an essential pre-requirement for vasodilatation is high vascular tone. Basal vascular 
tone is regulated predominantly by the tonic release of vasodilators, particularly NO. 
NO is generated by endothelial NOS at a continuous low, basal rate in response to flow, 
exerting a continuous vasodilator influence on the arterial system. If production of NO 
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is prevented, for example, using L-NAME, the balance between vasodilator and 
vasoconstrictor influences over vascular tone is shifted towards vasoconstriction. From 
Figure 3.2 it can be seen that despite raising tone, responses to 12(S)-HETE in the 
presence of L-NAME were smaller than control responses. 
 
control L-NAME
0
5
10
15
20
25
M
e
a
n
 r
e
d
u
c
ti
o
n
 i
n
 C
P
P
 (
m
m
H
g
)
 
Figure 3.2. Effect of NOS inhibition on 12(S)-HETE-induced vasodilatation. Effect of NOS 
inhibition with L-NAME (300 M) on responses to 12(S)-HETE (10 pmol) in isolated rat heart. 
Vasodilator responses are expressed as a reduction in CPP (mmHg). Data shown as arithmetic 
mean  S.E.M. (n=4, control; n=2, plus L-NAME). Insufficient data to perform statistical 
analysis. 
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12(S)-HpETE (10
-20–10-15 mol) caused dose-dependent vasodilatation (approximate 
pEC50 = 18.2  0.7, maximum response = 10.2  3.2 mmHg, n=6-7), although again 
variability of responses was a problem, as had been the case with 12(S)-HETE. An 
example of the vasodilator response to a bolus dose of 12(S)-HpETE is shown in Figure 
3.3 below. 
 
 
Figure 3.3. Example trace showing the vasodilator response to 12(S)-HpETE. Section taken 
from trace illustrating the vasodilator response to a bolus dose of 12(S)-HpETE (0.1 fmol) in 
isolated rat heart. 
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3.1.1. The role of sensory C-fibres and TRPV1 in 12(S)-HpETE-induced 
vasodilatation 
Despite the variability in the responses to 12(S)-HpETE, responses were abolished by 
C-fibre desensitisation (P<0.001, n=6-7) or by capsazepine treatment (P<0.001, n=5-7) 
(Figure 3.4). 
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Figure 3.4. Effect of C-fibre desensitisation and TRPV1 blockade on 12(S)-HpETE-
induced vasodilatation. Effect of C-fibre desensitisation with capsaicin (1 M, 20 min; 30-min 
washout) and TRPV1 blockade with capsazepine (3 M, 20 min) on 12(S)-HpETE-induced 
coronary vasodilatation in the isolated rat heart. Vasodilator responses are expressed as a 
reduction in CPP (mmHg). Data obtained in the presence of indomethacin (5 M). Data shown 
as arithmetic mean ± S.E.M. (n=5-7). Significant difference is shown as ***P<0.001 compared 
to control using two-way ANOVA, and as 
#
P<0.05 with Bonferroni post-test. 
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3.1.2. The effect of sensory neuropeptide antagonists on 12(S)-HpETE-induced 
vasodilatation 
It can be seen from the previous figure that there was considerable variability in 
responses to 12(S)-HpETE, and this posed an even greater problem when trying to 
compare responses to a single dose of 12(S)-HpETE (0.1 fmol) in the absence and then 
in the presence of various antagonists. This dose was chosen since it had caused the 
maximal response to 12(S)-HpETE in the previous set of experiments (maximum 
response = 10.2  3.2 mmHg, n=7). 
 
The CGRP receptor antagonist CGRP8-37 (0.3 M) appeared to reduce the response to 
12(S)-HpETE by almost 50%; however this did not reach statistical significance 
(P=0.3750, n=4; Figure 3.5). Results from a few experiments showed that this 
concentration of CGRP8-37 also suppressed vasodilator responses to CGRP (30 pmol), 
by approximately 85% (P=0.2500, n=3; data not shown). 
 
The NK1 receptor antagonist SR 140333 (1 M) also reduced the response to 12(S)-
HpETE, but this did not reach statistical significance (P=0.3048, n=7; Figure 3.6). This 
concentration of SR 140333 was tested against vasodilator responses to SP (30 pmol), 
and was found to suppress responses by approximately 40% (n=2; data not shown). 
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Figure 3.5. Effect of CGRP receptor blockade on 12(S)-HpETE-induced vasodilatation. 
Responses to 12(S)-HpETE (0.1 fmol) before and after infusion of CGRP8-37 (0.3 M, 20 min). 
Vasodilator responses are expressed as a reduction in CPP (mmHg). Data obtained in the 
presence of indomethacin (5 M). Data shown as arithmetic mean  S.E.M. (n=4). Statistical 
analysis performed using non-parametric Wilcoxon matched-pairs signed rank test. 
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Figure 3.6. Effect of NK1 receptor blockade on 12(S)-HpETE-induced vasodilatation. 
Responses to 12(S)-HpETE (0.1 fmol) before and after infusion of SR 140333 (1 M, 20 min). 
Vasodilator responses are expressed as a reduction in CPP (mmHg). Data obtained in the 
presence of indomethacin (5 M). Data shown as arithmetic mean  S.E.M. (n=7). Statistical 
analysis performed using paired Student’s t-test. 
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Despite the small sample sizes for tests to check that both the NK1 and CGRP receptor 
antagonists blocked responses to SP and CGRP respectively, both antagonists at the 
concentrations used have already been well validated, and these cursory tests confirmed 
that their activity was as described in the literature. 
 
The NK2 receptor antagonist MEN 11420 (1 µM) and the NK3 receptor antagonist SR 
142801 (1 µM) did not block the responses to either NKA (25 nmol) or NKB (25 nmol). 
The maximum vasodilator response to NKA in the absence of MEN 11420 was 3.1  
3.6 mmHg (n=6) and 7.7  3.3 mmHg (n=6) in the presence of MEN 11420. In a similar 
vein, NKB (which caused vasoconstriction) caused an increase in CPP of 12.3  3.6 
mmHg (n=5) in the absence of, and 13.3  4.1 mmHg (n=5) in the presence of, 
SR142801. Since responses to NKA and NKB were not blocked by MEN 11420 and SR 
142801 respectively, it would suggest that there were either no or few NK2 and NK3 
receptors present in the tissue preparation. These antagonists had no significant effect 
on responses to 12(S)-HpETE (n=5-6). 
 
The responses to 12(S)-HpETE were profoundly variable in the above experiments – an 
effect that was not dependent upon level of tone, or the timing of the dose, suggesting 
that issues of stability likely were influencing the findings. In light of this data, an 
alternative approach to investigating 12-LOX product activity was devised. 
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3.2. 12-LOX and AA: an alternative approach to studying 12(S)-
HpETE-induced vasodilatation 
Pilot studies demonstrated that a bolus dose of AA (30 nmol) caused a decrease in CPP, 
in both the absence and presence of exogenous 12-LOX. Initial tests with the 12-LOX 
inhibitor baicalein demonstrated that the vasodilator response to AA in the absence of 
12-LOX was likely to be attributable to (endogenous) 12-LOX activity. As shown in 
Figure 3.7, the response to AA was attenuated by approximately 45% after a 30-min 
infusion of baicalein (10 M). 
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Figure 3.7. Effect of 12-LOX inhibition on AA-induced vasodilatation. Effect of 12-LOX 
inhibition with baicalein (10 M, 30 min) on responses to AA (30 nmol) in isolated rat heart, in 
the absence of exogenous 12-LOX. Vasodilator responses are expressed as a reduction in CPP 
(mmHg). Data obtained in the presence of indomethacin (5 M). Bolus doses tested in single 
heart (n=4, before infusion; n=3, after infusion). (Insert: Data shown as arithmetic mean ± 
S.E.M.. Statistical analysis performed using unpaired Student’s t-test. Significant difference is 
shown as *P<0.05.) 
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However, construction of dose-response curves demonstrated that co-infusion of hearts 
with exogenous 12-LOX produced responses of greater reproducibility between hearts. 
AA-induced vasodilator responses were compared with or without infusion of 
exogenous 12-LOX (2 g ml-1). Figure 3.8 demonstrates that AA produced dose-
dependent vasodilatation that is enhanced in the presence of 12-LOX: however, 
construction of repeat dose-response curves was not possible, regardless of whether or 
not exogenous 12-LOX was infused. 
 
It was therefore decided that exogenous 12-LOX (2 g ml-1) would be infused in all 
future experiments with AA, but that it would not be possible to compare dose-response 
curves to AA before or after drug treatment in any single heart. Thus, from here on in 
all studies, only a single dose-response curve was constructed in any heart and in all 
investigations comparing dose-response curves in the absence and presence of drug 
antagonists or inhibitors, unpaired statistical analyses were used for determination of 
significance. 
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Figure 3.8. Effect of exogenous 12-LOX on magnitude and reproducibility of vasodilator 
responses to AA. Comparison between dose-response curves to AA constructed 30 min apart, 
(A) in the absence of 12-LOX and (B) in the presence of exogenous 12-LOX (2 g ml-1). 
Vasodilator responses are expressed as a reduction in CPP (mmHg). Data obtained in presence 
of indomethacin (5 M). Data shown as arithmetic mean ± S.E.M. (n=3, minus 12-LOX; n=5, 
plus 12-LOX). 
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3.3. Characterisation of coronary vasodilator responses to AA in rat 
heart 
AA (10
-10–10-6 mol) caused dose-dependent vasodilatation (pEC50 = 7.1  0.1, 
maximum response = 22.4  1.6 mmHg, n=5) that was abolished by treatment with 
NDGA (P<0.0001, n=5-8; Figure 3.9). 
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Figure 3.9. Effect of LOX inhibition on AA-induced vasodilatation. Effect of 12-LOX 
inhibition achieved using NDGA (10 M, 30 min) on AA-induced coronary vasodilatation in 
the isolated 12-LOX (2 g ml-1)-perfused rat heart. Vasodilator responses are expressed as a 
reduction in CPP (mmHg). Data obtained in the presence of indomethacin (5 M). Data shown 
as arithmetic mean ± S.E.M. (n=5-8). Significant difference is shown as ***P<0.0001 compared 
to control using two-way ANOVA, and as 
###
P<0.001 with Bonferroni post-test. 
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The vasodilator response to AA (pEC50 = 6.9  0.1, maximum response = 32.9  2.6 
mmHg, n=4) was also abolished by treatment with baicalein (P<0.0001, n=4-8; Figure 
3.10). That the vasodilator response to AA appears to be mediated by a 12-LOX 
product, and that 12(S)-HpETE also produces coronary vasodilatation, offers support 
for our approach to studying the effects of 12(S)-HpETE by administering the enzyme 
involved in production of 12(S)-HpETE together with its substrate. 
 
-11 -10 -9 -8 -7 -6 -5
0
10
20
30
40 control (n=4)
+ baicalein (n=8)
***
###
###
###
log10 AA dose (mol)
M
e
a
n
 r
e
d
u
c
ti
o
n
 i
n
 C
P
P
 (
m
m
H
g
)
 
Figure 3.10. Effect of 12-LOX inhibition on AA-induced vasodilatation. Effect of 12-LOX 
inhibition achieved using baicalein (10 M, 30 min) on AA-induced coronary vasodilatation in 
the isolated 12-LOX (2 g ml-1)-perfused rat heart. Vasodilator responses are expressed as a 
reduction in CPP (mmHg). Data obtained in the presence of indomethacin (5 M). Data shown 
as arithmetic mean ± S.E.M. (n=4-8). Significant difference is shown as ***P<0.0001 compared 
to control using two-way ANOVA, and as 
###
P<0.001 with Bonferroni post-test. 
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3.3.1. The role of sensory C-fibres and TRPV1 in 12-LOX/AA-induced 
vasodilatation 
Vasodilator responses to AA (pEC50 = 7.0  0.1, maximum response = 34.2  5.9 
mmHg, n=5) were also blocked by a desensitising dose of capsaicin (P0.001, n=5) or 
capsazepine (P<0.001, n=7) (Figure 3.11). Since the vasodilator response to 12(S)-
HpETE had also been blocked by capsazepine, it was proposed that AA, metabolised to 
12(S)-HpETE via 12-LOX, activates TRPV1 on C-fibres, to cause vasodilatation. 
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Figure 3.11. Effect of C-fibre desensitisation and TRPV1 blockade on AA-induced 
vasodilatation. Effect of C-fibre desensitisation achieved using capsaicin (1 M, 20 min; 30-
min washout) and TRPV1 blockade using capsazepine (3 M, 20 min) on AA-induced coronary 
vasodilatation in the isolated 12-LOX (2 g ml-1)-perfused rat heart. Vasodilator responses are 
expressed as a reduction in CPP (mmHg). Data obtained in the presence of indomethacin (5 
M). Data shown as arithmetic mean ± S.E.M. (n=5-7). Significant difference is shown as 
***P<0.0001 compared to control using two-way ANOVA, and as 
##
P<0.01 and 
#
P<0.05 with 
Bonferroni post-test. 
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3.3.2. The effect of sensory neuropeptide antagonists on 12-LOX/AA-induced 
vasodilatation 
Vasodilator responses to AA (pEC50 = 7.0  0.1, maximum response = 25.9  1.8 
mmHg, n=4) were profoundly attenuated by CGRP8-37 (P<0.0001, n=6; Figure 3.12, 
which suppressed the maximum response by approximately 80%. 
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Figure 3.12. Effect of CGRP receptor blockade on AA-induced vasodilatation. Effect of 
blockade of CGRP receptors achieved using CGRP8-37 (0.3 M, 20 min) on AA-induced 
coronary vasodilatation in the isolated 12-LOX (2 g ml-1)-perfused rat heart. Vasodilator 
responses are expressed as a reduction in CPP (mmHg). Data obtained in the presence of 
indomethacin (5 M). Data shown as arithmetic mean ± S.E.M. (n=4-6). Significant difference 
is shown as ***P<0.0001 compared to control using two-way ANOVA, and as 
###
P<0.001 with 
Bonferroni post-test. 
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Vasodilator responses to AA (pEC50 = 7.0  0.1, maximum response = 30.7  2.6 
mmHg, n=6) were also attenuated by SR 140333, which caused a rightward shift 
(approximately 10-fold) of the dose-response curve (P<0.0001, n=8; Figure 3.13), and 
suppressed the maximum response by approximately 60%. 
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Figure 3.13. Effect of NK1 receptor blockade on AA-induced vasodilatation. Effect of 
blockade of NK1 receptors achieved using SR 140333 (1 M, 15 min) on AA-induced coronary 
vasodilatation in the isolated 12-LOX (2 g ml-1)-perfused rat heart. Vasodilator responses are 
expressed as a reduction in CPP (mmHg). Data obtained in the presence of indomethacin (5 
M). Data shown as arithmetic mean ± S.E.M. (n=6-8). Significant difference is shown as 
***P<0.0001 compared to control using two-way ANOVA, and as 
###
P<0.001 with Bonferroni 
post-test. 
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Vasodilator responses to AA (approximate pEC50 = 6.5  0.2, maximum response = 
30.9  6.0 mmHg, n=6) were attenuated by combined treatment with CGRP8-37 and SR 
140333 (P0.0001, n=6; Figure 3.14), but interestingly combined treatment did not 
result in greater suppression of responses to AA than did treatment with either 
antagonist alone – the maximum response to AA being suppressed by approximately 
70%. 
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Figure 3.14. Combined effect of CGRP and NK1 receptor blockade on AA-induced 
vasodilatation. Effect of blockade of CGRP receptors achieved using CGRP8-37 (0.3 M, 20 
min) and NK1 receptors using SR 140333 (1 M, 15 min) on AA-induced coronary 
vasodilatation in the isolated 12-LOX (2 g ml-1)-perfused rat heart. Vasodilator responses are 
expressed as a reduction in CPP (mmHg). Data obtained in the presence of indomethacin (5 
M). Data shown as arithmetic mean ± S.E.M. (n=6). Significant difference is shown as 
***P<0.0001 compared to control using two-way ANOVA, and as 
###
P<0.001 with Bonferroni 
post-test. 
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Comparison of the pEC50 in all vehicle control experiments demonstrated that in most 
instances the vehicle had no effect on pEC50. However, as can be seen in Table 3.1, this 
was not the case for experiments with combined CGRP and NK1 receptor blockade; 
although statistical analysis using one-way ANOVA showed that means were not 
significantly different (P=0.1810, n=4-6). 
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Table 3.1. Effect of various drug treatments on pEC50 and maximum response to 
AA 
Treatment; n pEC50 AA Max. response (mmHg) 
no vehicle; 5 6.9  0.1 32.4  2.6 
vehicle; 5 
NDGA; 8 
7.1  0.1 22.4  1.6 
ND 2.9  1.1 
vehicle; 4 
baicalein; 8 
6.9  0.1 32.9  2.6 
ND 8.3  2.2 
vehicle; 5 
capsaicin; 5 
capsazepine; 7 
7.0  0.1 34.2  5.9 
ND 12.7  4.0 
ND 6.0  1.5 
vehicle; 4 
CGRP8-37; 6 
7.0  0.1 25.9  1.8 
ND 6.4  2.6 
vehicle; 6 
SR 140333; 8 
7.0  0.1 30.7  2.6 
6.4  0.2 14.1  2.6 
vehicle; 6 
CGRP8-37 + SR 140333; 6 
6.5  0.2 30.9  6.0 
ND 8.7  2.6 
NB. In some instances, a maximum response was not reached on the dose-response curve for 
an individual data set. In this case the corresponding pEC50 value quoted is an approximate 
value, as indicated in the previous text. Data shown as arithmetic mean  S.E.M. (n=4-6). 
Statistical analysis performed on vehicle data using one-way ANOVA with Dunnett’s Multiple 
Comparison Test. No significant difference found between vehicle means, P>0.05. ND signifies 
where it was not possible to determine a pEC50. 
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3.4. 12-LOX/AA-induced vasodilatation in TRPV1 KO mice 
AA (10
-10–10-6 mol) also caused dose-dependent vasodilatation in hearts from WT mice 
(pEC50 = 8.2  0.2, maximum response = 22.0  8.5 mmHg, n=5). This response was 
significantly (P0.05) shifted to the right by approximately 30-fold in hearts from 
TRPV1 KO mice, but the maximum response was unaffected (pEC50 = 6.6  0.4, 
maximum response = 24.9  7.7 mmHg, n=5; Figure 3.15). There was no difference in 
basal CPP between WT and KO animals (WT, 112.3  6.7 mmHg and KO, 97.6  14.3 
mmHg; P0.05, n=5). 
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Figure 3.15. Effect of TRPV1 gene deletion on AA-induced vasodilatation. Effect of TRPV1 
gene deletion on AA-induced coronary vasodilatation in the isolated 12-LOX (2 g ml-1)-
perfused murine heart. Vasodilator responses are expressed as a reduction in CPP (mmHg). 
Data obtained in the presence of indomethacin (5 M). Data shown as arithmetic mean ± S.E.M. 
(n=5). Significant difference is shown as *P<0.05 using two-way ANOVA. 
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3.5. Summary 
In the isolated rat heart, 12(S)-HpETE caused NO-independent vasodilatation that was 
abolished by sensory C-fibre desensitisation resulting from treatment with capsaicin, 
and also by blockade of TRPV1 with capsazepine. 
 
AA also produced coronary vasodilatation, and the response to AA was greater in the 
presence of exogenous 12-LOX. AA-induced vasodilatation was blocked by both the 
non-selective LOX inhibitor NDGA, and the selective 12-LOX inhibitor baicalein. It 
was also abolished by desensitisation of C-fibres with capsaicin, and TRPV1 blockade 
with capsazepine. 
 
That the coronary response to AA appears to be mediated by a 12-LOX product, and 
that both AA and 12(S)-HpETE cause vasodilatation of the coronary vasculature, lends 
support for 12-LOX and AA offering a valid alternative approach to studying the effects 
of 12(S)-HpETE, and for 12(S)-HpETE being the 12-LOX metabolite of AA 
responsible for coronary vasodilatation, via activation of sensory TRPV1. 
 
Additional support for a role for sensory TRPV1 was given by the demonstration that 
blockade of receptors for sensory C-fibre-derived neuropeptides CGRP and SP using 
CGRP8-37 and SR 140333 respectively, significantly reduced responses to AA. 
 
Support for the TRPV1/sensory neuropeptide pathway in mediating the coronary 
vasodilator responses to AA was provided by the studies in hearts of TRPV1 KO mice, 
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where the dose-response curve to AA underwent a significant rightward shift in the 
hearts of TRPV1 KO mice compared to the WT. 
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4. I/R INJURY IN THE ISOLATED RAT HEART: THE 
ROLE OF 12-LOX, AA AND SENSORY C-FIBRES 
 
Having elucidated the principal mechanism underlying vasodilator responses to 12(S)-
HpETE and AA in the coronary vasculature (as detailed in the previous chapter) I then 
sought to investigate the possibility that this pathway might be involved in 12-LOX-
mediated cardioprotection against I/R injury. Initially I examined the effects of 12-LOX 
and AA on I/R injury – specifically infarct size and post-ischaemic LVDP and CPP - 
before going on to investigate the possible role of sensory C-fibres. 
 
4.1. Effects of 12-LOX and AA on I/R injury 
4.1.1. Infarct data 
Since in all of the vasoactivity experiments described in Chapter 3, indomethacin was 
used to isolate 12-LOX-dependent activity, I first conducted a few experiments to 
investigate whether indomethacin might have an effect on I/R injury per se. 
Indomethacin (5 M) had no significant effect on infarct size (P=0.1000, n=3; Figure 
4.1), as has been demonstrated previously (Aitchison and Coker, 1999, Fiedler and 
Mardin, 1985, Gres et al., 2002, Lagneux et al., 2003, Wen et al., 2004). 
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Figure 4.1. Effect of COX inhibition on infarct size. Infarct size, expressed as percentage of 
the total wet weight, in isolated rat heart subjected to 25 min global ischaemia followed by 120 
min reperfusion, in the absence and presence of indomethacin (5 M). Data shown as arithmetic 
mean  S.E.M. (n=3). Statistical analysis performed using the non-parametric Mann-Whitney 
test. 
 
In the presence of indomethacin, I/R produced an infarct size of approximately 60% 
(Figures 4.1 and 4.2). Using this same I/R protocol in previous studies in our laboratory, 
an infarct size of approximately 50% was achieved (Hobbs et al., 2004), therefore, 
infarct size in these experiments was slightly greater than in previous studies. Treatment 
with 12-LOX/AA prior to ischaemia significantly reduced infarct size by approximately 
40% (P<0.05, n=4-7; Figure 4.2). This protective effect was lost by inhibition of 12-
LOX with baicalein (mean infarct size 51.2 ± 1.7%, n=4; Figure 4.2). Baicalein 
treatment alone was found not to have any effect on infarct size per se (mean infarct 
size 65.1  4.4%, n=6, Figure 4.2). 
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Figure 4.2. Effect of 12-LOX/AA and inhibition of 12-LOX on infarct size. Infarct size, 
expressed as percentage of the total wet weight, in isolated rat heart subjected to 25 min global 
ischaemia followed by 120 min reperfusion, in the absence and presence of 12-LOX (2 g ml-1, 
30 min) and AA (30 M, 30 min). Also, the effect of inhibition of 12-LOX with baicalein (10 
M, 15 min pre-treatment) on 12-LOX/AA-mediated effects, and the effect of baicalein alone 
(10 M, 45 min) on infarct size. Data obtained in the presence of indomethacin (5 M). Data 
shown as arithmetic mean ± S.E.M. (n=4-7). Statistical analysis performed using one-way 
ANOVA with Dunnett’s Multiple Comparison Test. *P<0.05 compared to control. No 
significant difference is shown as n.s., P>0.05. 
 
4.1.2. LVDP data 
A reduction in LVDP was typically seen in hearts upon reperfusion, but treatment with 
12-LOX/AA improved post-ischaemic LVDP, reflecting an improvement in post-
ischaemic coronary function. Table 4.1 shows the effect of treatment with 12-LOX and 
AA (2 g ml-1 and 30 M respectively, 30 min) on post-ischaemic left ventricular 
function in the isolated rat heart. LVDP is given as a measure of left ventricular 
function, expressed as a percentage of the baseline LVDP. 
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Treatment with 12-LOX/AA significantly improved LVDP (P0.0001, n=4-6; Figure 
4.3), such improvement being evident after approximately 30 min reperfusion. It should 
be noted that whilst this result was statistically significant, post-ischaemic recovery of 
LVDP after treatment with 12-LOX/AA did not exceed 45%, and in control hearts, 
recovery did not exceed 25%. In previous experiments carried out in our laboratory, 
however, post-ischaemic recovery of LVDP in control hearts was approximately 50% 
after 25 min ischaemia (Hobbs et al., 2004). In two of the experiments with 12-
LOX/AA treatment, technical failure in pressure recordings occurred hence differences 
in n values to the infarct data. 
 
Also shown in Table 4.1 and Figure 4.3 is the effect of inhibition of 12-LOX with 
baicalein (10 M, 15 min pre-treatment) on the improvement of post-ischaemic left 
ventricular function by treatment with 12-LOX/AA. Whilst baicalein reduced 
improvements seen with 12-LOX/AA treatment up to 75 min after the onset of 
reperfusion, it did not appear to have any significant inhibitory effects in the later stages 
of reperfusion (n = 4). Baicalein (10 M, 45 min) did not affect LVDP per se (n=6). 
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Table 4.1. Effect of 12-LOX inhibition on LVDP 
Treatment Time (min) relative to onset of ischaemia LVDP (% baseline) n 
control -5.0 
25.5 
70.0 
85.0 
130.0 
94.8  4.8 
8.2  0.6 
17.0  4.8 
17.8  5.2 
21.3  3.7 
6 
+AA/LOX -5.0 
25.5 
70.0 
85.0 
130.0 
102.5  3.8 
12.7  5.4 
   41.4  2.2** 
     45.0  4.1*** 
  43.8  4.5** 
5 
+AA/LOX/
baicalein 
-5.0 
25.5 
70.0 
85.0 
130.0 
110.2  7.0 
10.2  2.1 
22.4  6.7 
29.2  5.0 
35.5  2.9 
4 
baicalein -5.0 
25.5 
70.0 
85.0 
130.0 
91.5  3.9 
9.3  2.0 
19.1  4.1 
24.1  2.1 
21.0  2.3 
6 
Effect of various treatments on post-ischaemic left ventricular function in isolated rat heart. 
LVDP is given as a measure of left ventricular function, expressed as a percentage of the 
baseline LVDP. Data shown as arithmetic mean  S.E.M.. Statistical analysis performed on 
reperfusion data only using two-way ANOVA followed by Bonferroni post-tests to compare 
differences in LVDP at 70, 85 and 130 min after the onset of ischaemia. **P0.01 and 
***P0.001 compared to control. 
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Figure 4.3. Effect of 12-LOX inhibition on post-ischaemic left ventricular function. Effect 
of inhibition of 12-LOX with baicalein (10 M, 45 min) on improvement of post-ischaemic left 
ventricular function by treatment with 12-LOX (2 g ml-1, 30 min) and AA (30 M, 30 min) in 
isolated rat heart; also, the effect of baicalein alone (10 M, 45 min). LVDP is given as a 
measure of left ventricular function, expressed as a percentage of LVDP at the start of 
treatment. The onset of ischaemia is at 0 min. Data shown as arithmetic mean ± S.E.M. (n=4-6). 
Statistical analysis performed on curves during reperfusion only. Significant difference is shown 
as ***P<0.0001 compared to control using two-way ANOVA, and as 
###
P<0.001, 
##
P<0.01, 
##
P<0.05 with Bonferroni post-test. 
 
4.1.3. CPP data 
CPP typically increased upon reperfusion of hearts, reflecting coronary 
vasoconstriction, and treatment with 12-LOX/AA reduced this increase in CPP. Table 
4.2 shows the effect of treatment with 12-LOX and AA (2 g ml-1 and 30 M 
respectively, 30 min) on post-ischaemic CPP in the isolated rat heart. CPP is expressed 
as a percentage of the baseline CPP. Table 4.2 also includes data obtained from 
experiments with baicalein alone (10 M, 45 min). 
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Table 4.2. Effect of 12-LOX inhibition on CPP 
Treatment Time (min) relative to onset of ischaemia CPP (% baseline) n 
control -5.0 
25.5 
70.0 
85.0 
130.0 
137.1  7.7 
188.1  12.8 
228.6  18.1 
241.6  17.6 
265.4  21.3 
6 
+AA/LOX -5.0 
25.5 
70.0 
85.0 
130.0 
122.1  21.0 
166.5  33.2 
193.1  41.1 
199.7  43.0 
207.7  44.3 
5 
+AA/LOX/
baicalein 
-5.0 
25.5 
70.0 
85.0 
130.0 
81.7  7.2 
107.2  7.0 
116.9  3.9* 
115.6  3.8* 
 123.9  7.6** 
4 
baicalein -5.0 
25.5 
70.0 
85.0 
130.0 
116.4  6.6 
130.2  23.9 
147.7  31.0 
156.7  32.7 
 167.4  34.7* 
6 
Effect of various treatments on post-ischaemic CPP in isolated rat heart. CPP is expressed as a 
percentage of the baseline CPP. Data shown as arithmetic mean  S.E.M.. Statistical analysis 
performed on reperfusion data only using two-way ANOVA followed by Bonferroni post-tests 
to compare differences in LVDP at 70, 85 and 130 min after the onset of ischaemia. *P0.05 
and **P0.01 compared to control. 
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In contrast to the other indices of I/R injury, baicalein treatment per se suppressed the 
post-ischaemic increase in CPP in the absence of 12-LOX/AA: at 120 min reperfusion 
control CPP = 265.1  22.6% (n=6), whereas plus baicalein, CPP = 170.1  34.1% 
(n=6). Post-ischaemic CPP was further reduced after baicalein treatment (10 M, 15 
min pre-treatment) in the presence of AA/LOX: at 120 min reperfusion, CPP = 123.3  
7.5% (P0.01, n=4). 
 
4.2. The role of sensory C-fibres in 12-LOX/AA-mediated 
cardioprotection 
4.2.1. Infarct data 
As discussed in section 4.1.1, I/R produced an infarct size of approximately 60% in 
control untreated hearts, and treatment with 12-LOX and AA prior to ischaemia 
significantly reduced infarct size (P<0.05, n=4-7). As can be seen in Figure 4.4, this 
protective effect was lost by prior in vivo C-fibre desensitisation with capsaicin (mean 
infarct size 55.2 ± 0.7%, n=5). In vitro capsaicin treatment alone was found not to have 
any effect on infarct size per se (mean infarct size 56.1  4.9%, n=4). 
 
NB. The ‘control’ and ‘+ 12-LOX/AA’ data shown in Figure 4.4 are the same as 
shown in Figure 4.2. Whilst capsaicin and baicalein data have been separated for 
illustrative purposes, statistical analysis was performed across the six groups together 
at once. 
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Figure 4.4. Effect of 12-LOX/AA and C-fibre desensitisation on infarct size. Infarct size, 
expressed as percentage of the total wet weight, in isolated rat heart subjected to 25 min global 
ischaemia followed by 120 min reperfusion, in the absence and presence of 12-LOX (2 g ml-1, 
30 min) and AA (30 M, 30 min). Also, the effect of C-fibre desensitisation with in vivo 
capsaicin treatment (50 mg kg
-1
, 2 ml kg
-1
) on 12-LOX/AA-mediated effects, and the effect of 
(in vitro) capsaicin alone (1 M, 20 min: 30-min washout) on infarct size. Data obtained in the 
presence of indomethacin (5 M). Data shown as arithmetic mean ± S.E.M. (n=4-7). Statistical 
analysis performed using one-way ANOVA with Dunnett’s Multiple Comparison Test. *P<0.05 
compared to control. No significant difference is shown as n.s., P>0.05. 
 
4.2.2. LVDP data 
It can be seen from Table 4.3 and Figure 4.5 that in vivo treatment with capsaicin (n=5) 
had relatively little effect on the improved post-ischaemic LVDP seen with treatment 
with 12-LOX/AA. Capsaicin, like baicalein, reduced improvements seen with 12-
LOX/AA treatment up to 75 min after the onset of reperfusion, but it did not appear to 
have any significant inhibitory effects in the later stages of reperfusion. In vitro 
desensitisation of C-fibres with capsaicin did not affect LVDP per se (n=4). 
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NB. The ‘control’ and ‘+ 12-LOX/AA’ data shown in Table 4.3 are the same as 
shown in Table 4.1. Likewise, the ‘control’ and ‘+ 12-LOX/AA’ data shown in Figure 
4.5 are the same as shown in Figure 4.4. Whilst capsaicin and baicalein data have 
been separated for illustrative purposes, statistical analysis was performed across the 
six groups together at once. 
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Figure 4.5. Effect of C-fibre desensitisation on post-ischaemic left ventricular function. 
Effect of C-fibre desensitisation with capsaicin treatment in vivo (50 mg kg
-1
, 2 ml kg
-1
) on 
improvement of post-ischaemic left ventricular function by treatment with 12-LOX (2 g ml-1, 
30 min) and AA (30 M, 30 min) in isolated rat heart; also, the effect of (in vitro) capsaicin 
alone (1 M, 20 min: 30-min washout). LVDP is given as a measure of left ventricular function, 
expressed as a percentage of LVDP at the start of treatment. The onset of ischaemia is time=0. 
Data shown as arithmetic mean ± S.E.M. (n=4-6). Statistical analysis performed on curves 
during reperfusion only. Significant difference is shown as ***P<0.0001 compared to control 
using two-way ANOVA, and as 
###
P<0.001, 
##
P<0.01, 
##
P<0.05 with Bonferroni post-test. 
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Table 4.3. Effect of C-fibre desensitisation on LVDP 
Treatment Time (min) relative to onset of ischaemia LVDP (% baseline) n 
control -5.0 
25.5 
70.0 
85.0 
130.0 
94.8  4.8 
8.2  0.6 
17.0  4.8 
17.8  5.2 
21.3  3.7 
6 
+AA/LOX -5.0 
25.5 
70.0 
85.0 
130.0 
102.5  3.8 
12.7  5.4 
    41.4  2.2** 
    45.0  4.1*** 
 43.8  4.5** 
5 
+AA/LOX 
capsaicin-
treated 
-5.0 
25.5 
70.0 
85.0 
130.0 
92.6  3.6 
8.2 0.3 
30.7  11.4 
31.3  11.1 
38.6  5.4  
5 
capsaicin -5.0 
25.5 
70.0 
85.0 
130.0 
94.7  8.5 
12.7  3.3 
22.6  8.2 
24.4  9.0 
20.6  4.3 
4 
Effect of various treatments on post-ischaemic left ventricular function in isolated rat heart. 
LVDP is given as a measure of left ventricular function, expressed as a percentage of the 
baseline LVDP. Data shown as arithmetic mean  S.E.M.. Statistical analysis performed on 
reperfusion data only using two-way ANOVA followed by Bonferroni post-tests to compare 
differences in LVDP at 70, 85 and 130 min after the onset of ischaemia. **P0.01 and 
***P0.001 compared to control. 
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4.2.3. CPP data 
As described in section 4.1.3, CPP typically increased upon reperfusion of hearts, 
reflecting coronary vasoconstriction, and treatment with 12-LOX/AA reduced this 
increase (Table 4.2). Similar to baicalein treatment, in contrast to the other indices of 
I/R injury, C-fibre desensitisation with capsaicin per se both profoundly and 
significantly suppressed the post-ischaemic increase in CPP in the absence of 12-
LOX/AA: at 120 min reperfusion control CPP = 265.1  22.6% (n=6), whereas plus 
capsaicin, CPP = 146.7  9.6% (n=4, P0.05). Post-ischaemic CPP was also reduced 
further in the presence of AA/LOX after in vivo capsaicin treatment: at 120 min 
reperfusion, CPP = 124.4  23.3% (P0.01, n=5). 
 
NB. The ‘control’ and ‘+ 12-LOX/AA’ data shown in Table 4.4 are the same as 
shown in Table 4.2. Whilst capsaicin and baicalein data have been separated for 
illustrative purposes, statistical analysis was performed across the six groups together 
at once. 
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Table 4.4. Effect of C-fibre desensitisation on CPP 
Treatment Time (min) relative to onset of ischaemia CPP (% baseline) n 
control -5.0 
25.5 
70.0 
85.0 
130.0 
137.1  7.7 
188.1  12.8 
228.6  18.1 
241.6  17.6 
265.4  21.3 
6 
+AA/LOX -5.0 
25.5 
70.0 
85.0 
130.0 
122.1  21.0 
166.3  33.2 
193.1  41.1 
199.7  43.0 
207.7  44.3 
5 
+AA/LOX 
capsaicin-
treated 
-5.0 
25.5 
70.0 
85.0 
130.0 
86.4  15.8 
111.9  25.2 
118.4  26.9* 
116.1  29.2** 
124.3  25.5** 
5 
capsaicin -5.0 
25.5 
70.0 
85.0 
130.0 
122.3  8.9 
103.8  6.6 
121.8  7.2 
126.8  7.3* 
 137.0  11.5** 
4 
Effect of various treatments on post-ischaemic left ventricular function in isolated rat heart. CPP 
is expressed as a percentage of the baseline CPP. Data shown as arithmetic mean  S.E.M.. 
Statistical analysis performed on reperfusion data only using two-way ANOVA followed by 
Bonferroni post-tests to compare differences in LVDP at 70, 85 and 130 min after the onset of 
ischaemia. *P0.05 and **P0.01 compared to control. 
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4.3. Summary 
In the isolated rat heart, treatment with 12-LOX/AA prior to ischaemia was found to 
offer protection against I/R injury, when infarct size was taken as an end-point of 
cardioprotection. Such protection was lost when hearts were additionally treated with 
baicalein prior to ischaemia, or if hearts were taken from animals that had been treated 
in vivo with capsaicin. 
 
Post-ischaemic coronary function was also improved by treatment with 12-LOX/AA. 
This effect on LVDP was reduced slightly in the early, but not the later, stages of 
reperfusion, if hearts had been additionally treated with baicalein. In vivo treatment with 
capsaicin also slightly reduced the improved post-ischaemic LVDP seen with 12-
LOX/AA, but as with baicalein, this improvement was only evident in the early stages 
of reperfusion. 
 
Treatment with 12-LOX/AA also improved coronary perfusion post-ischaemia, 
reducing the increase in CPP associated with myocardial reperfusion. Interestingly, in 
the absence of 12-LOX/AA, both baicalein and capsaicin per se were found to block the 
characteristic rise in post-ischaemic CPP, and CPP was further reduced by combined 
treatment with 12-LOX/AA and baicalein or capsaicin. However, neither baicalein nor 
capsaicin per se affected infarct size or LVDP. 
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5. THE EFFECTS OF I/R INJURY ON RAT TRPV1 
EXPRESSION 
 
In the previous chapter I showed that 12-LOX and AA offer significant protection 
against I/R injury in isolated perfused rat hearts, and that sensory C-fibres appear to 
have a role in mediating this protective effect. Having already confirmed (Chapter 3) 
that TRPV1 is a target for 12(S)-HpETE, which is generated upon activation of the 12-
LOX pathway of AA metabolism by periods of myocardial ischaemia (Chen et al., 
1999), I then went on to investigate whether, firstly, measureable levels of TRPV1 
could be found under control conditions in the heart, and secondly, whether any changes 
in this expression might occur after an I/R insult, that might underlie some of the 
changes in functionality of this pathway under I/R conditions. For the studies detailed in 
this chapter, heart and DRG tissue was used from animals subjected to an I/R insult in 
vitro as well as in vivo, the latter serving as a control, since hearts were detached from 
the DRG so that transport of mRNA for TRPV1 and other gene products was prevented. 
 
As mentioned in Chapter 1, immunohistochemical studies have demonstrated that 
TRPV1 is expressed throughout the cardiovascular system, for example, in vascular 
smooth muscle cells (Kark et al., 2008) and vascular endothelial cells (Golech et al., 
2004, Luo et al., 2008a), as well as the ventricles of the heart (Funakoshi et al., 2006, 
Zahner et al., 2003). More recently, TRPV1 expression within the heart has been 
demonstrated in cardiac blood vessels and perivascular nerves, as well as in 
cardiomyocytes on the epicardial surface (Zhong and Wang, 2009). 
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In order to determine whether any possible changes were specific to TRPV1, TRPV1 
mRNA levels were measured together with TRPV2 and TRPV4 mRNA levels. 
 
5.1. Optimisation of conditions for real-time PCR 
Ideally, the results from a standard curve should show an increase of 1CT for every 1:2 
dilution of cDNA. This principle is explained in Figure 5.1 below. Specificity of primer 
pairs was further confirmed by the presence of a single specific peak in the dissociation 
curve. 
 
Figure 5.1. Diagram to illustrate why an increase of 1CT should be seen with every 1:2 
dilution of cDNA in a standard curve. Each square represents one strand of cDNA. To obtain 
the same number of strands of cDNA, an additional PCR cycle is required each time the initial 
number of strands of cDNA is halved. 
 
The dissociation curves and standard curves obtained with primers for TRPV1, TRPV2, 
TRPV4 and -actin, using the optimal conditions as determined by preliminary 
experiments (refer to Table 2.2) are shown in Figures 5.2, 5.3, 5.4 and 5.5 respectively. 
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  A 
 
 
Figure 5.2. TRPV1 primer pair specificity. Demonstrated in rat heart tissue from animals 
subjected to I/R insult in vitro. (A) dissociation curve and (B) standard curve. The dissociation 
curve shows a single peak at 84.5C, and the value of R2 for the standard curve is 0.965. (The 
R
2
 value for each standard curve indicates the goodness of fit of the regression line to the data 
points – a value of 1 denoting a perfect fit.) 
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Figure 5.3. TRPV2 primer pair specificity. Demonstrated in rat heart tissue from animals 
subjected to I/R insult in vitro. (A) dissociation curve and (B) standard curve. The dissociation 
curve shows a single peak at 83.5C, and the value of R2 for the standard curve is 0.995. 
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Figure 5.4. TRPV4 primer pair specificity. Demonstrated in rat heart tissue from animals 
subjected to I/R insult in vitro. (A) dissociation curve and (B) standard curve. The dissociation 
curve shows a single peak at 85.5C, and the value of R2 for the standard curve is 0.994. 
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Figure 5.5. β-actin primer pair specificity. Demonstrated in rat heart tissue from animals 
subjected to I/R insult in vitro. (A) dissociation curve and (B) standard curve. The dissociation 
curve shows a single peak at 85.5C, and the value of R2 for the standard curve is 0.992. 
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Figure 5.6 shows the single bands of amplified cDNA obtained with primers for 
TRPV1, TRPV2, TRPV4 and -actin, using the optimal conditions for each pair of 
primers determined as described in section 2.3.3.4b (refer to Table 2.2). 
 
Figure 5.6. Representative gel pictures from electrophoretic analysis of PCR products. 
Pictures of sections taken from gels demonstrating the single bands of cDNA seen with each set 
of primers, for (A) TRPV1, (B) TRPV2, (C) TRPV4 and (D) -actin. DNA extracted from rat 
hearts (TRPV1 and β-actin: controls; TRPV2 and TRPV4: ischaemic). 
 
5.2. Effects of I/R injury on TRPV1 mRNA levels 
Real-time PCR of cDNA prepared from control and ischaemic heart samples from in 
vitro experiments revealed the presence of TRPV1, TRPV2 and TRPV4 mRNA in all 
samples, although at a lower level than that of the internal control, β-actin (see Table 
5.1). Statistical analysis using unpaired Student’s t-test analysis showed that there was 
no significant difference between levels of mRNA in control hearts and hearts subjected 
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to an ischaemic insult for TRPV1 (P=0.1375, n=5; Figure 5.7A), TRPV2 (P=0.2119, 
n=5-6; Figure 5.7B) or TRPV4 (P=0.9153, n=4-6; Figure 5.7C). 
 
Real-time PCR of cDNA prepared from control and ischaemic heart samples from in 
vivo experiments revealed the presence of TRPV1, TRPV2 and TRPV4 mRNA in all 
samples, again at a lower level than that of the internal control, β-actin, as indicated by 
the higher mean CT values shown in Table 5.1. Furthermore, levels of TRPV1 and 
TRPV2 mRNA were found to be lower in heart samples than in DRG samples, whilst 
levels of TRPV4 mRNA were found to be higher in heart samples than in DRG samples 
(refer to Table 5.1 for mean CT values). 
 
Statistical analysis using unpaired Student’s t-test showed that TRPV1 mRNA levels 
were significantly lower in hearts subjected to an ischaemic insult than in hearts taken 
from animals that had undergone a sham operation (P0.05, n=7-9; Figure 5.8A). 
However, there was no significant difference between levels of mRNA in sham control 
hearts and hearts subjected to an ischaemic insult for TRPV2 (P=0.7799, n=4-5; Figure 
5.8B) or TRPV4 (P=0.1082, n=5; Figure 5.8C). 
 
Moreover, no significant difference was found in TRPV1 mRNA levels from DRG 
removed from either sham control animals or animals subjected to an ischaemic insult 
(P=0.8782, n=6; Figure 5.9A). Similarly, it appeared that there was no difference 
between levels of mRNA in DRG removed from either sham control animals or animals 
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subjected to an ischaemic insult for TRPV2 (n=2-3; Figure 5.9B) and TRPV4 (n=2; 
Figure 5.9C), although there were insufficient data for statistical analysis. 
 
Table 5.1. Mean CT values for TRPV1, TRPV2, TRPV4 and -actin 
mRNA Tissue sample; n CT 
-actin heart, in vitro; 5 
heart, in vivo; 9 
DRG, in vivo; 7 
19.1  0.1 
19.1  0.1 
18.6  0.4 
TRPV1 heart, in vitro; 5 
heart, in vivo; 7 
DRG, in vivo; 6 
29.4  0.2 
28.1  0.5 
22.5  0.1 
TRPV2 heart, in vitro; 5 
heart, in vivo; 5 
DRG, in vivo; 3 
26.7  0.2 
25.8  0.1 
22.6  0.6 
TRPV4 heart, in vitro; 4 
heart, in vivo; 5 
DRG, in vivo; 2 
26.6  0.2 
25.6  0.1 
29.4 
Comparison of levels of mRNA (indicated by CT values) for TRPV1, TRPV2 and TRPV4 and 
internal control, -actin, in different tissue samples. Data shown as arithmetic mean  S.E.M., 
or where n=2, arithmetic mean. 
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Figure 5.7. Effect of I/R injury in vitro on levels of TRPV mRNA in rat hearts. (A) TRPV1, 
(B) TRPV2 and (C) TRPV4 mRNA. Data shown as arithmetic mean  S.E.M. (ratio of levels of 
TRPV mRNA relative to the internal control, -actin, expressed in arbitrary units). Statistical 
analysis performed using unpaired Student’s t-test (n=4-6). 
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Figure 5.8. Effect of I/R injury in vivo on levels of TRPV mRNA in rat hearts. (A) TRPV1, 
(B) TRPV2 and (C) TRPV4 mRNA. Data shown as arithmetic mean  S.E.M. (ratio of levels of 
TRPV mRNA relative to the internal control, -actin, expressed in arbitrary units). Statistical 
analysis performed using unpaired Student’s t-test (n=4-9). *P0.05 compared to control. 
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Figure 5.9. Effect of I/R injury in vivo on levels of TRPV mRNA in rat DRG. (A) TRPV1 
mRNA in rat DRG. Data shown as arithmetic mean  S.E.M. (ratio of levels of TRPV mRNA 
relative to the internal control, -actin, expressed in arbitrary units). Statistical analysis 
performed using unpaired Student’s t-test (n=6). (B) TRPV2 and (C) TRPV4 mRNA in rat 
DRG. Insufficient data to perform statistical analysis. Where n<3, data shown as arithmetic 
mean. 
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5.3. Effects of I/R injury on TRPV1 protein expression 
Western blot analysis of tissue samples from in vitro and in vivo experiments showed 
that TRPV1 protein was present in heart and DRG samples – the TRPV1 antibody used 
producing a band at approximately 95 kDa, that was not evident in pre-adsorption 
experiments when the TRPV1 antibody was pre-bound with the control peptide (see 
Figure 5.10). Protein levels were measured as band density  area, and then normalised 
with levels of -actin which served as a loading control. As can be seen in Figure 5.11 
the -actin antibody used produced a band at approximately 42 kDa. 
 
 
Figure 5.10. Sections from a Western immunoblot incubated with anti-TRPV1 antibody. 
Left panel, in the absence of, and right panel, in the presence of, the control peptide. The dark 
band at approximately 95 kDa (left panel) that is not evident in the presence of the control 
peptide, corresponds to TRPV1. DRG samples taken from rats not subjected to I/R insult, either 
in vivo or in vitro, or to sham operation. 
 
 
Figure 5.11. Sections from a representative Western immunoblot of TRPV1 protein 
expression in rat heart, from in vitro I/R experiments. Lane 1, sample from rat subjected to 
I/R protocol; lane 2, control. Protein per well, 100 g. 
 175 kDa 
 
 
 83 kDa 
~95 kDa 
   TRPV1                                          TRPV1 
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Densitometric analysis of scanned images followed by statistical analysis using 
unpaired Student’s t-test showed that TRPV1 protein expression was significantly lower 
in hearts subjected to an ischaemic insult in vitro than in control hearts (P0.05, n=4-5; 
Figure 5.12A). However, after I/R in vivo, expression of TRPV1 protein was 
significantly higher than in hearts from animals that had undergone a sham operation 
(P0.05, n=6; Figure 5.12B). TRPV1 protein expression was also found to be higher in 
DRG from animals that had been subjected to I/R in vivo than in DRG taken from sham 
controls (P0.05, n=6-8; Figure 5.12C). 
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Figure 5.12. Effect of I/R injury in vitro and in vivo on TRPV1 protein expression. (A) rat 
hearts, in vitro, (B) rat hearts, in vivo and (C) rat DRG, in vivo. Data shown as arithmetic mean 
 S.E.M. (ratio of levels of TRPV1 protein relative to the control, -actin, expressed in arbitrary 
units). Statistical analysis performed using unpaired Student’s t test (n=4-8). *P0.05 compared 
to control. 
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5.4. Summary 
In the isolated rat heart, I/R injury had no effect on levels of TRPV1, TRPV2 or TRPV4 
mRNA. Levels of heart TRPV2 and TRPV4 mRNA were also unaffected by I/R injury 
in vivo, as were levels of TRPV1, TRPV2 and TRPV4 mRNA in DRG. However, 
TRPV1 mRNA levels were lower in hearts subjected to an I/R insult in vivo than in 
sham controls. 
 
In contrast, I/R injury in vitro resulted in a decrease in expression of TRPV1 protein in 
rat hearts, whilst in vivo, both in hearts and DRG, levels of TRPV1 protein expression 
were higher after an I/R insult than in sham controls. 
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6. DISCUSSION 
 
The 12-LOX pathway of AA metabolism is known to be stimulated within the 
myocardium by ischaemia or hypoxia (Chen et al., 1999), and there is a substantial body 
of evidence suggesting that eicosanoids derived via this metabolic pathway protect 
against the damaging effects of myocardial I/R injury (Chen et al., 1999, Gabel et al., 
2001, Murphy et al., 1995, Patel et al., 2003, Starkopf et al., 1998, Tsutsumi et al., 
2006). The results from this thesis suggest that 12-LOX-mediated cardioprotection can 
be attributed, in part, to the activity of sensory neuropeptides released as a consequence 
of 12(S)-HpETE-induced activation of TRPV1, thereby supporting the hypothesis for 
this thesis outlined in Chapter 1. In addition, the data suggest that I/R injury in vivo 
results in increased TRPV1 synthesis in DRG and transport of TRPV1 to cardiac nerve 
terminals. It is therefore a possibility that during I/R, activation or up-regulation of this 
12-LOX/AA/TRPV1 pathway represents an endogenous mechanism to limit I/R injury. 
 
6.1. 12(S)-HETE and 12(S)-HpETE cause vasodilatation in the isolated 
rat heart, and the response to 12(S)-HpETE involves sensory C-fibres 
and TRPV1 
As described in Chapter 3, 12(S)-HETE caused dose-dependent vasodilatation in 
isolated rat hearts; however, responses were typically small, and highly variable. 
Although it was hoped that vasodilator responses to 12(S)-HETE would be easier to 
detect if hearts were preconstricted, no improvement was seen either after treatment 
with the NOS inhibitor L-NAME, or with the thromboxane mimetic U46619. 
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In agreement with findings from previous studies in our laboratory, 12(S)-HpETE also 
caused transient dose-dependent vasodilatation (McLean et al., 2002), and whilst the 
vasodilator response to 12(S)-HpETE was greater than to 12(S)-HETE, responses varied 
considerably. 12(S)-HpETE-induced vasodilatation was blocked by in vitro 
desensitisation of sensory C-fibres by capsaicin, and by treatment with the TRPV1 
antagonist capsazepine. These findings indicate that 12(S)-HpETE-induced 
vasodilatation involves activation of cardiac sensory C-fibres, and the non-selective 
sensory cation channel TRPV1. 
 
It is likely that the variability seen with vasodilator responses to 12(S)-HpETE is, at 
least in part, due to the unstable nature of this compound, which is readily oxidised to 
12(S)-HETE via conversion of the hydroperoxyl moiety to a hydroxyl group (Luo et al., 
2006). As already explained, it was due to the known stability issues with 12(S)-HpETE 
that I initially chose to work with 12(S)-HETE – but the lack of activity of this 
compound was disappointing. Although 12(S)-HETE is more stable than 12(S)-HpETE, 
responses to 12(S)-HETE were found to be substantially smaller than those to 12(S)-
HpETE, intimating the involvement perhaps of the peroxide group in TRPV1 activation. 
However, that the vasodilator response to 12(S)-HpETE was greater than that to 12(S)-
HETE is supportive of a role for TRPV1 since Hwang and co-workers demonstrated 
that whilst a number of LOX products including 15(S)-HpETE, 5(S)-HETE and LTB4 
activate TRPV1, 12(S)-HpETE is the most potent (Hwang et al., 2000). Evidence 
suggests that the relatively high potency of 12(S)-HpETE compared to other LOX 
products is due to its structural similarity to capsaicin. Hwang and co-workers compared 
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the three-dimensional structures of the LOX products with capsaicin and found that the 
structures of 12(S)-HpETE and capsaicin could be superimposed when the molecules 
were in their lowest electronic energy state. In contrast, LOX products with lower 
potency showed a lower degree of structural similarity to capsaicin (Hwang et al., 
2000). In particular, the carboxylic acid and hydroperoxide moieties in 12(S)-HpETE 
overlap precisely with the phenolic hydroxide and amide moieties in capsaicin – two 
regions of the capsaicin molecule known to form important hydrogen bonds with 
TRPV1 – and in addition, the aliphatic chain of 12(S)-HpETE is similar in length to the 
alkyl chain of capsaicin (Hwang et al., 2000). 
 
As described in Chapter 2, to minimise 12(S)-HpETE oxidation, solutions were made 
up in ethanol or Krebs that had been first bubbled with 95% N2/5% CO2. It is attractive 
to speculate, however, that the instability of 12(S)-HpETE serves an important 
regulatory function whereby activity is limited under oxygenated conditions. In turn, 
one could speculate further that under conditions where oxygen levels are reduced (such 
as ischaemia), degradation of 12(S)-HpETE to 12(S)-HETE is prevented, thereby 
dramatically increasing local concentrations and therefore the importance of 12(S)-
HpETE as a signalling molecule. However, conventional LOX activity involves a 
bimolecular reaction requiring the simultaneous presence of atmospheric oxygen and 
lipid substrate, catalysing the stereoselective oxygenation of polyunsaturated fatty acids 
to their corresponding hydroperoxy derivative. If one substrate is limiting such as 
oxygen in hypoxia, LOX activity is altered and a different set of reaction products is 
formed. Under hypoxic conditions, the hydroperoxidase activity of LOX is favoured 
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over its oxygenase activity, resulting in formation of aldehydes, alkanes and ketodienes 
as opposed to hydroperoxy fatty acids (Kuhn and O'Donnell, 2006) – suggesting that 
hypoxia decreases synthesis of 12(S)-HpETE. Thus, whilst hypoxia might enhance the 
half-life of 12(S)-HpETE it is likely to also result in a decreased synthesis and therefore 
whether increased endogenous levels of 12(S)-HpETE might translate to consequent 
increased activity of TRPV1 is unknown. However, the utility of such an oxygen-
dependent pathway might be to provide an endogenous reflex protective mechanism, 
and an increased half-life of 12(S)-HpETE might conceivably translate to increased 
vasodilatation. Such an effect could lead to increased flow and thereby increased 
oxygen delivery. In order to test this hypothesis, it would be interesting to construct 
dose-response curves to 12(S)-HpETE under hypoxic conditions in the coronary 
circulation and to see if the magnitude and/or reproducibility of responses were 
improved compared to those obtained in the present study. In order to simulate hypoxic 
conditions in vitro for future experiments, a reduction in oxygen levels to 5% or below 
would be desirable, as discussed in section 6.4, and this could be achieved by aerating 
the perfusate with an appropriate O2/CO2 mix prior to perfusion into the heart, to reach 
equilibrium. 
 
Additional support for an involvement of sensory C-fibres in 12(S)-HpETE-induced 
vasodilator responses is provided by the findings that selective receptor antagonists for 
the sensory neuropeptides CGRP and SP also suppressed vasodilator responses. These 
findings indicate that these neuropeptides, released from the peripheral terminals of 
TRPV1-expressing fibres, mediate 12(S)-HpETE-induced vasodilatation. Despite 
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studies on the neuronal control of cardiovascular function focusing for many years on 
the sympathetic and parasympathetic branches of the autonomic nervous system, it is 
now well-established that there is a system of capsaicin-sensitive peptidergic neurones 
associated with the cardiovascular system, which plays a role in the neuronal control of 
vascular tone (Rubino and Burnstock, 1996). In terms of the tachykinin neuropeptides, 
SP-like immunoreactivity is distributed extensively throughout the mammalian body, 
principally localised to neurones within the CNS and the periphery; NKA-like 
immunoreactivity closely resembles that of SP since NKA is almost exclusively co-
localised with SP, although NKA is present in smaller amounts than SP; and NKB-like 
reactivity is mainly restricted to the CNS (Khawaja and Rogers, 1996). Although 
tachykinins are principally derived from neurones, both in the CNS and the periphery 
(Maggi et al., 1993), there is a growing body of evidence supporting the view that non-
neuronal sources of the three classical tachykinins, SP, NKA and NKB, exist within the 
periphery (Pennefather et al., 2004). It is important to note that despite the common co-
localisation of SP and NKA in sensory neurones, it has been demonstrated in rat sensory 
neurones that levels of SP and NKA may vary independently of one another, suggesting 
that the tenet that these two peptides are co-released and fulfil similar transmitter roles 
needs to be re-addressed (Bakhle and Bell, 1995). Similarly, comparison of the 
potencies and response profiles of SP and NKA in the isolated perfused guinea pig heart 
revealed qualitative and quantitative differences when responses were compared in the 
same hearts – for example, SP was much less potent than NKA in increasing the force 
of ventricular contractions, doses of 25 nmol or less actually having a negative inotropic 
effect (Hoover et al., 1998). Certainly the results obtained from the present study 
 
Chapter 6: Discussion 
 
 
 
 
190 
 
suggesting an involvement of SP, but not NKA, in 12(S)-HpETE-induced vasodilatation 
could be seen as evidence of SP and NKA fulfilling distinct neurotransmitter roles. 
 
Immunohistochemical studies have revealed that tachykinin nerve processes containing 
SP and NKA are present in the heart, concentrated within the adventitia of coronary 
arteries and intrinsic cardiac ganglia (where they are localised to varicose nerve fibres 
surrounding many of the principal neurones), and also present at a lower density in 
many myocardial sites (Chang et al., 2000). In the rat heart, immunocytochemical 
studies showed intense SP and moderate NKA immunostaining in nerve fibres in the 
right atrium, and also weak NKA immunostaining in the right ventricle (Onuoha et al., 
1999). Whilst autoradiographic studies in the guinea pig heart did not detect any 
tachykinin binding sites in atrial or ventricular myocardium, binding sites for SP and 
NKA restricted to coronary vessels and the intrinsic cardiac ganglia, were revealed 
(Hoover et al., 2000). However, there do not appear to be any reports in the literature of 
NKB-containing processes within the heart. Furthermore, whilst the presence of at least 
twelve different transmitters, including SP, NKA and CGRP, has been reported in 
neurones expressing TRPV1 (Wang, 2005), NKB is absent from both peripheral and 
central terminals of capsaicin-sensitive primary afferents (Maggi et al., 1993). The 
suggestion from the present study that NKB is not involved in 12(S)-HpETE-induced 
vasodilatation is therefore in line with our current knowledge from the literature. 
 
The tachykinins have numerous effects upon cardiac function. However, with specific 
relevance to this study there is substantial evidence demonstrating that these 
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neuropeptides modulate coronary tone. As reviewed by Hoover et al. (2000), both SP 
and NKA have vasodilator actions within the coronary vasculature of a number of 
different species, although NKA is less potent than SP, and in coronary resistance 
vessels of the guinea pig, NKA may also elicit vasoconstrictor responses – likely via 
activation of a different tachykinin receptor (Hoover et al., 2000). Similarly, the effect 
of NKB on coronary tone depends on the subtype of tachykinin receptor activated, and 
additional variables such as species and dose, although it generally causes 
vasodilatation of the coronary vasculature (Yang et al., 2007a). The effects of the 
tachykinins are mediated via interaction with three main subtypes of tachykinin 
receptor, termed NK1, NK2, and NK3, and whilst these have higher affinity for SP, NKA 
and NKB respectively, compared to the other tachykinins, it should be stressed that 
these three tachykinins are all capable of acting as full agonists at these three receptor 
subtypes (Maggi et al., 1993). Reports on the localisation of tachykinin receptors within 
the rat heart appear to be absent from the literature available. However, in the guinea 
pig heart, all three subtypes of the tachykinin receptor have been reported to be present 
– coronary vasodilatation being mediated via NK1 receptors, bradycardia via NK2 and 
NK3 receptors, and positive inotropism via NK3 receptors (Chang et al., 2000). 
Similarly, NK1, NK2 and NK3 receptors have been identified in canine intrinsic cardiac 
neurones involved in cardiac regulation (Thompson et al., 1998). Activation of NK3 
receptors located on cholinergic neurones within intrinsic cardiac ganglia can also have 
indirect effects on cardiac function and coronary tone – the latter mediated by M3 
muscarinic receptors situated on coronary endothelial and smooth muscle cells (Hoover 
et al., 2000). In the present study the NK1 receptor antagonist appeared the most 
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effective at inhibiting 12(S)-HpETE-induced vasodilatation. NK2 and NK3 receptor 
antagonists were also tested, and neither produced any significant inhibitory effect on 
responses to 12(S)-HpETE, although a tendency for suppression was evident. These 
effects appeared to be non-specific, since interestingly, these antagonists did not block 
responses to NKA or NKB respectively. Furthermore, NKB caused vasoconstriction as 
opposed to vasodilatation. The findings from this study suggest that functional NK2 and 
NK3 receptors were absent from the rat coronary circulation, since NKA only caused a 
very small vasodilator response, and neither this, nor the vasoconstrictor response to 
NKB were blocked by selective antagonists for NK2 and NK3 receptors respectively. It 
is likely, therefore, that any responses seen were due to activation of NK1 receptors. 
Alternatively, it is possible that in the presence of the NK2 receptor antagonist, NKA 
acted via NK1 or NK3 receptors, and that in the presence of the NK3 receptor antagonist, 
NKB acted via NK1 or NK2 receptors. This possibility could be explored in future 
experiments, by comparing the effects of co-infusion of MEN 11420 and either SR 
140333 or SR 142801 on responses to NKA; and comparison of the effects of co-
infusion of SR 142801 and either SR 140333 or MEN 11420 on responses to NKB. 
 
It seems unlikely that the concentrations of NK2 and NK3 receptor antagonists used in 
the present study were inadequate. SR 142801 was the first highly potent non-peptide 
NK3 receptor antagonist to be developed, and was shown to potently inhibit binding of 
[
125
I]-iodohistyl-[MePhe
7
]NKB to NK3 receptors from a number of species – including 
cloned human NK3 receptors, expressed in Chinese Hamster Ovary (CHO) cells 
(inhibition constant, Ki = 0.21  0.03 nM) – although it was less active on rat NK3 
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receptors (Ki = 15  3 nM) (Emonds-Alt et al., 1995). Similarly, MEN 11420 is a potent 
and selective antagonist of NK2 receptors – competitively binding to the human NK2 
receptor expressed in CHO cells and displacing [
125
I]-NKA with a Ki value of 2.5  0.7 
nM (Catalioto et al., 1998). A concentration of 1 M, 15min pre-treatment, was chosen 
for both MEN 11420 and SR 142801. MEN 11420 (1 M, 15 min) has also been 
reported to be effective in the guinea pig colon, causing a significant rightward shift of 
the concentration-response curve to NKA (Santicioli et al., 1997). Furthermore, using 
the Langendorff preparation, Chang and co-workers demonstrated that SR 142801 (0.1 
M, 60 min) significantly reduced vasodilator responses to NKA in the guinea pig heart 
(Chang et al., 2000), thus it seems reasonable to predict that using a higher 
concentration of antagonist against NKB, which has a higher affinity for NK3 receptors 
than NKA (Maggi et al., 1993), the response to NKB would be attenuated. 
 
Another important sensory neuropeptide is CGRP. CGRP is a very powerful vasodilator 
within the cardiovascular system, being approximately 100–1000 times more potent 
than other vasodilators such as SP (Deng and Li, 2005). CGRP has a wide distribution 
in the CNS and peripheral nervous system, located within C-fibres and also A-fibres 
that are generally within close proximity of blood vessels, and is frequently co-localised 
with SP and NKA (Brain and Grant, 2004). As is true of the tachykinins, non-neuronal 
sources of CGRP also exist such as chromaffin cells in the adrenal glands, thyroid 
parafollicular cells and airway neuroepithelial bodies (Maggi, 1995). CGRP is possibly 
best known for its actions within the cardiovascular system (Brain and Grant, 2004), 
which are mediated predominantly via CGRP receptors (Bell and McDermott, 1996). 
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The hearts of a number of mammalian species are innervated by nerves containing 
CGRP and SP, although at much lower levels than in major blood vessels (Bell and 
McDermott, 1996). The peripheral processes of CGRP-containing neurones are 
principally found within the coronary arteries, intrinsic cardiac ganglia, as well as a 
number of regions of the heart – although autoradiographic studies have shown that 
binding sites for CGRP are more widely distributed than for SP or NKA, and are also 
found in atrial and ventricular myocardium (Hoover et al., 2000). CGRP-like 
immunoreactivity within the ventricles is consistently higher than in the atria, and 
myocardium is much less densely innervated than epicardium, endocardium or 
pericardium, whilst coronary blood vessels are moderately innervated by CGRP-
containing nerves (Bell and McDermott, 1996). Although SP, acting via NK1 receptors, 
also causes vasodilatation within the cardiovasculature, it plays a lesser role than CGRP 
in the mammalian heart (Harrison and Geppetti, 2001). Indeed, this is reflected in the 
findings from this study, which suggest that CGRP plays a more major role in 12(S)-
HpETE-induced vasodilatation than SP – since responses to 12(S)-HpETE were 
reduced to a greater extent by CGRP8-37 than SR 140333. 
 
6.2. 12-LOX/AA-induced vasodilatation involves sensory C-fibres and 
TRPV1 
In an attempt to overcome the problems with stability and reproducibility experienced 
with both 12(S)-HETE and 12(S)-HpETE, hearts were perfused with 12-LOX and AA 
to allow for local production of 12-LOX products within the coronary preparation – an 
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adaptation of a protocol devised by Gryglewski and Vane (1972). This method proved 
vastly superior to direct administration of 12(S)-HETE and 12(S)-HpETE. 
 
In isolated perfused rat hearts, AA elicited dose-dependent vasodilatation, which was 
blocked by treatment with the non-selective LOX inhibitor NDGA, and also by the 
selective 12-LOX inhibitor baicalein. These findings suggest that AA-induced coronary 
vasodilatation was due to metabolism of AA via the 12-LOX pathway and the resultant 
generation of 12(S)-HpETE. 12-LOX metabolites have been shown to mediate the 
vasodilator action of AA in a number of different vessel types, including the rat basilar 
artery (Faraci et al., 2001, Nishiyama et al., 1998) and mesenteric arteries (Miller et al., 
2003), and also in the porcine coronary microcirculation (Zink et al., 2001). It is 
unlikely that AA-induced coronary vasodilatation was mediated by prostaglandins, 
since the COX inhibitor indomethacin was present in all experiments. 
 
Application of AA in the absence of exogenous 12-LOX also caused dose-dependent 
vasodilatation. Whether this was due to metabolism of AA by endothelial enzymes is 
unclear; however it cannot be excluded that the response to AA may be, in part, 
attributed to the metabolism of AA by endogenous 12-LOX. Comparison of the AA 
response curves in the absence and presence of exogenous 12-LOX demonstrated a 
clear superiority of the latter since the maximum response was increased and variability 
between heart preparations substantially reduced in comparison to the former. However, 
vasodilator responses to AA in the absence or presence of exogenous 12-LOX were not 
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reproducible, being prone to significant tachyphylaxis, and for this reason only a single 
dose-response curve was constructed in any heart in experiments with AA. 
 
Studies have shown that within the heart, 12-LOX is expressed by vascular endothelial 
cells, for example, bovine aortic endothelial cells (Alpert et al., 2002) and human aortic 
endothelial cells (Kim et al., 1995); smooth muscle cells, for example, from bovine 
aorta (Alpert et al., 2002), human aorta (Kim et al., 1995) and porcine aorta (Natarajan 
et al., 1996, Natarajan et al., 1997). Evidence obtained from studies using rat foetal 
cardiac fibroblasts suggests that 12-LOX plays an important role in cardiac cell growth 
(Wen et al., 2001). 12-LOX is also expressed by circulating monocytes in humans (Kim 
et al., 1995). Activity of cytosolic PLA2 releases AA from glycerophospholipids within 
both the plasma membrane and also the nuclear envelope (Kim et al., 2008b), 
whereupon it may be metabolised by 12-LOX. Immunocytochemical and biochemical 
methods have revealed that 12-LOX is predominantly localised in the cytosol, although 
there is evidence to suggest that it may also associate with membrane structures 
(Yamamoto et al., 1997) – indeed, translocation from the cytosol to membranes is a 
requirement for activation of human platelet 12-LOX (Yoshimoto and Takahashi, 
2002). Furthermore, it has recently been suggested that metabolism of AA to 
eicosanoids can occur in the nucleus (Luo et al., 2006). Although the present study was 
concerned with generation of 12-LOX metabolites from exogenous AA within the 
vasculature, there is a possibility that in vivo, AA might be generated endogenously in 
other cells such as cardiomyocytes and then taken up by vascular endothelial cells or 
vascular smooth muscle cells for 12-LOX metabolism. AA is a long chain fatty acid, 
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and due to its lipid nature, it may move in or out of cells through membranes (Luo et al., 
2006). Fatty acids are able to enter and cross the plasma membrane via passive 
diffusion, with or without the help of membrane-associated proteins (Glatz et al., 1997), 
and heart tissue contains a number of so-called ‘fatty acid-binding proteins’, believed to 
assist cellular uptake of the majority of fatty acids via a carrier-mediated mechanism 
(Schaap et al., 1998). 
 
AA-induced vasodilatation was also abolished by in vitro desensitisation of sensory C-
fibres with capsaicin, and by treatment with the TRPV1 antagonist capsazepine, as were 
12(S)-HpETE-induced responses. These results suggest that the AA-induced vasodilator 
response involves sensory C-fibre and TRPV1 activation. As with vasodilator responses 
to 12(S)-HpETE, responses to AA were suppressed by CGRP receptor and NK1 
receptor antagonists, offering further support for an involvement of sensory C-fibres in 
AA-induced vasodilatation. In addition, the findings that CGRP8-37 and to a lesser 
extent SR 140333, attenuated responses to AA, suggests that both CGRP and SP are 
involved in AA- and 12(S)-HpETE-induced vasodilator responses. As with responses to 
12(S)-HpETE, CGRP8-37 had a greater effect on responses to AA than did SR 140333 
supporting the view that CGRP plays a greater role, than SP, in the mammalian heart 
(Harrison and Geppetti, 2001). Moreover, the difference between the effects seen with 
the two antagonists was more marked with AA than with 12(S)-HpETE. SP and CGRP 
are co-localised in large, secretory granules within the central and peripheral terminals 
of sensory neurones and therefore co-released (Maggi, 1995). The studies in this thesis 
suggest that the co-release of these neuropeptides occurs in the rat heart in response to 
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12(S)-HpETE and AA, although confirmation of this by measurement of these 
neuropeptides, possibly by measurement of the coronary effluent, is required. Thus 
dependence of the response on both neuropeptides might suggest that in the presence of 
the NK1 receptor antagonist, the remaining response to AA is mediated by CGRP, 
whereas in the presence of the CGRP receptor antagonist, the remaining response to AA 
is likely mediated by SP. One might expect, therefore, that combined treatment with 
NK1 and CGRP receptor antagonists would result in even greater inhibition of responses 
to AA than with either antagonist alone, since both SP- and CGRP-mediated 
components of the response would be blocked. Interestingly combined treatment with 
CGRP8-37 and SR 140333 did not inhibit responses to a greater extent than treatment 
with CGRP8-37 alone, suggesting that CGRP and SP might activate the same signalling 
pathway to cause vasodilatation, thereby limiting the expected additive inhibitory effect 
on AA-induced responses. 
 
NK1 receptor-mediated coronary vasodilatation in response to SP occurs via release of 
NO from vascular endothelial cells (Whittle et al., 1989) and relaxation of adjacent 
smooth muscle. Vasodilator responses to CGRP in the coronary vasculature exhibit 
regional differences in both endothelium-dependence and also receptor pharmacology: 
for example, in the rat, CGRP-induced vasodilatation is endothelium-dependent in 
proximal intramyocardial arteries, but endothelium-independent in distal coronary 
arteries (Bell and McDermott, 1996). Furthermore, in the proximal coronary arteries, 
prostacyclin has been implicated as a mediator of endothelium-dependent vasodilatation 
as opposed to NO (Bell and McDermott, 1996). Indeed, three mechanisms have been 
 
Chapter 6: Discussion 
 
 
 
 
199 
 
proposed to underlie CGRP-induced vasodilatation: (1) binding of CGRP to CGRP 
receptors located on vascular endothelial cells leads to an increase in intracellular cAMP 
levels and the production and release of NO, which then diffuses into vascular smooth 
muscle cells, leading to the generation of guanosine 3’,5’-cyclic monophosphate 
(cGMP), followed by smooth muscle relaxation; (2) binding of CGRP to CGRP 
receptors on vascular smooth muscle cells leads to an increase in both cGMP and cAMP 
levels, thereby causing relaxation; and (3) CGRP activates glibenclamide-sensitive KATP 
channels in the plasma membrane of vascular smooth muscle cells, causing an efflux of 
K
+
 and thereby relaxation (Maggi, 1995). 
 
Both NK1 and CGRP receptors are GPCRs. Agonist binding and receptor activation 
causes a conformational change within the receptor such that a guanosine 5’-
diphosphate (GDP)-bound G-protein will associate, thereby causing a conformational 
change in the G-protein in turn causing GDP to dissociate and be replaced by GTP, and 
resulting in dissociation of the G-protein into its component  and  subunits. Either 
the  subunit (bound to GTP) or  subunit then binds to an intracellular effector, and 
effector activation is terminated by hydrolysis of GTP to GDP, and the re-association of 
 and  subunits (Rang et al., 1999). Tachykinin receptors such as NK1 receptors 
couple principally via Gq/11 proteins to the intracellular effector PLC, which hydrolyses 
PIP2 into IP3 and DAG – both of which act to elevate intracellular Ca
2+
 levels, the 
former by opening channels within the sarcoplasmic reticulum to release intracellular 
stores of Ca
2+
, thereby eliciting a response (Khawaja and Rogers, 1996). Transfection of 
CHO cells with human NK1 receptors has demonstrated that the receptors can also 
 
Chapter 6: Discussion 
 
 
 
 
200 
 
couple to Gs and Go proteins (Roush and Kwatra, 1998), which supports the earlier 
findings that NK1 receptors are also capable of coupling to adenylate cyclase (AC) to 
stimulate cAMP formation (Nakajima et al., 1992) and that activation of NK1 receptors 
may also lead to release of AA (Garcia et al., 1994). Although evidence suggests that 
CGRP receptors are also able to activate PLC by coupling to Gq/11 proteins, the principal 
mechanisms of endothelium-independent CGRP-induced vasodilatation involve 
coupling to AC via Gs proteins. The activation of AC leads to an increase in 
intracellular cAMP levels, stimulating PKA and K
+
 channel opening, leading to K
+
 
efflux and Ca
2+
sequestration that results in relaxation (Brain and Grant, 2004). 
 
If, in the present study, CGRP receptor-mediated vasodilatation was NO- and 
endothelium-independent, then the CGRP and SP signalling pathways would only 
appear to converge at the level of K
+
 channels, whereas if CGRP receptor-mediated 
vasodilatation was NO- and endothelium-dependent, and involved coupling of the 
receptors to Gs, the signalling pathways would seem to converge at the point of NOS 
activation and conversion of L-arginine to NO. An even greater degree of overlap of the 
SP and CGRP pathways would occur if CGRP receptors coupled to Gq/11. The possible 
involvement of NO could be determined in future experiments by including L-NAME 
in the perfusate, and seeing if vasodilatation was inhibited in the presence of a NOS 
inhibitor. However, it is unlikely that this is the case since vasodilator responses to 
12(S)-HpETE were unaffected by the NOS inhibitor L-NAME. Future experiments 
could also ascertain which G-proteins were involved in the responses seen in the present 
study, by use of either Cholera toxin (CTx) or Pertussis toxin (PTx). Gq/11 is insensitive 
 
Chapter 6: Discussion 
 
 
 
 
201 
 
to both CTx and PTx; however, Gs is sensitive to CTx, which causes simultaneous 
inhibition of the intrinsic GTPase activity of the  subunit and enhancement of AC 
activation (Cassel and Selinger, 1977); and Go, like Gi, is sensitive to PTx (Albert and 
Robillard, 2002), which inactivates the G-protein, thereby blocking the effect of 
agonists on downstream effector molecules (Moss et al., 1984). 
 
Additional support for a role for TRPV1 in the coronary vasodilator effects of AA was 
gained from studies with TRPV1 KO mice. Indeed, the dose-response curve to AA was 
shifted rightwards in hearts from TRPV1 KO mice compared with hearts of WT mice, 
suggesting that a major component of 12-LOX-mediated activity in the heart can be 
attributed to activation of TRPV1. The TRPV1 KO was developed after successful 
cloning of the capsaicin receptor by Caterina et al. (1997), and has facilitated extensive 
investigation into the role of this channel in physiology and pathology, contributing 
significantly to the current view that TRPV1 plays a major role in nociception, 
especially in inflammation (Immke and Gavva, 2006). An advantage of the TRPV1 KO, 
over pharmacological methods of down-regulating TRPV1, is that it is specific to 
TRPV1 – whereas chronic afferent denervation achieved via neonatal capsaicin 
treatment additionally results in sensory neuropeptide depletion (Wang and Wang, 
2005). Generation of TRPV1 KO mice has been described in detail by Davis and co-
workers (Davis et al., 2000). The TRPV1 KO has been validated in numerous models 
where TRPV1 has previously been implicated. For example, in joint inflammation 
(Keeble et al., 2005), acid-sensing (Leffler et al., 2006), and heat hyperalgesia 
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(Pogatzki-Zahn et al., 2005), responses are reduced in TRPV1 KO compared to WT 
mice. 
 
Although a rightward shift in the dose-response curve to AA was seen in TRPV1 KO 
mice, responses to AA were not abolished as might have been expected, since responses 
were near abolished in rat hearts treated with the TRPV1 antagonist capsazepine. At 
first sight, this response may appear to undermine the hypothesis that TRPV1 is 
involved in mediating vasodilator responses to AA. However, an alternative explanation 
for the results obtained is that although TRPV1 is involved in mediating vasodilator 
responses to AA, the response is not solely dependent upon the presence of functional 
TRPV1 channels and furthermore, that compensatory changes may have occurred in 
TRPV1 null mice. Indeed, a similar observation has been reported by Wang and Wang 
(2005), who investigated the effects of TRPV1 gene deletion on post-ischaemic 
recovery of function in isolated perfused murine hearts. They found that (1) whilst 
TRPV1 null mice demonstrated impaired recovery of cardiac function compared to WT 
mice, acute blockade of TRPV1 with capsazepine in WT hearts resulted in even greater 
impairment, suggesting that the effects of blocking channel activity acutely are partly 
cancelled out by compensatory changes that occur in the chronic absence of TRPV1; (2) 
whilst release of endogenous SP was reduced in TRPV1 KO compared to WT mice, it 
was greater than in WT mice treated with capsazepine, suggesting that non-TRPV1-
dependent release of SP is enhanced in TRPV1 KO mice; and (3) post-ischaemic 
recovery in terms of increased LVDP was better after treatment with exogenous SP in 
TRPV1 KO than WT mice, which the authors attributed to an increase in SP receptor 
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function in TRPV1 KO mice, since there was no significant difference between NK1 
receptor expression in TRPV1 KO and WT mice (Wang and Wang, 2005). 
 
One possible explanation for the vasodilator response to AA observed in TRPV1 KO 
mice in the present study is that the response was mediated by other TRP channels. The 
presence of several different TRP channels has been detected in the heart and 
vasculature, and both transient receptor potential canonical receptor (TRPC)4 and 
TRPV4 channels have been implicated in endothelium-dependent vasodilatation 
(Watanabe et al., 2008). TRPC4 is activated in endothelial cells by ATP and BK, with 
the resulting elevation in intracellular Ca
2+
 leading to generation and release of 
vasodilators such as NO (Yao and Garland, 2005). TRPV4 is a mechanosensitive 
channel important in shear stress-induced NO-mediated vasodilatation (Kohler et al., 
2006), and is also activated by AA, via its CYP metabolite 5,6-EET (Meves, 2008, 
Nilius et al., 2004, Watanabe et al., 2003). Thus AA, acting through EETs, can not only 
cause vasorelaxation by activation of large conductance, Ca
2+
-activated K
+
 channels and 
hyperpolarisation of vascular smooth muscle cells, but also by activation of TRPV4 on 
endothelial cells, increased intracellular Ca
2+
 and production of NO (Watanabe et al., 
2008). Considering the ability of some TRP channels to heteromultimerise (Hellwig et 
al., 2005), and the very recent report of a novel GPCR-activated TRP channel formed 
by heteromultimerisation of TRPC1 and transient receptor potential polycystin receptor 
2 subunits (Bai et al., 2008), there is also the remote possibility that in the present study, 
TRPV1-independent vasodilatation was mediated by a hitherto unknown TRP channel. 
The possible involvement of TRPV4 could be investigated by repeating dose-response 
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curves to AA in TRPV1 KO mice in the presence of the TRPV4 channel blocker 
ruthenium red (Kohler et al., 2006). 
 
6.3. The 12-LOX/AA/TRPV1 signalling pathway is involved in 
cardioprotection against I/R injury 
Having identified the primary mechanism underlying the vasoactive effects of AA, I 
then proceeded to investigate whether or not the 12-LOX/AA/TRPV1 signalling 
pathway is involved in 12-LOX-mediated protection against the damaging effects of 
I/R, as described in Chapter 4. 
 
There is substantial evidence to support the thesis that sensory neuropeptides, in 
particular CGRP (Kallner and Franco-Cereceda, 1998) and SP (Ustinova et al., 1995), 
act as endogenous cardioprotective factors, their production being increased locally 
during periods of ischaemia. In particular, that CGRP is a potent vasodilator and is 
widely distributed within the periphery makes it an ideal candidate for protecting tissues 
against injury (Brain and Grant, 2004). Indeed, the findings from a number of studies 
indicate that CGRP plays an important role in IPC, protecting against experimentally 
induced myocardial I/R injury in a number of models including isolated perfused rat 
hearts (Chai et al., 2006, Zhou et al., 1999), rat hearts in vivo (Wolfrum et al., 2005), 
and porcine hearts in vivo (Kallner and Franco-Cereceda, 1998). CGRP (Zhong and 
Wang, 2007) and SP (Wang and Wang, 2005, Zhong and Wang, 2007) have also been 
implicated in IPC using an isolated murine heart model of I/R, a convincing finding 
supported, in part, by observations that mice lacking the gene for αCGRP are more 
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susceptible to myocardial I/R injury (Huang et al., 2008). In humans, CGRP appears to 
be up-regulated by ischaemia, and has demonstrated protective effects against 
myocardial ischaemia in patients with chronic angina subjected to treadmill exercise 
(Brain and Grant, 2004). 
 
LOX metabolites have also been implicated in IPC (Chen et al., 1999, Gabel et al., 
2001, Patel et al., 2003, Starkopf et al., 1998, Tsutsumi et al., 2006), specifically 12(S)-
HpETE (Chen et al., 1999) and 12(S)-HETE (Murphy et al., 1995), although the exact 
mechanism underlying their cardioprotective effects remains to be elucidated. However, 
LOX metabolites are among the growing list of endogenous substances identified as 
activators of TRPV1, 12(S)-HpETE exhibiting the highest potency (Hwang et al., 
2000), and 12-LOX products have been shown to mediate signalling via TRPV1 in a 
number of pathways. For example, it has been demonstrated that BK causes 
inflammatory hyperalgesia by activating TRPV1 channels, via generation of 12(S)-
HpETE (Shin et al., 2002), and that excitation of cardiac sensory neurones by BK is 
mediated by 12-LOX products (Wu and Pan, 2007). Histamine-induced itching has also 
been shown to involve activation of TRPV1 via 12(S)-HpETE (Shim et al., 2007). 
TRPV1 has also been shown to play a role in cardioprotection afforded by heat-stress; 
activation of capsaicin-sensitive neurones resulting in increased synthesis and release of 
CGRP (Bhave et al., 2003). Furthermore, acid-evoked release of CGRP from mouse 
hearts appears to be primarily mediated by TRPV1 (Strecker et al., 2005), and since 
tissue acidosis is an important characteristic of myocardial I/R, these findings raise the 
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possibility that TRPV1-mediated CGRP release in the heart may represent an 
endogenous damage-limiting mechanism. 
 
Recent evidence suggests that TRPV1 may also play an important role in the protection 
against myocardial I/R injury afforded by IPC and it is thought that such protection is 
mediated by the activity of sensory neuropeptides released upon TRPV1 activation 
(Wang and Wang, 2005, Zhong and Wang, 2007). Wang and Wang demonstrated that 
in hearts isolated from WT and also TRPV1 KO mice; (1) perfusion of hearts with 
CGRP or SP improved post-ischaemic recovery, although (2) blockade of CGRP 
receptors with CGRP8-37 had no effect on post-ischaemic recovery; (3) blockade of 
NK1 receptors with the NK1 receptor antagonist RP-67580 impaired post-ischaemic 
recovery, although coronary flow in hearts from TRPV1 KO mice was unaffected; and 
(4) SP release was markedly increased by an I/R insult, although to a lesser extent in 
hearts from TRPV1 KO mice (Wang and Wang, 2005). Similarly, Zhong and Wang 
demonstrated that in hearts isolated from WT and TRPV1 KO mice; (1) blockade of 
CGRP receptors with CGRP8-37 impaired IPC-induced protection in WT but not 
TRPV1 KO mice, (2) blockade of NK1 receptors with RP-67580 also impaired IPC-
induced protection in WT but not TRPV1 KO mice, and (3) both SP and CGRP release 
was markedly increased after IPC, although to a lesser extent in TRPV1 KO than WT 
hearts (Zhong and Wang, 2007). However, whether the 12-LOX pathway of AA 
metabolism and the sensory C-fibre/TRPV1/neuropeptide pathways are linked in I/R 
injury has not previously been explored. 
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In control hearts, a period of 25 min normothermic global ischaemia caused a 
characteristic increase in CPP and reduction in LVDP during the following 120 min 
reperfusion, and an infarct size of approximately 60%. As already mentioned, in 
previous studies carried out in our laboratory, the same I/R protocol produced an infarct 
size of approximately 50% (Hobbs et al., 2004), and it is not clear why, in the present 
study, a greater infarct size was produced. Normothermic conditions were achieved by 
suspending hearts in beakers that were continually filled with Krebs solution at 37C, so 
that the temperature of the hearts did not fall when perfusion was stopped during 
ischaemia. This was of utmost importance, since temperature has been shown to have a 
profound effect on the extent of tissue damage caused. For example, Duncker and co-
workers demonstrated that in open-chest swine subjected to 45 min coronary occlusion 
followed by 240 min reperfusion, no infarction occurred at 35C, but with each 1C 
increase in body temperature, an additional 20% of the area at risk became infarcted so 
that by around 39C, approximately 80% of the area at risk was infarcted (Duncker et 
al., 1996). A positive correlation between myocardial temperature and infarct size has 
also been demonstrated in dogs (Schwartz et al., 1997) and rabbits (Hale and Kloner, 
1997). Furthermore, whilst relatively small reductions in myocardial temperature within 
the normothermic range reduce infarct size, there is evidence to suggest that 
hypothermia (25C) can increase the threshold for IPC (Dote et al., 1998). Indomethacin 
(used in all vasoactivity experiments, in order to exclude the possible involvement of 
COX-derived PGs) had no significant effect on infarct size per se, and whilst only a 
small sample size was used, this has been previously demonstrated in a number of 
studies – for example, in rat (Lagneux et al., 2003, Wen et al., 2004) as well as rabbit 
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(Aitchison and Coker, 1999), porcine (Gres et al., 2002) and canine (Fiedler and 
Mardin, 1985) hearts. 
 
Treatment with 12-LOX/AA prior to ischaemia reduced the post-ischaemic increase in 
CPP, improved LVDP and significantly reduced infarct size. The protective effects of 
12-LOX/AA on infarct size were inhibited by pre-treatment of hearts with baicalein or 
in vivo desensitisation of sensory C-fibres by capsaicin. Capsaicin had no effect on the 
improvement in post-ischaemic LVDP seen with 12-LOX/AA; however, baicalein 
reduced the 12-LOX/AA-mediated improvement in LVDP up to 75 min after the onset 
of reperfusion, although it did not appear to have any significant inhibitory effects in the 
later stages of reperfusion. These findings establish a definitive link between sensory C-
fibre/neuropeptide- and 12-LOX-mediated cardioprotection, identifying a novel 
pathway whose activation limits myocardial damage induced by I/R. The precise 
mechanism underlying this protective effect is not known, although a role for PKC has 
been demonstrated in the protection afforded by 12-LOX metabolites (Chen et al., 
1999) and CGRP (Wolfrum et al., 2005). In the former study, investigators showed that 
the increase in production of cardioprotective 12(S)-HETE seen in IPC was reversed by 
the PKC inhibitor chelerythrine (Chen et al., 1999), whilst in the latter study, it was 
shown that PKC also plays a role in remote preconditioning (i.e. at a distance) - 
myocardial PKC being activated by brief occlusion of the anterior mesenteric artery, 
and inhibition of PKC using chelerythrine blocking the reduction in infarct size seen 
with CGRP infusion (Wolfrum et al., 2005). Expression of PKC ( and  isoforms) 
increases in the human brain after ischaemic stroke (Krupinksi et al., 1998), whilst in 
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isolated rat hearts, ischaemia has been reported to cause an increase in mRNA for both 
PKC and PKC (Simonis et al., 2007). As discussed below, PKC plays an important 
role in modulating TRPV1 activity, including sensitisation of TRPV1. It is possible that 
the apparent involvement of PKC in cardioprotection against I/R injury can, in part, be 
attributed to PKC-mediated sensitisation of TRPV1. 
 
An important characteristic of TRPV1, considering its major role in nociception, is its 
plasticity, and sensitisation of TRPV1 represents one of the principal mechanisms via 
which channel activity is modulated. TRPV1 possesses multiple sites for 
phosphorylation by protein kinases – seven for PKA, six for PKC and six for CaMK II - 
and these play a central role in regulating TRPV1 activity (De Petrocellis and Di Marzo, 
2005). A number of molecules released during inflammation, including histamine, BK, 
NGF, prostaglandins and protons, cause sensitisation of nociceptors – and in several 
cases this has been demonstrated to involve phosphorylation of TRPV1 via PKA or 
PKC (Zhu and Oxford, 2007). Other kinases associated with sensitisation of TRPV1 
include the tyrosine kinase c-Src kinase (Jin et al., 2004), and kinases of both the 
phosphatidylinositol 3-kinase and mitogen activated protein kinase pathways, which 
have been implicated in sensitisation by NGF (Zhu and Oxford, 2007). 
 
Phosphorylation by PKC has been demonstrated to underlie sensitisation of TRPV1 to 
heat, protons, capsaicin and anandamide (Vellani et al., 2001); sensitisation of the heat 
response by BK having been more specifically attributed to the -isoform of PKC 
(Cesare et al., 1999). The sensitivity to protons may be of particular relevance to this 
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thesis since myocardial ischaemia results in a substantial acidosis that may have an 
important physiological role (Graham et al., 2004). In addition to BK, a number of other 
GPCR agonists have been implicated in sensitisation of TRPV1 via PKC, including 
PAR2 agonists (Amadesi et al., 2004) and ATP (Hwang and Oh, 2002). PKC 
phosphorylation has also been shown to mediate sensitisation of TRPV1 by PGE2 
(Moriyama et al., 2005); however, there is also evidence to suggest that this is mediated 
by PKA (Lopshire and Nicol, 1997, Lopshire and Nicol, 1998, Moriyama et al., 2005, 
Singh Tahim et al., 2005). 
 
The prostaglandin PGE2 is known to play a major role in regulation of immunity and 
inflammation (Harris et al., 2002), and has been reported to sensitise TRPV1 in a PKC-
dependent manner via the prostanoid receptor subtype EP1, and to a lesser extent in a 
PKA-dependent manner, via the EP4 subtype (Moriyama et al., 2005); however, very 
brief investigation of this potential suggested that this was not the case in the present 
study (see Figure 6.1). Although the vasodilator response to AA was reproducible, 
under the conditions tested, treatment with PGE2 did not potentiate responses to AA – in 
fact vasodilator responses to AA were smaller in the presence of PGE2 than before 
treatment. 
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Figure 6.1. Effect of TRPV1 sensitisation on AA-induced vasodilatation. Effect of TRPV1 
sensitisation with PGE2 (100 nM, 5 min) on responses to AA (300 nmol) in isolated rat heart. 
Vasodilator responses are expressed as a reduction in CPP (mmHg). Data obtained in presence 
of indomethacin (5 M). Bolus doses tested in a single heart. 
 
A concentration of 100 nM PGE2 was chosen since studies in rat DRG have previously 
demonstrated significant sensitisation with this concentration (Lopshire and Nicol, 
1997). A number of other studies have also used higher concentrations of PGE2 – for 
example, 250 nM (Hu et al., 2002), 1 M (Lopshire and Nicol, 1998, Moriyama et al., 
2005), and even 10 M (Fischer and Reeh, 2007, Singh Tahim et al., 2005). Lopshire 
and Nicol also demonstrated that PGE2 sensitisation occurs in a time-dependent manner: 
using 100 nM PGE2, the time to peak sensitisation was 8.6  1.2 min (range 6–14 min), 
and using 1 M PGE2, 8.9  0.6 min (range 6–10 min) (Lopshire and Nicol, 1997). In 
the present study, the response to AA was measured after 5 min exposure to PGE2, 
therefore it is also a possibility that peak sensitisation had not been reached by this time. 
A further consideration is whether concentrations of PGE2 ranging from 0.25–10 M, 
reported by other investigators to sensitise TRPV1 in vitro, are representative of 
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circulating PGE2 levels under inflammatory conditions when sensitisation would likely 
occur, although it has been suggested that 1 M PGE2 is a realistic concentration to use 
in the context of inflammation (Moriyama et al., 2005). It is possible that the lack of 
sensitisation of 12-LOX/AA responses by PGE2 seen in the current study reflects a 
response of TRPV1 activation unaffected by PKA or PKC phosphorylation of TRPV1, 
unlike heat (Cesare et al., 1999, Cesare and McNaughton, 1996, Sugiura et al., 2002), 
capsaicin (Crandall et al., 2002) and anandamide (Singh Tahim et al., 2005). Perhaps 
the chemical structures of AA, 12(S)-HETE and 12(S)-HpETE differ sufficiently to 
those of capsaicin and anandamide that phosphorylation of TRPV1 by PKA or PKC 
does not enhance the interaction of AA, 12(S)-HETE or 12(S)-HpETE with ligand 
binding sites. A further possibility is that scaffolding proteins necessary for TRPV1 
modulation by PGE2 are absent in the rat heart. It has been recently reported that in 
mouse sensory neurones, phosphorylation of TRPV1 by PKA requires the A-kinase 
anchoring protein (AKAP)150, and that in mice with a truncated form of AKAP150, 
PGE2/PKA-dependent modulation of TRPV1 is impaired (Schnizler et al., 2008). It has 
also been reported that AKAP150 plays a role in PKA-dependent modulation of TRPV1 
in the rat, being expressed by neurones in the trigeminal ganglia and contributing to the 
development of thermal hyperalgesia (Jeske et al., 2008). However, there are currently 
no reports in the literature of AKAP150 being expressed in the heart, and this may 
explain why there was no evidence of PGE2-mediated sensitisation of TRPV1 in this 
study. To determine the potential of sensitisation of TRPV1 in the heart, further work 
investigating the impact of direct PKA/PKC activation is required, for example, using 
different sensitising agents, a variety of doses, and different timescales for sensitisation. 
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Cardiac afferents are activated by a number of chemical mediators that are released 
during myocardial ischaemia, including BK (Foreman, 1999). Ischaemia/hypoxia is also 
associated with a fall in pH, and acidic pH ( 7) has been demonstrated to evoke large 
depolarising currents in cultured cardiac sensory neurones (Benson et al., 1999). Indeed, 
in the case of abdominal ischaemia, it has been suggested that the resulting tissue 
hypoxia causes indirect stimulation of abdominal visceral afferents by metabolites such 
as lactic acid, a by-product of anaerobic metabolism induced by hypoxic conditions (Fu 
et al., 1996). Other investigators have reported that protons derived from lactic acid also 
activate cardiac afferents during myocardial ischaemia (Longhurst et al., 2001). Whilst 
mildly acidic conditions may lead to sensitisation of TRPV1 (which, as discussed 
above, may not actually affect responses to 12-LOX metabolites), if pH falls below pH 
6, protons may themselves activate TRPV1 (Leffler et al., 2006). It is therefore possible 
that in myocardial ischaemia, C-fibres are activated by hypoxia-induced acidosis, 
perhaps at least in part via activation of TRPV1. 
 
‘Hypoxia’ is a somewhat general term, used to describe low levels of molecular oxygen 
(Simon et al., 2008). However, the normal partial pressure of oxygen (pO2) varies both 
within and among different tissues, and therefore what is considered ‘normoxic’ or 
‘hypoxic’ depends on the tissue or cellular location in question – for example, the pO2 
of arterial blood is approximately 100 mmHg compared to approximately 40 mmHg in 
venous blood (Lee et al., 2007). Furthermore, since transport of oxygen from the blood 
in capillaries to the site of oxygen consumption within the mitochondria occurs via 
passive diffusion, this relies on the existence of pO2 gradients from the lumen of the 
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capillaries to the inner mitochondrial membrane: in the heart, such gradients are 
considerable and a major determinant of the pO2 at the mitochondria and hence 
oxidative phosphorylation (Takahashi and Doi, 1998). 
 
Whilst almost all mammalian cells are capable of oxygen sensing, it is the 
neurosecretory chemoreceptor glomus cells of the carotid body (situated at the 
bifurcation of the common carotid artery close to the heart) which sense blood pO2 for 
the organism as a whole, detecting decreases as small as 1 mmHg (Lahiri et al., 2006). 
Stimulation of peripheral chemoreceptors leads to activation of both ventilatory and 
cardiovascular control centres in the brain; the acute cardiovascular response to hypoxia 
(characterised by tachycardia and increased cardiac output) being triggered by 
stimulation of the adrenergic nervous system (Favret and Richalet, 2007). In addition to 
acute physiological responses, hypoxia also induces chronic responses that occur over a 
period of minutes or more, and which involve alterations in gene expression and 
subsequent protein synthesis – oxygen-regulated gene expression occurring in all cells, 
including those of the carotid body (Lahiri et al., 2006). Alterations in gene expression 
in response to changes in availability of oxygen occurs by various mechanisms, 
including regulation of gene transcription by the transcription factor hypoxia-inducible 
factor 1 (HIF-1) (Giordano, 2005). 
 
HIF-1 regulates genes that encode proteins involved in adaptive responses to hypoxia 
such as angiogenesis, erythropoesis, vasodilatation and glycolysis, that serve to 
maintain ATP levels by increasing tissue perfusion and anaerobic metabolism (Taylor 
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and Pouyssegur, 2007). Activity of HIF-1 is tightly regulated in an oxygen-dependent 
manner: under normoxic conditions, it is rapidly hydroxylated at specific proline 
residues by HIF--specific prolyl hydroxylases and then targeted for degradation by 
proteases, having a half-life of less than 5 min, whereas hypoxic conditions inhibit 
hydroxylation and stabilise the protein so that it can translocate to the nucleus and 
heterodimerise with HIF-1 and then bind to hypoxia response elements (HREs) of 
target genes (Lisy and Peet, 2008). HIF-1 becomes increasingly stable and dimerises 
with HIF-1 at oxygen levels below 5% (Simon et al., 2008). Therefore experiments to 
test the possibility that the 12-LOX/AA/TRPV1 vasodilator pathway might be up-
regulated in the heart should be conducted at O2 tensions commensurate with the above, 
i.e. a reduction of O2 levels to 5% or below. 
 
That treatment with 12-LOX/AA reduced infarct size suggests that 12-LOX/AA 
protects against cell death in the model of myocardial I/R used in the present study. As 
mentioned in Chapter 1, death of cardiomyocytes in response to I/R occurs via cell 
swelling (oncosis) (Majno and Joris, 1995) and cell shrinkage (apoptosis) (Buja, 2005, 
Buja and Vela, 2008, Jugdutt and Idikio, 2005) The extent to which each process 
contributes to cell death remains under debate, but since apoptosis is an ATP-dependent 
process, and ATP production is decreased in ischaemia, one suggestion is that apoptotic 
mechanisms play a more dominant role in the early stages of development of 
myocardial injury (Buja and Vela, 2008). That the reduction in infarct size observed 
after treatment with 12-LOX/AA prior to I/R was reversed in hearts taken from animals 
that had been subjected to in vivo C-fibre desensitisation with capsaicin, suggests that 
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the protection against cell death afforded by 12-LOX/AA treatment involves sensory C-
fibres and sensory C-fibre-derived neuropeptides such as CGRP and SP. It is possible 
that cell death was reduced due in part to the vasodilator effects of 12-LOX/AA 
(mediated by vasoactive peptides), which would help to increase blood flow and hence 
supply of oxygen and other nutrients to ischaemic tissue, perhaps thereby delaying the 
initiation of cell death pathways – although the evidence from this thesis would suggest 
that vasodilatation has a minor role to play (see below), largely due to the use of a 
global model rather than a regional model of ischaemia being used in these studies, 
which eliminated the possibility of recruiting coronary collaterals after the onset of 
ischaemia. Further in vitro studies investigating the effects of CGRP and/or SP on 
cardiac myocytes or coronary endothelial cells in culture subjected to an I/R insult 
would be informative. Techniques such as fluorescence activated cell sorting to detect 
cells expressing markers for apoptosis and/or necrosis, such as annexin-5, would enable 
determination of which pathways of cell death these neuropeptides might improve. 
 
CGRP has been previously reported to reduce infarct size in isolated rat hearts (Chai et 
al., 2006), and whilst the precise mechanisms underlying its protective effects are 
unknown, there is evidence to suggest that they may be related to reduced damage due 
to oxidative stress. For example, in cultured vascular smooth muscle cells, pre-treatment 
with CGRP offers protection against apoptosis induced by oxidative stress (generated 
using glucose oxidase) (Schaeffer et al., 2003). The possible involvement of CGRP in 
mediating the protection afforded by 12-LOX/AA against infarct size in the present 
study could be investigated in future experiments by comparing infarct size after 
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treatment with 12-LOX/AA, with infarct size after 12-LOX/AA treatment in the 
presence of CGRP8-37. Similarly, the possible involvement of SP could be investigated 
using SR 140333. However, it should be noted that although evidence suggests that SP 
is released from cardiac afferent fibres during myocardial ischaemia (Hua et al., 2004) 
and protects against I/R injury (Ustinova et al., 1995, Wang and Wang, 2005, Zhong 
and Wang, 2007, Zhong and Wang, 2008, Zhong and Wang, 2009), there are currently 
no reports in the literature of SP specifically reducing infarct size. 
 
The effect of 12-LOX/AA treatment on CPP was surprisingly small, indicating only a 
minor improvement in coronary flow in response to AA. This finding would therefore 
imply that the reduction in infarct size seen after treatment with 12-LOX/AA was not 
related to vasodilator actions of AA or its 12-LOX metabolites, but rather due to 
inhibition of cell death, as discussed above. Furthermore, in contrast to the other two 
indices of I/R injury, baicalein treatment or desensitisation of sensory C-fibres per se 
profoundly and significantly suppressed the post-ischaemic increase in CPP; therefore 
there was no observable effect of these treatments in the presence of exogenous 12-
LOX/AA. This result is in direct contrast to the previous studies demonstrating 
vasodilator effects of the 12-LOX/AA/C-fibre pathway. Indeed, these results suggest 
that LOX production and C-fibre activation contribute to the post-ischaemic increase in 
CPP. 
 
Baicalein belongs to a group of compounds known as flavonoids, which are contained 
in plants such as Scutellaria baicalensis, and which have anti-inflammatory, anti-
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ischaemic, vasodilator and chemoprotective properties, in addition to acting as free 
radical scavengers and chelating agents (Psotova et al., 2004). Baicalein itself has a 
number of pharmacological properties in addition to inhibiting 12-LOX, for example, it 
is a potent antioxidant and free radical scavenger, and has anti-inflammatory, anti-
thrombotic, anti-proliferative and anti-mitogenic effects (Lapchak et al., 2007). It has 
also been reported to suppress intracellular Ca
2+
 accumulation in cultured 
cardiomyocytes undergoing metabolic inhibition to simulate myocardial ischaemia 
(Woo et al., 2005), and it is perhaps via this cardioprotective effect of baicalein that 
post-ischaemic CPP was reduced in the absence of endogenous 12-LOX/AA. Similarly, 
whilst treatment with capsaicin is recognised as a standard method for desensitising 
sensory C-fibres, a limitation of this method is that capsaicin has a number of non-
selective actions, such as inhibition of voltage-gated Na
+
 and K
+
 channels – although 
higher concentrations of capsaicin than were used in the present study (3 M) are 
typically required to elicit these non-specific effects (Holzer, 1991). It therefore remains 
a possibility that capsaicin attenuated the characteristic rise in post-ischaemic CPP via 
non-specific actions. 
 
The improvement in LVDP was evident after approximately 30 min reperfusion; 
however, post-ischaemic recovery of LVDP after treatment with 12-LOX/AA did not 
exceed 45%, and in control hearts, recovery did not exceed 25%. Since the effect of 12-
LOX/AA treatment on LVDP was relatively small, this raises the possibility that whilst 
it appears that a 12-LOX/AA/TRPV1/sensory neuropeptide pathway may reduce cell 
death caused by myocardial I/R injury, this pathway does not protect against other 
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consequences of I/R such as myocardial stunning. However, the findings from the 
present study contrast with findings from previous experiments conducted in our 
laboratory, which showed that in control hearts, post-ischaemic recovery of LVDP was 
approximately 50% after 25 min (Hobbs et al., 2004) to 30 min (Webb et al., 2004) 
ischaemia. It is possible that the I/R protocol used in this study resulted in a greater 
degree of injury than previously, which may have made it harder to see the effects of 
pre-ischaemic treatments on I/R injury. Indeed, the ability to observe a protective effect 
of a particular treatment depends on the extent of injury – if it is either too great or too 
little, then it is difficult to ascertain whether protection has been achieved (Gabel et al., 
2001). It is possible that seasonal variations, source of rats, or variations in diet underlie 
the differences in the extent of injury. To test this possibility, it would be worth 
repeating experiments but altering the protocol such that a lesser degree of injury is 
sustained, i.e. in controls, at least 50% recovery of LVDP. 
 
6.4. Myocardial I/R injury alters TRPV1 expression 
As previously mentioned, TRPV1 channel activity is modulated by a number of 
mechanisms, including reversible phosphorylation. However, longer-term alterations in 
TRPV1 activity can be achieved via control of gene expression, down-regulation being 
caused by factors such as deprivation of NGF and up-regulation occurring as a result of 
inflammation (Cortright and Szallasi, 2004). Indeed, an increase in the number of 
unmyelinated sensory axons expressing TRPV1 channels has been proposed as a 
mechanism underlying the peripheral sensitisation that leads to heat hyperalgesia in the 
inflamed state (Carlton and Coggeshall, 2001). Increased TRPV1 protein expression has 
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also been documented in DRG in response to peripheral inflammation (Amaya et al., 
2003), and in the spiral and vestibular ganglia in response to ROS generation (Kitahara 
et al., 2005). Some studies have reported increased expression of TRPV1 protein with 
no apparent change in TRPV1 mRNA levels (Ji et al., 2002, Schicho et al., 2004). 
 
As described in Chapter 5, in the present study, TRPV1 protein expression was 
decreased by approximately 50% in hearts subjected to an I/R insult in vitro compared 
to control hearts whilst TRPV1 mRNA levels remained unchanged (as expected, due to 
C-fibres being detached from their cell bodies in the DRG). This observation suggests 
‘consumption’ of TRPV1, as might have been expected – perhaps due to decreased 
protein stability associated with myocardial ischaemic injury (Sprengel et al., 1995) or 
decreased protein synthesis. Indeed, although hypoxia triggers up-regulation of genes 
essential for adaptation of cells to hypoxic conditions, via transcription factors such as 
HIF-1 (Lee et al., 2007), in the majority of cells, protein synthesis is reduced in 
response to hypoxia, as a means of conserving energy (Simon et al., 2008). Such a 
decrease would theoretically result in suppression of 12-LOX/AA/TRPV1-mediated 
cardioprotection. However, in hearts subjected to I/R in vivo, TRPV1 mRNA levels 
were reduced by approximately 60%, whilst TRPV1 protein expression was increased. 
This result suggests that at least in vivo, there is an increase in mRNA translation, 
possibly in a bid to maintain TRPV1 protein levels. In DRG, TRPV1 mRNA levels 
remained unchanged after I/R, whilst TRPV1 protein expression was increased. It was 
long believed that for sensory neurones, protein synthesis occurs exclusively in 
neuronal cell bodies (i.e. within the DRG) and that these proteins are then transported to 
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the central and peripheral terminals of the neurones via slow, anterograde transport 
along the axon. However, it has become evident that mRNA is also present in the distal 
domains of the neurone, and that protein synthesis can take place en route within the 
axon (Koenig et al., 2000) as well as in the nerve terminals (Kaplan et al., 2004). 
Indeed, it has been demonstrated that carrageenan treatment in the rat hindpaw leads to 
axonal transport of TRPV1 mRNA from the DRG to the nerve terminals, where it is 
then translated, increasing the number of TRPV1 channels and thereby increasing 
sensitivity to capsaicin (Tohda et al., 2001). This so-called local protein synthesis 
allows for a much more rapid increase in protein expression, since due to its compact 
nature, mRNA can be transported along the axon faster than protein. At the present 
time, however, it is not clear the rate at which axonal transport of mRNA occurs – 
although as a guide, fast anterograde transport of Golgi-derived vesicles occurs at an 
overall rate of 2–5 m s-1, compared to the slow transport of microtubules and 
neurofilaments, which occurs at an overall rate of 0.002-0.01 m s-1 (Brown, 2003). 
Although the rate at which TRPV1 mRNA or protein is transported along axons is 
unknown, these figures suggest that there may not have been adequate time in the in 
vivo I/R experiments for transport from the DRG to the heart to occur. Indeed, in the 
study by Tohda and co-workers, carrageenan was injected into the rat hindpaw and then 
2 h later, the sciatic nerve was ligated. Although an accumulation of TRPV1 mRNA 
was evident on the side proximal to the sciatic nerve ligation, this was after the nerve 
had been ligated for two hours, and an increase in sensitivity to capsaicin was found to 
occur 4 h after treatment with carrageenan (Tohda et al., 2001). Using tongue tissue as a 
representative model of TRPV1 expression, Orliac and co-workers reported a 
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significant increase in TRPV1 protein 6 h after administration of lipopolysaccharide 
(Orliac et al., 2007). Even if there was insufficient time in the present study for TRPV1 
mRNA to be transported from the DRG to nerve terminals within the heart, it remains a 
possibility that, since mRNA can be translated outside of the DRG, the increase in 
TRPV1 protein seen after I/R in vivo is due to translation of pre-existing mRNA in 
efferent nerve terminals. 
 
Clearly, as indicated in Figure 6.2, in the in vitro model of I/R injury used in the present 
study, the neurones innervating the heart were no longer associated with their cell 
bodies, and therefore there could be no transport of mRNA to the peripheral terminals 
and subsequent translation to increase numbers of TRPV1 channels. Samples from in 
vitro experiments therefore served as a control – and, in agreement with expectations, 
no increase in TRPV1 mRNA levels was detected in ischaemic hearts from in vitro 
experiments. It should be remembered that in addition to TRPV1, transport of other 
gene products was also prevented in this model of I/R - and neurotrophic factors such as 
NGF, which are retrogradely transported to the DRG, have been shown to play an 
essential role in regulating TRPV1 expression, for example in inflammatory thermal 
hyperalgesia (Amaya et al., 2004). 
 
Chapter 6: Discussion 
 
 
 
 
223 
 
 
Figure 6.2. Schematic diagram summarising the effects of I/R on TRPV1 mRNA levels and 
TRPV1 protein expression in the rat heart and DRG. The effects of I/R in vitro are shown in 
italics. 
 
Indeed, it has been recently reported that the rat TRPV1 gene contains two promoter 
regions that direct transcription, which are positively regulated by NGF (Xue et al., 
2007). Some studies have reported an increase in TRPV1 mRNA levels in DRG in 
response to NGF (Winston et al., 2001), whereas others have only detected an increase 
in TRPV1 protein expression (Ji et al., 2002). However, axotomy of sensory neurones 
from adult rat dorsal root and nodose ganglia reduces TRPV1 mRNA (Michael and 
Priestley, 1999) and protein (Hudson et al., 2001) in DRG, due to block of NGF 
transport. Thus, whilst in the present study no change in mRNA levels was detected in 
hearts subjected to I/R injury in vitro compared to controls, based on findings from 
previous studies, it was predicted that in vivo an increase in TRPV1 protein expression 
would be apparent. Indeed, TRPV1 protein expression was increased in hearts and DRG 
from animals subjected to I/R injury in vivo, associated with a reduction in TRPV1 
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mRNA levels in heart tissue, but no change detected in TRPV1 mRNA levels in DRG. 
Although one might have expected parallel changes in mRNA levels and protein 
expression after I/R in vivo, the findings from the present study showing increased 
TRPV1 expression with no detectable increase in mRNA levels in DRG, are consistent 
with those of Ji et al. (2002) and Schicho et al. (2004). 
 
In addition to transcriptional regulation of TRPV1 being mediated by NGF, which is 
synthesised and released by both mast cells and T cells under the control of the pro-
inflammatory cytokines interleukin-1 and TNF (Rang et al., 1999), it is possible that 
NGF and/or TRPV1 expression is additionally regulated by HIFs, although there are no 
reports in the literature to date of either gene containing HREs. HIF-1 is known to 
accumulate during ischaemia, and cause an increase in expression of a variety of genes 
that promote cell survival, including genes involved in the protection conferred by IPC 
against myocardial I/R injury (Loor and Schumacker, 2008). In rat myocytes, HIF-1 
has been shown to protect against simulated I/R injury, and levels of HIF-1 protein to 
increase with IPC (Date et al., 2005). It would be of interest to determine whether 
inhibition of HIF, for example, by use of a pharmacological agent such as echinomycin 
(Cairns et al., 2007, Kong et al., 2005) alters the changes in TRPV1 expression seen in 
the in vivo model of I/R; also, to examine the TRPV1 promoter to see if it contains an 
HRE. 
 
The changes in TRPV1 expression observed in the present study were not due to an 
artefact caused by changes in cell viability number, nor due to a general alteration in 
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TRP channel expression in response to I/R, since I/R had no effect on TRPV2 or 
TRPV4 mRNA levels, either in hearts subjected to I/R in vitro, or in DRG. TRPV2 
mRNA levels were also unaffected in hearts subjected to I/R in vivo, and whilst levels 
of TRPV4 mRNA were higher in ischaemic hearts than in sham controls, this difference 
was not statistically significant. If increased TRPV1 expression is in part under the 
control of HIF, as postulated above, then the lack of increase in TRPV2 and TRPV4 
expression would suggest that the promoters for these genes are subject to different 
controls – although there appears to be very little information available about the 
promoters of these genes. Indeed, that there was no significant difference found between 
levels of TRPV2 and TRPV4 mRNA levels in hearts or DRG from animals subjected to 
I/R in vitro or in vivo is in agreement with the absence of reports in the literature 
suggesting a role for these receptors in I/R injury or mechanisms protecting against this 
phenomenon. 
 
It would also be interesting to determine whether the changes in TRPV1 expression 
observed in the current study resulted from ischaemia or I/R. Future experiments could 
address this question by comparing mRNA levels and protein expression in hearts and 
DRG subjected to an I/R protocol, to those from tissue samples subjected to ischaemia 
alone. The findings from the present study therefore suggest that myocardial I/R triggers 
transport of TRPV1 mRNA and possibly also protein, from the DRG to the peripheral 
terminals of capsaicin-sensitive sensory C-fibres within the heart, to protect against I/R 
injury. 
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When attempting to interpret the findings from real-time PCR and Western blot 
experiments in the present study, there are a number of limitations that should be 
considered. Firstly, the concentration of mRNA or protein at any one time is dependent 
on both its rate of synthesis and its rate of degradation. The half-life of mRNA depends 
on the particular gene product, ranging from seconds to several cell generations 
depending on the length of time the gene product is required. Similarly, the lifetime of 
different proteins varies considerably. The concentration of a particular mRNA or 
protein thus depends partly on the time-point at which it is measured. If the half-life of 
the mRNA or protein is short, for example seconds, then if measurement is taken 
minutes later, any increase in mRNA levels will go unnoticed. A number of studies by 
other groups have looked for changes in levels of TRPV1 mRNA and/or protein 
expression in response to various stimuli; however, to some extent the findings seem to 
depend upon the time-course of the experiment. For example, Carlton and Coggeshall 
demonstrated a marked increase in TRPV1 in the inflamed rat hindpaw, 48 h after 
intraplantar injection of Complete Freund’s Adjuvant (Carlton and Coggeshall, 2001). 
In contrast, Tohda and co-workers found that carrageenan-induced inflammation caused 
a decrease in TRPV1 in DRG, and that this response peaked at 4 h (Tohda et al., 2001). 
However, this apparent disparity between the findings of these two studies highlights 
another point to consider when attempting to interpret the findings from the present 
study in the context of findings from previous work. Whilst Tohda et al. (2001) were 
looking for changes in levels of TRPV1 mRNA, Carlton and Coggeshall (2001) were 
looking for changes in TRPV1 protein expression. As previously mentioned, a number 
of studies have demonstrated an increase in TRPV1 protein expression in response to 
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peripheral inflammation (Amaya et al., 2003, Carlton and Coggeshall, 2001, Ji et al., 
2002) whilst some have been unable to detect an increase in TRPV1 mRNA levels (Ji et 
al., 2002, Schicho et al., 2004). Furthermore, it is also important to distinguish between 
changes in TRPV1 (mRNA levels or protein expression) in DRG and nerve terminals. 
For example, whilst Tohda et al. (2001) found a decrease in TRPV1 mRNA in DRG in 
response to carrageenan injection, an increase was detected in nerve terminals – which 
was taken as evidence for the axonal transport of mRNA from the DRG to central and 
peripheral nerve terminals, as discussed earlier. It should also be remembered that the in 
vitro I/R protocol used in the present study caused global ischaemia and the in vivo I/R 
protocol caused regional ischaemia which itself may underlie the differences seen. 
However, since both models result in similar infarct sizes, it seems unlikely that 
differences in the results obtained from in vitro and in vivo experiments are due to 
differences in methodology, but rather the dissociation from or association with the 
DRG. Ideally regional ischaemia would have been used for both in vivo and in vitro 
models of I/R, since this is a more realistic model of myocardial infarct whilst that of 
global ischaemia is more relevant to heart failure. However, the purpose of the in vitro 
I/R experiments detailed in Chapter 4 was to gain insight into the mechanisms 
underlying the involvement of LOX-derived eicosanoids in myocardial I/R injury using 
a simple model (i.e. global ischaemia), with the intention that a more representative 
model of I/R (i.e. regional ischaemia) would be used for further experiments based on 
the results from experiments in vitro. 
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It had been intended that the possible involvement of the 12-LOX/AA/TRPV1 pathway 
was investigated in vivo, either using a COX KO mouse, or by treating animals with 
indomethacin. Had such experiments been carried out, then the LAD would have been 
re-occluded at the end of the experiment in order to distinguish between perfused and 
non-perfused tissue using Evans Blue dye – a procedure that was omitted in the current 
study since tissues were being collected for expression analysis and needed to be snap 
frozen immediately at the end of experiments. An important consideration for future 
experiments would be that of experimental design, which could be improved by using a 
single-blind protocol and by introducing a standardised method of randomisation. 
Regrettably however, due to time constraints, it was not possible to further investigate 
the findings from this thesis – which has consequently left some important unanswered 
questions, such as why pre-ischaemic CPP is lower in hearts treated with 12-LOX and 
baicalein. One final point to consider is the use of constant flow conditions as opposed 
to constant pressure conditions in isolated heart experiments. As mentioned in section 
2.2, perfusion under the former overrides autoregulatory mechanisms that usually alter 
the amount of perfusate delivered to the whole heart – however, since a model of global 
ischaemia was used for isolated heart experiments, possible increases in flow to non-
ischaemic regions as a result of regional ischaemia could not occur. Future experiments 
using a regional model of ischaemia would require use of constant pressure mode and 
would then provide a system to assess the role of autoregulation. 
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6.5. Conclusions 
In conclusion, the present study has demonstrated that in the coronary circulation, 
sensory C-fibres and TRPV1 are involved in the vasodilator response to 12(S)-HpETE 
and AA, supporting the proposal that AA-induced vasodilatation is mediated by the 12-
LOX product 12(S)-HpETE, and that the vasoactive sensory neuropeptides CGRP and 
SP play a role in sensory C-fibre/TRPV1-mediated responses to 12(S)-HpETE and AA. 
I have also shown that 12-LOX/AA protects against myocardial I/R injury and that such 
protection is, in part, dependent upon activation of sensory C-fibres, although it appears 
that, as may have been expected, this is not due to vasodilator actions but rather an 
effect on cell death. The data from this study also intimate that myocardial I/R injury 
results in a decrease in TRPV1 protein expression in the isolated heart, but that in vivo, 
increased TRPV1 protein synthesis occurs within DRG and also cardiac nerve 
terminals, in addition to transport of TRPV1 protein from DRG to nerve terminals, in 
order to maintain expression levels of TRPV1 channels. It is possible that, during 
myocardial I/R, up-regulation or activation of this 12-LOX/AA/TRPV1 pathway 
represents an endogenous mechanism to limit tissue injury. 
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